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ABSTRACT
DEVELOPMENT AND EVALUATION OF MACHINE LEARNING AND DATA
MINING ALGORITHMS FOR BIOMEDICAL APPLICATIONS
by
Turki Talal Turki
Gene network inference and drug response prediction are two important problems in
computational biomedicine. The former helps scientists better understand the functional
elements and regulatory circuits of cells. The latter helps a physician gain full
understanding of the effective treatment on patients. Both problems have been widely
studied, though current solutions are far from perfect. More research is needed to
improve the accuracy of existing approaches.
This dissertation develops machine learning and data mining algorithms, and
applies these algorithms to solve the two important biomedical problems. Specifically, to
tackle the gene network inference problem, the dissertation proposes (i) new techniques
for selecting topological features suitable for link prediction in gene networks;
(ii) a graph sparsification method for network sampling; (iii) combined supervised and
unsupervised methods to infer gene networks; and (iv) sampling and boosting techniques
for reverse engineering gene networks. For drug sensitivity prediction problem, the
dissertation presents (i) an instance selection technique and hybrid method for drug
sensitivity prediction; (ii) a link prediction approach to drug sensitivity prediction;
(iii) a noise-filtering method for drug sensitivity prediction; and (iv) transfer learning
approaches for enhancing the performance of drug sensitivity prediction. Substantial
experiments are conducted to evaluate the effectiveness and efficiency of the proposed

algorithms. Experimental results demonstrate the feasibility of the algorithms and their
superiority over the existing approaches.
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CHAPTER 1
BACKGROUND

1.1 Gene Network Inference
Inference of gene regulatory networks (GRNs) from steady-state and time-series gene
expression data is an important biological problem that has received increasing attention
for advancing genomics research. Many computational approaches to solving this
problem have been developed to correctly infer gene regulatory networks from gene
expression data. However, existing approaches are not sufficiently accurate and robust to
convert gene expression data to regulatory relationships between transcription factors and
target genes.
The first part of this dissertation proposes several computational approaches for
making accurate and robust network inference. Chapter 2 develops a supervised link
prediction approach that combines gene expression data with topological features
extracted from a partially known gene regulatory network, and uses machine learning
algorithms for training and predicting unseen links in the gene regulatory network.
Chapter 3 introduces a learning framework that receives as input a network constructed
by an unsupervised method and employs a graph sparsification technique for network
sampling and principal component analysis for feature selection to obtain better quality
training data for regulatory link prediction. Chapter 4 develops a data cleaning algorithm
that takes as input a network constructed by an unsupervised method, and produces a
better quality training set by incorporating techniques from linear algebra and machine
learning. Then, the training set is passed to machine learning and deep learning
algorithms for training and performing predictions on a test set. Chapter 5 proposes
1

several methods for regulatory link prediction using sampling and boosting techniques.
These methods include (i) an upward extension of AdaBoost, called Boost I, that takes as
input a training set corresponding to a partially observed gene regulatory network and
iteratively boosts the performance of a weighted decision tree during training and
classifying remaining unobserved links; (ii) Boost I+U which is the same as Boost I
except that Boost I+U adopts an additional undersampling technique for improving
prediction performance; (iii) Boost I+O which is the same as Boost I+U except that Boost
I+O uses an oversampling technique instead of an undersampling technique;
(iv) a different extension of AdaBoost, called Boost II, that iteratively boosts the
performance of a weighted decision tree for training and testing; (v) Boost II+U which is
the same as Boost I+U except that Boost II+U uses a different boosting technique;
(vi) Boost II+O which also works the same as Boost I+O except that Boost II+O uses a
different boosting technique; (vii) Boost III which is a new boosting technique that is
different from Boost I and Boost II; (viii) Boost III+U which is the same as Boost II+U
except that Boost III is a different boosting technique; and (ix) Boost III+O which works
the same as Boost II+O except that Boost III is different from Boost II.
To evaluate the performance of the proposed approaches and compare them
against existing approaches, comprehensive experiments were conducted on many
datasets. Experimental results showed that the proposed approaches are robust and
outperform the existing approaches.
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1.1.1 Link Prediction in Gene Regulatory Networks
Link prediction is an important data mining problem that finds many applications in
social network analysis. One of the methods for solving the link prediction problem is to
extract features from a given partially observed network and incorporate these features
into a classifier. The links (i.e., edges) between entities (i.e., nodes or vertices) in the
given partially observed network are labeled [1, 2]. One then uses the classifier built from
the given partially observed network to predict the presence of links for unobserved pairs
of entities in the network. Liben-Nowell and Kleinberg [3] showed that topological
features can be used to increase the accuracy of link prediction in social network analysis.
Several authors have developed supervised methods for GRN inference [4-6]. For
example, Gillani et al. [7] presented CompareSVM, which uses support vector machines
(SVMs) to predict the regulatory relationship between a transcription factor (TF) and a
target gene where the regulatory relationship is represented by a directed edge (link), and
both the TF and target gene are nodes in a gene network. SIRENE [4, 8] is another
supervised method, which splits the network inference problem into many binary
classification problems using one SVM for each TF. The trained SVM classifiers are then
used to predict which genes are regulated. The final step is to combine all SVM
classifiers to produce a ranked list of TF-gene interactions in decreasing order, and to
construct a network based on the ranked list. Cerulo et al. [5] developed a SVM-based
method for GRN inference, which uses positive and unlabeled data for training the SVM
classifier. Ernst et al. [9] developed a similar semi-supervised approach for GRN
inference.
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1.1.2 Network Inference Through Link Prediction
Network inference through link prediction is a major research topic in computational
social science [1, 10, 11] and biomedicine [12-14]. For example, computational biologists
develop different methods for reconstructing gene regulatory networks (GRNs) using
high throughput genomics data. Maetschke et al. [15] categorized the existing GRN
reconstruction

algorithms

into

three

groups:

unsupervised,

supervised

and

semi-supervised. While supervised algorithms are capable of achieving the highest
accuracy among all the network inference methods, these algorithms require a large
number of positive and negative training examples, which are difficult to obtain in many
organisms [15-17]. Unsupervised algorithms infer networks based solely on gene
expression profiles and do not need any training example; however, the accuracy of the
unsupervised algorithms is low as they often create missing and spurious links [15].
GRNs inferred by unsupervised methods use time-series gene expression data.
These methods include BANJO (Bayesian Network Inference with Java Objects) [18],
TimeDelay-ARACNE (Algorithm for the Reconstruction of Accurate Cellular Networks)
[19], tlCLR (Time-Lagged Context Likelihood of Relatedness) [20, 21], DFG (Dynamic
Factor Graphs) [22], BPDS (Boolean Polynomial Dynamical Systems) [23], MIDER
[24], Jump3 [25], ScanBMA [26], and Inferelator [27]. BANJO models networks as a
first-order Markov process; it searches through all possible networks, seeking the
network with the best score. TimeDelay-ARACNE infers networks from time-series data
using mutual information from information theory.
The tlCLR method also uses mutual information and depends on ordinary differential
equations to model time-series data. DFG models experimental noise as a fitted Gaussian
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and then infers networks based on an assumed underlying, idealized gene expression
pattern. Jump3 uses a non-parametric procedure based on decision trees to reconstruct
GRNs. ScanBMA is a Bayesian inference method that incorporates external information
to improve the accuracy of GRN inference. Inferelator uses ordinary differential
equations that learn a dynamical model for each gene using time-series data. Recent
extensions of Inferelator incorporate prior knowledge into the tool, and are resilient to
noisy inputs.
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1.1.3 Network Inference via Supervised and Unsupervised Methods
Current biotechnology has allowed researchers in various fields to obtain immense
amounts of experimental information, ranging from macromolecular sequences, gene
expression data to proteomics and metabolomics. In addition to large-scale genomic
information obtained through such methods as third generation DNA sequencing, newer
technology, such as RNA-seq and ChIP-seq, has allowed researchers to fine tune the
analysis of gene expression patterns [28]. More information on interactions between
transcription factors and DNA, both qualitative and quantitative, is increasingly emerging
from microarray data.
Although microarrays alone do not provide direct evidence of functional
connections among genes, the attachment of transcription factors (TFs) and their binding
sites (TFBSs), located at specific gene promoters, influences transcription and modulates
RNA production from that particular gene, thus establishing a first level of functional
interaction. Since the TFs are gene-encoded polypeptides and the target TFBSs belong to
different genes, analyses of TFs-TFBSs interactions could uncover gene networks and
may even contribute to elucidate unknown GRNs [29]. Besides contributing to infer and
understand these interactions, determining GRNs also aims to provide explanatory
models of such connections [30]. GRNs could be the basis to infer more complex
networks, encompassing gene, protein, and metabolic spaces, as well as the entangled and
often overlooked signaling pathways that interconnect them [14, 31, 32].
Maetschke et al. [33] categorized GRN inference methods into three groups:
supervised, unsupervised and semi-supervised. While supervised algorithms are capable
of achieving the highest accuracy among all the GRN inference methods, these
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algorithms require a large number of positive and negative training examples, which are
difficult to obtain in many organisms [5, 34, 35]. Unsupervised algorithms infer GRNs
based solely on gene expression profiles and do not need any training example; however,
the accuracy of the unsupervised algorithms is low [33].
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1.1.4 Networks Inference Using Sampling and Boosting Techniques
Gene regulation is a series of processes that control gene expression and its extent. The
connections among genes and their regulatory molecules, usually transcription factors,
and a descriptive model of such connections, are known as gene regulatory networks
(GRNs). Elucidating GRNs is crucial to understand the inner workings of the cell and the
interactions among genes. Furthermore, GRNs could be the basis to infer more complex
networks, encompassing gene, protein, and metabolic spaces, as well as the entangled and
often over-looked signaling pathways that interconnect them [36-40].
Existing GRN inference methods can be broadly categorized into two groups:
unsupervised and supervised [41]. Unsupervised methods infer GRNs based solely on
gene expression data. The accuracy of these methods is usually low. By contrast,
supervised methods use machine learning algorithms and training data to achieve higher
accuracy. These methods work as follows. We represent a GRN by a directed graph in
which each node is a gene or transcription factor, and a directed link or edge from node A
to node B indicates that gene A regulates the expression of gene B. The training data
contains a partially known network with known present edges and absent edges between
nodes. These known present edges are positive training examples, and the known absent
edges are negative training examples. We train a machine learning algorithm using the
training data and apply the trained model to predict the remaining unknown edges in the
network. With the predicted present and absent edges, we are able to infer or construct a
complete GRN.
GRNs are always sparse graphs. The ratio between the number of

gene

interactions (i.e., edges or links) and the number of genes (i.e., nodes) falls between 1.5
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and 2.75 regardless of the differences in phylogeny, phenotypic complexity, life history,
and the total number of genes in an organism [42]. Thus, all GRNs have relatively few
present edges and a lot of absent edges. This means there are few positive examples and a
lot of negative examples when modeling the GRN inference problem as the link
prediction problem described above. This poses an imbalanced classification problem in
which the positive class (i.e., the minority class) is much smaller than the negative class
(i.e., the majority class). However, existing supervised GRN inference methods [8] [43]
do not take into consideration the imbalanced datasets, and hence their performance is
unsatisfactory.
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1.2 Cancer Drug Sensitivity Prediction
The problem of cancer drug sensitivity prediction has attracted considerable recent
attention from various domains such as computational biology, machine learning, and
data mining. As a result, many computational approaches have been proposed to predict
correctly the response of cancer to drugs using genomic information with the associated
drug values, where both are modeled as a single data matrix. However, many of these
approaches are not accurate and robust enough to connect genomic information to drug
values and cancer response. This dissertation presents computational approaches to make
accurate and robust cancer drug sensitivity predictions.
The second part of this dissertation proposes different computational approaches
to improve the prediction performance of cancer drug sensitivity prediction. Specifically,
Chapter 6 presents: (i) instance selection approach to select the most important samples
(i.e., examples), which are then provided to the standard machine learning algorithm to
train and perform prediction on new samples (i.e., test set); (ii) an oversampling approach
to generate synthetic samples, which are provided as input along with the original
samples to a machine learning algorithm for training and performing prediction on a
testing set; (iii) a hybrid approach that performs a majority vote on predictions obtained
on the test set based on models generated using machine learning algorithms trained on
different selected samples and genes. Chapter 7 introduces: (i) a link prediction approach
to cancer drug sensitivity prediction; (ii) an algorithm employing the link prediction
approach and a modified version of Query by Committee to select samples and provide
them as input to a machine learning algorithm for training and predicting a test set;
(iii) an extended algorithm to the previous one that performs an additional step, gene
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selection using statistical leverage scores. Chapter 8 develops a noise filtering approach
derived from numerical linear algebra and information retrieval techniques to select the
most important samples and pass them to a standard machine learning algorithm for
training and performing prediction on the test set. Chapter 9 proposes: (i) a transfer
learning approach that changes the representation of auxiliary data from the related task
to a new representation that is closer to the target training set and incorporating the data
with changed representation and the target training set, where both are passed to a
standard machine learning algorithm for training and performing prediction on testing;
(ii) an extended transfer learning approach to the previous approach, which includes a
modified version of Adaboost to boost the performance on the test set.
To compare the proposed prediction algorithms against existing approaches,
experimental evaluations of all approaches were performed using the Area Under the
ROC Curve (AUC) on test sets corresponding to real clinical trial datasets of cancer
patients. Experimental results demonstrate the stability and superiority of the proposed
approaches over the existing approaches in terms of statistical significance and accuracy.
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1.2.1 Approaches to Cancer Drug Sensitivity Prediction
Cancer is a major public health problem in the world and the second leading cause of
deaths in the Unites States of America [44]. Patients respond differently to cancer
chemotherapy owing to genetic heterogeneity, tumor heterogeneity, and environmental
factors, which make cancer drug discovery very difficult [45-48]. Cancer, because it
tends to be a progressive threat, has attracted attention of researchers from various
domains for identifying novel cancer genes and for cancer drug discovery [49-52].
Costello et al. [53] assessed 44 drug sensitivity prediction algorithms based on profiling
datasets (i.e., genomic, proteomic, and epigenomic data) of patients in breast cancer cell
lines. The training set consist of 35 cell lines (i.e., instances), where each cell line was
associated with 28 drugs response (output) values. The test set consist of 18 cell lines
(i.e., instances). The task of each algorithm was to predict the response (i.e., ranking 28
drugs from most sensitive to most resistant) for each cell line of the test set. The 44
algorithms were assigned to six categories: (i) kernel methods, (ii) nonlinear regression,
(iii) sparse linear regression (SLR), (iv) partial least-squares or principal component
regression, (v) ensemble/model selection and (vi) other (those methods not falling cleanly
into the previous five categories). Georgii et al. [53], the top-performing team, presented
Bayesian multitask multiple kernel learning (MKL) that integrates multiple profiling
datasets and enhanced data representations into probabilistic nonlinear regression model
to learn and predict drug sensitivity for all drugs simultaneously. Wan et al. [53], the
second-best performing team, employed random forest regression trees to address drug
sensitivity prediction task. Prediction algorithms were evaluated using weighted
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probabilistic c-index (wpc-index) [53]. The other teams were not statistically
significantly different according to the performed analysis on the algorithms.
Geeleher et al. [54] proposed an approach to drug sensitivity

prediction

performing homogenization and filtering on input data (baseline gene expression levels
with drug response values and in vivo tumor gene expression). A Learning algorithm is
applied to the baseline gene expression levels in the cell lines with associated drug
response values, to learn a model. The resulting learned model is then applied to the
baseline tumor expression data from the clinical trial, to yield drug sensitivity predictions.
Several problems are associated with the previous supervised approaches:
(i) The poor quality of cell lines, especially when cell lines are not screened against all
the compounds [55]; (ii) The lack of sufficiently large and representative cancer cell
lines, as they provide the basis to improve the accuracy of prediction algorithms.
However, this requires larger infrastructures and associated with higher costs of screening
size [56].
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1.2.2 Cancer Drug Sensitivity Prediction Through Link Prediction
Cancer has a significant global impact on public health; it is the second leading cause of
death in the United States of America [44]. Cancer patients respond differently to
potential drugs (i.e., chemotherapy) due to environmental causes, tumor heterogeneity,
and genetic factors, making cancer drug discovery difficult [45-48]. The increasing
number of deaths associated with cancer has attracted the attention of researchers from
numerous domains, such as computational biology, machine learning, and data mining
[49-52]. Costello et al. [53] assessed the performance of 44 drug sensitivity prediction
algorithms based on profiling datasets (i.e., genomic, proteomic, and epigenomic data) in
breast cancer cell lines. The training set consists of 35 cell lines, in which each cell line is
associated with 28 drug responses. The test set consists of 18 cell lines. The task of each
prediction algorithm is to learn a model from the training cell lines and perform
predictions on the test set. The predictions correspond to a ranking of the 28 drugs—from
the most sensitive to the most resistant for each cell line on the test set. The
top-performing approach [53] improved the performance by integrating several profiling
datasets with improved representation with a probabilistic nonlinear regression model.
The second-best performing approach employed random forest regression to make
predictions on the test set. The prediction algorithms were evaluated using the weighted
probabilistic c-index (wpc-index) and resampled Spearman correlations [53]. The
remaining prediction algorithms were not statistically different.
Geeleher et al. [54] proposed the following approach to drug sensitivity in which
the input data are baseline expressions with drug IC50 values in cell lines and in vivo
tumor gene expressions. The raw microarray data for the cell lines and clinical trials are
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processed separately and then combined and homogenized. The homogenized expression
data consist of cell line expression data (i.e., baseline gene expression levels in the cell
lines) and clinical trial expression data (i.e., baseline tumor expression data from the
clinical trial). A learning algorithm is applied to the cell line expression data with the
associated drug IC50 values for cell lines to learn a model. The resulting model is applied
to clinical trial expression data to yield drug sensitivity predictions.
Two problems associated with the previous drug sensitivity prediction algorithms
contribute to the degradation of the performance: (1) the poor quality of cell lines,
especially when cell lines are not screened against all compounds [55]; and (2) the failure
to adopt a new feature representation, because new feature representations provide a basis
for improving the performance of learning algorithms [57-59].
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1.2.3 Filtering Noisy Cancer Cell Lines for Drug Sensitivity Prediction
Cancer has a significant impact on public health worldwide and is the second leading
cause of death in the US [60]. In 2016, the American Cancer Society [61] predicted that
1,685,210 new cancer cases will be diagnosed, resulting in 595,690 deaths attributable to
cancer in the US. Many of these cancer patients respond differently to the same cancer
drug (i.e., during chemotherapy). These response differences are attributable to
environmental (i.e., external) factors such as tobacco, infectious organisms, and an
unhealthy diet, as well as to genetic (i.e., internal) factors such as inherited genetic
mutations, hormones, or immune conditions, and cancer cell heterogeneity, all of which
make cancer drug discovery very difficult [45, 46, 48, 62]. Because of the significant
numbers of deaths associated with cancer, its study has attracted the attention of
researchers from numerous domains including computational biology, machine learning,
and data mining [49, 52, 63].
Many existing drug sensitivity prediction algorithms do not take sample quality
into consideration [53, 54] , which degrades their performance in the real world. Cell
lines of poor quality exist, especially when cell lines are not screened against all of the
compounds [55]. These existing approaches fail to remove the poor cell lines, which
correspond to noisy samples in machine learning terms, and this failure leads to the
degraded performance of machine learning algorithms [58].
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1.2.4 Improving Drug Sensitivity Prediction via Transfer Learning
Cancer has a significant impact on public health worldwide and is the second leading
cause of death in the US [60]. In 2016, the American Cancer Society predicts that
1,685,210 new cancer cases will be diagnosed, resulting in 595,690 deaths attributable to
cancer in the US. Many of these cancer patients respond differently to the same cancer
drug during chemotherapy. These response differences are attributable to not only
environmental (i.e., external) factors such as tobacco, infectious organisms and an
unhealthy diet, but also genetic (i.e., internal) factors such as inherited genetic mutations,
hormones, immune conditions, and cancer cell heterogeneity, all of which make cancer
drug discovery very difficult [45-49]. Because of the significant numbers of deaths
associated with cancer, its study has attracted the attention of researchers from numerous
domains including computational biology, machine learning, and data mining
[50, 51, 63-65].
Traditional machine learning approaches to drug sensitivity prediction have been
adopted to improve the performance of prediction algorithms. For example, Riddick et al.
[66] presented an approach that employs random forests as a learning algorithm trained
on gene expression signatures of selected cancer cell lines and the corresponding drug

IC50 values (i.e., labels), to induce (i.e., learn) a model. The learned model is then
applied to gene expression signatures of cancer cell lines in the test set, to yield drug
sensitivity predictions. Geeleher et al. [54] proposed an approach to drug sensitivity
prediction that works as follows. The input data consisted of baseline expressions with
drug IC50 values in cell lines and in vivo tumor gene expression. The raw microarray
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data for the cell lines and clinical trials were processed separately and then combined and
homogenized. The homogenized expression data consisted of cell lines expression data
(i.e., baseline gene expression levels in the cell lines) and clinical trial expression data
(i.e., baseline tumor expression data from clinical trials). A learning algorithm was
applied to the training set (cell lines expression data along with the associated drug IC50
values for those cell lines), to learn a model. The resulting model was applied to the
clinical trial expression data in the test set, to yield drug sensitivity predictions.
Costello et al. [53] assessed the performance of 44 drug sensitivity prediction
algorithms based on genomic, proteomic, and epigenomic profiling data for 53 breast
cancer cell lines. The training set consisted of several profiling data for 35 cell lines,
where each cell line was associated with responses of 28 drugs. The test set consisted of
profiling data for 18 cell lines. The drug response data (also called the ground truth) were
hidden for evaluation purposes. The goal of each prediction algorithm is to induce (i.e.,
learn) a model from the training set and, then perform predictions on the test set. The
predicted drug responses corresponded to a ranked list of the most sensitive (to be ranked
first) to the most resistant (to be ranked last) cell lines for each drug across all the 18 cell
lines in the test set. The top-performing approach worked by integrating several profiling
data with improved representation combined with a probabilistic nonlinear regression
model [53]. The second-best performing approach employed random forest regression to
learn a model from profiling data of the training set and perform prediction on the test
set. The algorithms' predictions were evaluated against the ground truth using a weighted
probabilistic c-index (wpc-index) to report the final team rankings and resampled
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Spearman correlations for verifying the consistency between team rankings [53]. The
remaining prediction algorithms were not statistically different.
The previous approaches work well only under the common assumption: the
training set and test set are in the same feature space and with the same distribution.
However, this assumption does not hold in real-world applications [67]. As an example,
consider the task of predicting drug sensitivity in multiple myeloma (referred to as the
target task) where we have limited training data (called target training data). On the other
hand, there exist an abundance of labeled auxiliary data in the task of predicting drug
sensitivity in patients with a cancer type (referred to as the related task), where the
auxiliary data are in a different feature space or come from a different distribution. In
addition, collecting additional training data to improve the accuracy of prediction
algorithms of the target task requires larger infrastructures and is associated with higher
costs of screening size [56]. Therefore, there is a need to create high-performance
prediction algorithms trained with more easily obtained data from a related task. This
methodology is referred to as transfer learning [68].
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CHAPTER 2
A NEW APPROACH TO LINK PREDICTION
IN GENE REGULATORY NETWORKS

2.1 Introduction
Link prediction is an important data mining problem that has many applications in
different domains such as social network analysis and computational biology. For
example, biologists model gene regulatory networks (GRNs) as directed graphs where
nodes are genes and links show regulatory relationships between the genes. By predicting
links in GRNs, biologists can gain a better understanding of the cell regulatory circuits
and functional elements. Existing supervised methods for GRN inference work by
building a feature-based classifier from gene expression data and using the classifier to
predict links in the GRNs.
Feature extraction is crucial in building efficient classifiers for link prediction [3,
69, 70]. This chapter presents a new supervised approach for link prediction in GRNs.
The proposed approach employs both gene expression data and topological features
extracted from the GRNs, in combination with three machine learning algorithms
including random forests, support vector machines and neural networks. Experimental
results on different datasets demonstrate the good performance of the proposed approach
and its superiority over the existing methods.
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2.2 Proposed Approach
2.2.1 Feature Extraction
Let G  (V , E ) be the directed graph that represents the topological structure of a gene
regulatory network (GRN) where E is the set of edges or links and V is the set of nodes
or vertices in G . The goal is to build a classifier that includes topological features alone
or combined with gene expression data. There are totally sixteen topological features,
which are described in detail below.
Node Degree. In considering node degrees, each directed edge e  (u, v)  E has four
topological features, indeg (u ) , outdeg (u ) , indeg (v) , and outdeg (v) , which are defined
as the number of edges entering u , leaving u , entering v , and leaving v , respectively.
Normalized Closeness Centrality. Normalized closeness centrality measures the
closeness between a node and all other nodes in the graph G . For each node or vertex

v V , the normalized closeness centrality C(vin ) is defined as

C (vin ) 

| V | 1
 d (i, v)

(2.1)

i v

where d (i, v) , i  v , is the distance from i V to v V , and | V | is the number of
vertices in the graph G [71]. The distance from i to v is the number of edges on the
shortest path from i to v . If no such path exists, then the distance is set equal to  .
Since G is a directed graph, the distance from i to v is not necessarily the same as the
distance from v to i . The normalized closeness centrality C (vout ) is defined as

C (vout ) 

| V | 1
 d (v, i)
vi
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(2.2)

where d (v, i ) , v  i , is the distance from v V to i V . In considering normalized
closeness centrality, each directed edge e  (u, v)  E has four topological features,

C(uin ) , C (u out ) , C(vin ) , and C (vout ) .
Eccentricity. The eccentricity of a vertex v V is the maximum distance between v and
any other vertex i V [72]. For each vertex v V , the eccentricity (vin ) is defined as

(vin )  max iV d (i, v)

(2.3)

The eccentricity (vout ) is defined as

(vout )  max iV d (v, i)

(2.4)

In considering eccentricity, each directed edge e  (u, v)  E has four topological
features, (u in ) , (u out ) , (vin ) , and (vout ) .
Betweenness Centrality. Betweenness centrality measures the centrality of a vertex
in the graph G [73]. For each vertex v V , the betweenness centrality of v , denoted

Between(v) , is defined as

Between(v) 

i , j ( v )
i  v  j i , j



(2.5)

where i , j is the total number of shortest paths from vertex i to vertex j and  i , j (v) is
the total number of shortest paths from vertex i to vertex j that pass through v [71, 73].
In considering betweenness centrality, each directed edge e  (u, v)  E has two
topological features, Between(u ) and Between(v) .
Eigenvector Centrality. Eigenvector centrality is another centrality measure where
vertices in the graph have different importance. A vertex connected to a very important
vertex is different from a vertex that is connected to a less important one. This concept is
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incorporated into eigenvector centrality [74]. For each vertex v V , the eigenvector
centrality of v , denoted Eigen(v) , is defined as [75].

Eigen(v) 

1

a

 iV

v ,i

Eigen(i)

(2.6)

where  is a constant and A = (av,i ) is the adjacency matrix, i.e., av,i = 1 if vertex v is
linked to vertex i , and av,i = 0 otherwise. The above eigenvector centrality formula can
be rewritten in the matrix form as

Ax  x

(2.7)

where x is the eigenvector of the adjacency matrix A with the eigenvalue  . In
considering eigenvector centrality, each directed edge e  (u, v)  E has two topological
features, Eigen(u ) and Eigen(v) .

2.2.2 Feature Vector Construction
Given n genes where each gene has p expression values. The gene expression profiles
of these genes is denoted by G  Rn p , which contains n rows, each row corresponding
to a gene, and p columns, each column corresponding to an expression value [8]. To
train a classifier, the regulatory relationships among some genes have to be known.
Suppose these regulatory relationships are stored in a matrix H  Rm3 . H contains m
rows, where each row shows a known regulatory relationship between two genes, and
three columns. The first column shows a transcription factor (TF). The second column
shows a target gene. The third column shows the label, which is 1 if the TF is known to
regulate the target gene or 1 if the TF is known not to regulate the target gene.
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The matrix H represents a partially observed or known gene regulatory network for the

n genes. If the label of a row in H is 1, then the TF in that row regulates the target
gene in that row, and hence that row represents a link or edge of the network. If the label
of a row in H is 1, then there is no link between the corresponding TF and target gene
in that row.
Given a pair of genes g1 and g2 where the regulatory relationship between g1
and g2 is unknown, the goal is to use the trained classifier to predict the label of the gene
pair. The predicted label is either 1 (i.e., a link is predicted to be present between g1
and g2 ) or 1 (i.e., a link is predicted to be missing between g1 and g2 ). Using
biological terms, the present link means g1 (transcription factor) regulates g2 (target
gene) whereas the missing link means g1 does not regulate g2 .
To perform training and predictions, a feature matrix D  Rk2 p is constructed
with k feature vectors based on the gene expression profiles G . For a pair of genes g1
and g2 , their feature vector d is created, which is stored in the feature matrix D , denoted
by Dd and defined as

Dd  [ g11, g12 ,, g1p , g12 , g22 ,, g2p ]

(2.8)

where g11, g12 ,, g1p are the gene expression values of g1 , and g12 , g22 ,, g2p are the gene
expression values of g2 .The above feature vector definition has been used by the existing
supervised network inference methods [4, 5, 7, 8]. In the rest of this paper the above
technique for constructing feature vectors is referred to as Ge, indicating that it is based
on gene expression data only.
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In addition, another feature matrix D'  Rk16 is constructed. Each feature vector

d in the feature matrix D' , denoted by Dd' , is defined as

Dd'  [t1, t2 ]

(2.9)

t1  indeg ( g1 ), C ( g1in ), ( g1in ), outdeg ( g1 ), C ( g1out ), ( g1out ), Between( g1 ), Eigen( g1 )

(2.10)

t2  indeg ( g2 ), C ( g2in ), ( g2in ), C ( g2out ), ( g2out ), Between( g2 ), Eigen( g2 ), outdeg ( g2 )

(2.11)

This feature vector construction technique is referred to as To, indicating that it is based
on the sixteen topological features proposed in the paper.
Finally, the third feature matrix D''  Rk(2 p16) is constructed. Each feature vector

d in the feature matrix D'' , denoted by Dd'' , contains both gene expression data and
topological features, and is defined as

Dd''  [ g11, g12 ,..., g1p , g12 , g22 ,..., g2p , t1, t2 ]

(2.12)

This feature vector construction technique is referred to as All, indicating that it is based
on all the features described in the paper.

2.3 Experiments and Results
This section conducts a series of experiments to evaluate the performance of the approach
and compare it with the existing methods for gene regulatory network (GRN) inference
[76]. Below, datasets used in the study is described, experimental methodology, and the
experimental results.
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2.3.1 Datasets
GeneNetWeaver [77] is used to generate the datasets related to yeast and E. coli. We first
built five different networks are first built and taken from yeast, where the networks
contained 50, 100, 150, 200, 250 genes (or nodes) respectively. For each network, three
files of gene expression data are generated. These files were labeled as knockouts,
knockdowns and multifactorial, respectively. A knockout is a technique to deactivate the
expression of a gene, which is simulated by setting the transcription rate of this gene to
zero [7, 77]. A knockdown is a technique to reduce the expression of a gene, which is
simulated by reducing the transcription rate of this gene by half [7, 77].Multifactorial
perturbations are simulated by randomly increasing or decreasing the activation of the
genes in a network simultaneously [77].
Table 2.1 presents details of the yeast networks, showing the number of nodes
(edges, respectively) in each network. The edges or links in a network form positive
examples. In addition, the same number of negative examples is randomly picked where
each negative example corresponds to a missing link in the network. The networks and
gene expression profiles for E. coli were generated similarly. Table 2.2 presents details of
the networks generated from E. coli.
Table 2.1 Yeast Networks Used in the Experiments
Network
Yeast 50
Yeast 100
Yeast 150
Yeast 200
Yeast 250

Directed
Yes
Yes
Yes
Yes
Yes

#Nodes
#Edges
#Pos examples
#Neg examples
50
63
63
63
100
281
281
281
150
333
333
333
200
517
517
517
250
613
613
613
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Table 2.2 E. Coli Networks Used in the Experiments
Network
E. coli 50
E. coli 100
E. coli 150
E. coli 200
E. coli 250

Directed
Yes
Yes
Yes
Yes
Yes

#Nodes
#Edges
#Pos examples
#Neg examples
50
68
68
68
100
177
177
177
150
270
270
270
200
415
415
415
250
552
552
552

2.3.2 Experimental Methodology
This section considers nine classification algorithms, denoted by RF+All, NN+All,
SVM+All, RF+Ge, NN+Ge, SVM+Ge, RF+To, NN+To, SVM+To, respectively. Table
2.3 lists these algorithms and their abbreviations. RF+All (RF+Ge, RF+To, respectively)
represents the random forest algorithm combined with all features including both gene
expression data and topological features (RF combined with only gene expression data,
RF combined with only topological features, respectively). NN+All (NN+Ge, NN+To,
respectively) represents the neural network algorithm combined with all features (NN
combined with only gene expression data, NN combined with only topological features,
respectively). SVM+All (SVM+Ge, SVM+To, respectively) represents the support vector
machine algorithm combined with all features (SVM combined with only gene
expression data, SVM combined with only topological features, respectively). SVM+Ge
is adopted by the existing supervised network inference methods [4, 5, 7, 8].
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Table 2.3 Nine Classification Algorithms and Their Abbreviations
Abbreviation
RF + All
NN + All
SVM + All
RF + Ge
NN + Ge
SVM + Ge
RF + To
NN + To
SVM + To

Classification algorithm and features
Random Forests with all features
Neural Networks with all features
Support Vector Machines with all features
Random Forests with gene expression features
Neural Networks with gene expression features
Support Vector Machines with gene expression features
Random Forests with topological features
Neural Networks with topological features
Support Vector Machines with topological features

Software used in this work included: the random forest package in R [78], the
neuralnet package in R [79], and the SVM with linear kernel in the LIBSVM package
[80]. We used R to write some utility tools for performing the experiments, and employed
the package, igraph, to extract topological features from a network [81] .
The performance of each classification algorithm was evaluated through 10-fold
cross validation. The size of each fold was approximately the same, and each fold
contained the same number of positive and negative examples. On each fold, the
balanced error rate [76, 82] (BER) of a classification algorithm was calculated where the
BER is defined as

1
FN
FP
BER   (

)
2 TP  FN FP  TN

(2.13)

FN is the number of false negatives (i.e., present links that were mistakenly predicted as
missing links).TP is the number of true positives (i.e., present links that were correctly
predicted as present links). FP is the number of false positives (i.e., missing links that
were mistakenly predicted as present links). TN is the number of true negatives (i.e.,
missing links that were correctly predicted as missing links). For each algorithm, the
mean BER, denoted MBER, over 10 folds was computed and recorded. The lower MBER
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an algorithm has, the better performance that algorithm achieves. Statistically significant
performance differences between classification algorithms were calculated using
Wilcoxon signed rank tests [76, 83] .As in [84, 85], p-values below 0.05 are considered to
be statistically significant.

2.3.3 Experimental Results
Table 2.4 shows the MBERs of the nine classifications on the fifteen yeast datasets used
in the experiments. For each dataset, the algorithm having the best performance (i.e., with
the lowest MBER) is in boldface. Table 2.5 shows, for each yeast dataset, the p-values of
Wilcoxon signed rank tests between the best algorithm, represented by '-', and the other
algorithms. A p-value in boldface (p  0.05) indicates that the corresponding result is
significant. It can be seen from Table 2.4 that random forests performed better than
support vector machines and neural networks. In particular, random forests combined
with all features (i.e., RF+All) performed the best on 10 out of 15 yeast datasets. For the
other five yeast datasets, RF+All was not statistically different from the best algorithms
according to Wilcoxon signed rank tests (p > 0.05); cf. Table 2.5.
Table 2.6 shows the MBERs of the nine classification algorithms on the fifteen
E. coli datasets used in the experiments. Table 2.7 shows, for each E. coli dataset, the
p-values of Wilcoxon signed rank tests between the best algorithm, represented by '-', and
the other algorithms. It can be seen from Table 2.6 that random forests combined with
topological features (i.e., RF+To) performed the best on 6 out of 15 E. coli datasets. For
the other nine E. coli datasets, RF+To was not statistically different from the best
algorithms according to Wilcoxon signed rank tests (p > 0.05); cf. Table 2.7.
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Table 2.4 MBERs of Nine Classification Algorithms on Fifteen Yeast Datasets
Dataset

Yeast 50 knockouts
Yeast 50 knockdowns
Yeast 50 multifactorial
Yeast 100 knockouts
Yeast 100 knockdowns
Yeast 100 multifactorial
Yeast 150 knockouts
Yeast 150 knockdowns
Yeast 150 multifactorial
Yeast 200 knockouts
Yeast 200 knockdowns
Yeast 200 multifactorial
Yeast 250 knockouts
Yeast 250 knockdowns
Yeast 250 multifactorial

RF+

NN+

SVM+

RF+

NN+

SVM+

RF+

NN+

SVM+

All

All

All

Ge

Ge

Ge

To

To

To

16.6
16.6
16.1
12.8
14.2
12.0
5.10
5.00
4.10
1.90
1.90
1.90
3.80
4.00
4.00

15.0
17.5
17.5
13.7
14.9
17.8
10.7
10.5
12.4
4.00
5.10
6.80
8.40
9.70
8.50

20.0
20.0
20.8
17.3
15.2
18.0
14.1
10.4
13.9
5.30
5.80
10.1
7.60
7.40
8.50

18.3
19.1
15.5
14.4
14.1
12.3
5.40
5.80
4.10
1.90
1.90
1.90
4.10
4.00
3.90

15.8
22.7
24.7
20.0
29.4
21.3
10.4
14.7
15.1
4.90
6.30
4.70
5.50
6.20
6.00

20.0
16.9
17.2
16.7
14.1
18.4
13.6
10.9
16.1
5.60
10.5
14.3
7.20
7.30
9.00

17.7
17.7
17.7
11.6
11.8
11.4
6.10
5.80
5.80
2.50
2.70
2.50
7.40
8.10
7.50

16.3
18.8
16.6
22.2
17.5
20.0
15.4
16.0
10.8
13.7
9.80
5.50
10.6
7.70
11.3

19.4
19.4
19.4
14.5
14.5
14.5
11.0
11.0
11.0
3.70
3.70
3.70
10.4
10.4
10.4

Table 2.5 P-Values of Wilcoxon Signed Rank Tests between the Best Algorithm,
Represented by '-', and the Other Algorithms for Each Yeast Dataset
RF+
Dataset
Yeast 50 knockouts
Yeast 50 knockdowns
Yeast 50 multifactorial
Yeast 100 knockouts
Yeast 100 knockdowns
Yeast 100 multifactorial
Yeast 150 knockouts
Yeast 150 knockdowns
Yeast 150 multifactorial
Yeast 200 knockouts
Yeast 200 knockdowns
Yeast 200 multifactorial
Yeast 250 knockouts
Yeast 250 knockdowns
Yeast 250 multifactorial

NN+

SVM+

All
All
All
0.75 0.28
0.79
0.46
0.7
0.28
0.34 0.44
0.05
0.22 0.24
0.16
0.46 0.13
0.02
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.04
0.01
0.04
0.01
0.20
0.03
0.01
0.10
1.00 0.05
0.11

30

RF+

NN+

SVM+

Ge
Ge
Ge
0.44 0.67
0.07
0.17 0.13
0.52
0.89 0.07
0.68
0.14 0.01
0.02
0.22 0.00
0.03
0.27 0.01
0.04
1.00 0.01
0.01
0.17 0.03
0.01
0.01
0.01
0.01
0.02
0.01
0.02
0.06
0.00
0.17 0.06
0.10
0.06
0.05
0.01
0.03

RF+

NN+

SVM+

To
To
To
0.46 0.78
0.27
0.58 0.86
0.33
0.58 0.68
0.33
0.15
0.04
0.08
0.12
0.12
0.00
0.10 0.01
0.02
0.17 0.00
0.02
0.17 0.01
0.02
0.50 0.01
0.17
0.10 0.01
0.17
0.50 0.01
0.17
0.17 0.09
0.02
0.07 0.20
0.05
0.18 0.05
0.03

Table 2.6 MBERs of Nine Classification Algorithms on Fifteen E. Coli Datasets
RF+
Dataset
E. coli 50 knockouts
E. coli 50 knockdowns
E. coli 50 multifactorial
E. coli 100 knockouts
E. coli 100 knockdowns
E. coli 100 multifactorial
E. coli 150 knockouts
E. coli 150 knockdowns
E. coli 150 multifactorial
E. coli 200 knockouts
E. coli 200 knockdowns
E. coli 200 multifactorial
E. coli 250 knockouts
E. coli 250 knockdowns
E. coli 250 multifactorial

NN+

SVM+

RF+

NN+

SVM+

RF+

NN+

SVM+

All
All
All
Ge
Ge
Ge
To
To
To
14.5 5.70
9.80 18.8 22.0
21.5 5.00 11.6
18.4
14.5 9.50
10.7 19.1 19.0
16.7 5.00 10.8
18.4
15.3 10.3
8.20 15.7 22.9
18.0 5.00 10.3
18.4
10.3 9.50
14.2 12.0 14.4
17.7 5.60 6.00
13.6
10.6 11.6
14.2 11.4 14.1
18.0 5.40 9.80
13.6
9.80 10.4
11.4 9.80 12.4
13.6 7.10 9.90
13.6
2.90 2.40 8.80
5.90 2.70 5.90
3.30
2.40 4.40
2.70 2.20 8.10
3.70 2.70 3.80
3.30
2.20 4.40
2.40 2.20 8.70
2.40 2.70 3.30
3.30
2.20 3.80
5.50 5.50
5.10 5.50 4.60
6.00
4.60 6.40 11.0
5.30 5.00
5.80 6.10 4.40
5.50 6.40 8.50
6.00
5.00 4.20
3.90 4.90 2.80
3.40 6.40 8.00
6.00
7.00 7.70 8.80
8.00 6.30 12.7
10.0
6.60 10.3
5.30 9.30
5.90 5.10 6.70
7.50 6.20 11.9
10.0
5.40 11.1
8.00 5.20 11.0
9.70 6.30 10.6
10.0

Table 2.7 P-Values of Wilcoxon signed Rank Tests between the Best Algorithm,
Represented by '-', and the Other Algorithms for Each E. Coli Dataset
RF+ NN+

SVM+

RF+ NN+

SVM+

RF+

NN+

SVM+

Dataset

All

All

All

Ge

Ge

Ge

To

To

To

E. coli 50 knockouts

0.06

1.00

0.46

0.03

0.00

0.01

-

0.04

E. coli 50 knockdowns

0.06

0.07

0.46

0.01

0.01

-

E. coli 50 multifactorial

0.06

0.49

0.46

0.01
0.08

0.10
0.46

0.01

0.04

-

0.04

E. coli 100 knockouts

0.08

0.04

0.01

0.01

0.00

0.01

-

0.04
0.68

E. coli 100 knockdowns

0.02

0.16
0.22

0.01
0.11

0.01
0.06

0.27

0.67

0.01
0.67

-

E. coli 100 multifactorial

0.01
0.17

-

0.79

0.04
0.17

E. coli 150 knockouts

-

0.10

0.25

-

0.06

0.65

E. coli 150 knockdowns

-

0.17

-

0.06

1.00

0.65
0.04
0.1.00 1.00

E. coli 150 multifactorial

-

0.04
0.06

0.02
0.06

1.00

-

0.10

1.00

0.100

1.00

E. coli 200 knockouts

0.91

0.50

0.46

0.91

0.68

1.00
-

0.41

0.46

E. coli 200 knockdowns

0.89

0.50

0.27

0.75

-

0.46

0.46

0.03
0.11

E. coli 200 multifactorial

0.67

0.09

0.14

0.67

-

0.28

0.13

0.13

0.20

E. coli 250 knockouts

-

0.02

0.23

0.65

0.00

0.12

0.71

0.12

0.05

E. coli 250 knockdowns

0.17

0.02

0.02

-

0.02

0.02

0.10

0.02

0.01

E. coli 250 multifactorial

1.00

0.02

0.01

-

0.01

0.01

0.72

0.01

0.02
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0.04
0.04

0.68

These results show that using random forests with the proposed topological
features alone or combined with gene expression data performed well. In particular, the
RF+All algorithm achieved the best performance on 14 out of all 30 datasets. This is far
better than the SVM+Ge algorithm used by the existing supervised network inference
methods [4, 5, 7, 8] which achieved the best performance on one dataset only (i.e., the
E. coli 200 knockouts dataset in Table 2.6).
It is worth pointing out that, for a fixed dataset size (e.g., 200), the SVM+To
algorithm always yielded the same mean balanced error rate (MBER) regardless of which
technique (knockout, knockdown or multifactorial) was used to generate the gene
expression profiles. This happens because these different gene expression profiles
correspond to the same network, and SVM+To uses only the topological features
extracted from the network without considering the gene expression data. On the other
hand, due to the randomness introduced in random forests and neural networks, RF+To
and NN+To yielded different MBERs even for the same network.

2.4 Summary
This chapter presents a new approach to network inference through link prediction with
topological features. The experimental results showed that using the topological features
alone or combined with gene expression data performs better than the existing network
inference methods that use only gene expression data. This work assumes that there are
exactly the same number of positive examples (i.e., links that are present) and negative
examples (i.e., links that are missing) in the datasets. In many biological networks,
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however, negative datasets (majority class) are usually much larger than positive datasets
(minority class).
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CHAPTER 3
A LEARNING FRAMEWORK TO IMPROVE UNSUPERVISED GENE
NETWORK INFERENCE

3.1 Introduction
Network inference through link prediction is an important data mining problem that finds
many applications in computational social science and biomedicine. For example, by
predicting links, i.e., regulatory relationships, between genes to infer gene regulatory
networks (GRNs), computational biologists gain a better understanding of the functional
elements and regulatory circuits in cells. Unsupervised methods have been widely used to
infer GRNs; however, these methods often create missing and spurious links. This
chapter proposes a learning framework to improve the unsupervised methods. Given a
network constructed by an unsupervised method, the proposed framework employs a
graph sparsification technique for network sampling and principal component analysis for
feature selection to obtain better quality training data, which guides three classifiers to
predict and clean the links of the given network. The three classifiers include neural
networks, random forests and support vector machines. Experimental results on several
datasets demonstrate the good performance of the proposed learning framework and the
classifiers used in the framework.

3.2 The Learning Framework
3.2.1 Graph Sparsification
The input of the proposed learning framework is a weighted directed graph G  (V , E )
that represents the topological structure of (a subgraph of) the gene regulatory network
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(GRN) constructed by Inferelator based on a time series gene expression dataset. E is the
set of edges or links, and V is the set of vertices or nodes in G ,where each link
represents a regulatory relationship and each node represents a gene. Each edge

e  (u, v)  E is associated with a weight, denoted by W (e) , where 0  W (e)  1 .
The proposed graph sparsification method, named GeneProbe (reminiscent of
LinkProbe [86] for social network analysis), takes as input the graph G and two genes of
interest: an origin or regulator gene, and a destination or regulated gene. GeneProbe
creates six sets of genes, described below, and produces as output an inference subgraph
that contains all genes in the six sets and all edges in E that connect the genes in the six
sets.
Two sets of k -backbone genes. These include one set of k -backbone hub genes and
one set of k -backbone authority genes. The k -backbone hub genes include all genes
whose weighted outgoing degree is greater than or equal to a user-specified positive real
value khub 



. The weighted outgoing degree of a gene or node u is defined as the sum

of edge weights for all outgoing edges of u . Likewise, the k -backbone authority genes
include all genes whose weighted incoming degree is greater than or equal to a
user-specified value kauthority 



. The weighted incoming degree of a node u is defined

as the sum of edge weights for all incoming edges of u . (In the study presented here, khub
= 15 and kauthority = 10.) Intuitively few ``highly social'' individuals who would represent
``social hubs/authorities'' for inference across geographical regions are selected. The
genes most likely to be regulators (with the largest weighted outgoing degrees) are
selected as the ``hubs'' of the network G for inclusion in the inference subgraph.
Furthermore, the genes most likely to be regulated genes (with the largest weighted
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incoming degrees) are selected as the ``authorities'' of the network G for inclusion in the
inference subgraph.
Formally, let W  out (u ) ( W  in( u), respectively) denote the weighted outgoing
(incoming, respectively) degree of node u. Then

W  out (u) 



W (e)

(3.1)

eE out (u )

W  in(u) 



W (e)

(3.2)

eE in (u )

where W (e) is the weight of edge e , and E  out (u ) ( E  in(u ) , respectively) denotes
the set of edges leaving (entering, respectively) u . GeneProbe retrieves all genes u  G
where W  out (u)  khub and W  in(u )  kauthority .
Two sets of d -local genes. These include one set of d -local genes for the origin and
one set of d -local genes for the destination. The d -local genes are the genes adjacent to
each of the two genes of interest, i.e., the origin and destination, with incident edge
weights greater than or equal to a user-specified positive real value d 



. (In the study

presented here, d = 0.95.)Intuitively, the d -local genes represent the genes most likely
to be regulated by and most likely to regulate the two genes of interest.
Two sets of random walk metropolis genes. These include one set of random walk
metropolis genes for the origin and one set of random walk metropolis genes for the
destination. The random walk metropolis (RWM) genes provide a stochastic path from
the genes of interest back to a k -backbone gene (if possible). The RWM does not
differentiate between k -backbone hub and k -backbone authority genes. All of the genes
encountered along the RWM path are added to the inference subgraph. For the origin or
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regulator gene, the random walk is a walk along outgoing edges towards the k -backbone,
whereas the random walk for the destination or regulated gene is a backtrack to the

k -backbone along incoming edges. Each step along the random walk metropolis is
selected based on a randomized chance until a k -backbone gene is reached (or a
maximum number of tries is exceeded).
The randomized chance at each step along the random walk for the regulator gene
(i.e., origin) can be characterized as follows. Given a current gene u , a random edge
from the list of outgoing edges of gene u is selected. Let w represent the gene at the end
of the randomly selected outgoing edge. The random walk will proceed from gene u to
gene w if a randomly selected number between 0 and 1 is less than or equal to the
minimum of 1 and the weighted outgoing degree of w divided by the weighted outgoing
degree of u . That is, w is accepted as the next state with the probability of less than or
equal to an acceptance rate out . Otherwise, another random outgoing edge of gene u is
selected and similar calculations are performed. This move can be formalized in Equation
(3.3). P(u  w) is the probability that a random walk proceeds from u to w where

out  P(u  w)  min{1,

W  out (w)
}
W  out (u)

(3.3)

This process is repeated until a maximum number of tries is reached (or a k -backbone
gene is reached). Note that given enough chances in a connected gene regulatory
network, the random walks will always reach a k -backbone gene. It logically follows
that a setting that includes few k -backbone genes will likely generate many RWM genes
and vice versa.
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The randomized chance at each step along the random walk for the regulated gene
(i.e., destination) can be characterized as follows. Given a current gene v , a random edge
from the list of incoming edges of gene v is selected. Let w represent the gene at the end
of the randomly selected incoming edge. The random walk will backtrack from gene v to
gene w if a randomly selected number between 0 and 1 is less than or equal to the
minimum of 1 and the weighted incoming degree of w divided by the weighted incoming
degree of v . That is, w is accepted as the next state with the probability of less than or
equal to an acceptance rate in . Otherwise, another random incoming edge of gene v is
selected and similar calculations are performed. This move is formalized in Equation
(3.4).

in  P(w  v)  min{1,

W  in(w)
}
W  in(v)

(3.4)

where P( w  v) is the probability that a random walk moves backward from v to w .
This process is repeated until a maximum number of tries is reached (or a k -backbone
gene is reached). Figure 3.1 illustrates an inference subgraph.
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Figure 3.1 Example of an inference subgraph containing an origin (green), a destination
(purple), d -local genes (black), k -backbone genes (blue) and random walk metropolis
genes (red).

3.2.2 Feature Selection
An inference subgraph may still have missing and spurious links. We select a more
reliable sample from the inference subgraph where the weight of each edge in the sample
is greater than or equal to 0.5. For each pair of genes u , v in the sample graph, a feature
vector B is created by concatenating the gene expression profiles of u and v , as in [4,
16]. That is,

B  [u1, u 2 ,, u p , v1, v2 ,, v p ]

39

(3.5)

where u1, u 2 ,, u p are the gene expression values of u , and v1, v2 ,, v p are the gene
expression values of v . Each gene expression value is a feature.

We employ principal component analysis (PCA) to reduce the dimensionality of
the feature vectors of a sample graph [87]. Specifically, the feature vectors are combined
into a 2 p  N matrix X where 2p is the total number of features and N is the number of
links in the sample graph. Let the rank of the matrix X be r where the rank represents
the maximum number of uncorrelated column vectors in X [88]. We represent X
through singular value decomposition (SVD) as

X  U  S V T

(3.6)

Both U and V are orthogonal matrices. Each column of U is one of the
eigenvectors of the covariance matrix X  X T where X T is the transpose of X . Each
column of V is one of the eigenvectors of the matrix X T  X . The r  r matrix S
contains eigenvalues of X on the diagonal line of S .
In this case, each column vector of the matrix X representsa (present or missing)
link of the sample graph. That is, each link of the sample graph is a vector in the

2 p  dimensional Euclidean space. The dot product between two column vectors reflects
the extent to which the two corresponding links share similar feature occurrences. Thus,
the dot product can be used to get pairwise link distances. Let M contain pairwise link
distances, i.e., M ij is the dot product distance between link Li and link L j . Then M can
be derived by:

M  XT  X
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(3.7)

which can be generalized as:

M  (U  S V T )T  (U  S V T )
 (V  S U T )  (U  S V T )
 V  S 2 V T
 (V  S )  (V  S )T

(3.8)
(3.9)
(3.10)
(3.11)

The new representation of the matrix M shows that the pairwise link comparison matrix

M can be obtained through the dot product of (V  S ) and (V  S )T . That is, the i th row
of the N  r matrix (V  S ) is an r -dimensional vector representing the i th link in the
sample graph. This result indicates that after performing projection transformation with
respect to the matrix V , pairwise distances are kept between link-vectors as in the
original setting.
SVD reduces the dimensionality (from 2 p to r where r  min(2 p, N ) ) of a
link-vector. However, the reduced r -dimensional link-vector might still contain
redundant dimensions. In practice, the dimensionality of these link-vectors could be
further reduced without losing characteristics of the link-vectors in the original
2 p  dimensional Euclidean space. Specifically, based on the optimal solution of the

squared-error criterion of PCA [87], an r -dimensional vector could be projected onto a

k -dimensional subspace, k  r , spanned by the eigenvectors corresponding to the k
largest eigenvalues of the covariance matrix X  X T . As a result, X k can be obtained,
which is an approximation of the original matrix X , by keeping the k largest
eigenvalues of the covariance matrix X  X T and replacing the remaining eigenvalues
with zeros. Then, Equation (3.6) can be rewritten as

X k  U k  Sk VkT
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(3.12)

Therefore, the N  k matrix (Vk  Sk ) replaces the matrix (V  S ) in Equation (3.11),
where the i th row of the matrix (Vk  Sk ) is a k dimensional vector that represents the

i th link in the sample graph.(In the study presented here, k = 10.)

3.2.3 The Link Prediction Algorithm
After explaining the concepts of graph sparsification and feature selection, the proposed
learning framework (i.e., link prediction algorithm) is now described as how it works.
The main assumption here is that the network G constructed by Inferelator is not
accurate, and there are many missing and spurious links in G . A missing link or edge em
refers to a regulatory relationship that exists in the ground truth but is not inferred by
Inferelator, and hence em 
 G . A spurious link es refers to a regulatory relationship that
does not exist in the ground truth, but is inferred by Inferelator, and hence es  G . The
goal here is for the link prediction algorithm to detect these missing and spurious links, so
as to clean them. To achieve this goal, the algorithm predicts whether there is a link
between two nodes and uses the predicted outcome to replace the result obtained from
Inferelator if the predicted outcome differs from Inferelator's result.
Let G  (V , E ) be the gene regulatory network (GRN) constructed by
Inferelatorbased on a time series gene expression dataset. The proposed algorithm first
creates two subgraphs G  (V , E ) and G  (V , E ) where V ( V , respectively)
contains incident nodes of the edges in E ( E , respectively),the weight of each edge in

E ( E , respectively) is greater than or equal to (less than, respectively) the median of
the weights of the edges in E , E  E   and E  E  E . Thus, the edges in G are
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likely to be positive instances and the edges in G are likely to be negative instances.
Note, however, that in practice these two subgraphs G and G have low quality
data,i.e., they contain many missing and spurious links.
The proposed link-prediction algorithm consists of five steps.
Step 1: Suppose the algorithm aims to predict whether there is a link from node/gene u
to node/gene v . There are two cases to consider. In case 1, the gene pair (u, v) is in G .
Then the algorithm creates an inference subgraph I   G by invoking GeneProbe and
using G , the origin u and the destination v as input. In addition, the algorithm
randomly selects a pair of genes x , y in G , and creates an inference subgraph I   G
by invoking GeneProbe and using G , the origin x and the destination y as input. In
case 2, the gene pair (u, v) is in G . Then the algorithm creates an inference subgraph

I   G by invoking GeneProbe and using G , the origin u and the destination v as
input. In addition, the algorithm randomly selects a pair of genes x , y in G , and creates
an inference subgraph I   G by invoking GeneProbe and using G , the origin x and
the destination y as input. Without loss of generality, case 1 is assumed to hold and case
1 will be used to describe the following steps. Thus, the algorithm creates dual graph
sparsifications I  and I  in step 1.
Step 2: Create a sample graph I '  I  . where I ' does not contain the testing gene pair

(u, v) , and the weight of each edge in I ' is greater than or equal to 0.5. We consider the
edges in I ' to have higher quality and are more likely to be positive instances. Suppose
there are K edges in I ' . We then randomly select K edges from I  and use the
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randomly selected edges to form a sample graph I '  I  . In training the three classifiers
including neural networks, random forests and support vector machines, the edges in I '
are used as positive training examples, and use the edges in I ' as negative training
examples. The dual sample graphs I ' and I ' together form the training dataset.
Step 3: Construct a feature vector for the testing gene pair (u, v) by concatenating the
gene expression values of u and v , as shown in Equation (3.5). Also, construct a feature
vector for each gene pair ( p, q ) in the training dataset by concatenating the gene
expression values of p and q .
Step 4: Reduce the dimensionality of the feature vectors constructed in step 3 using
principal component analysis (PCA), as described in Section 3.2.2.
Step 5: Use the training examples (reduced feature vectors obtained from step 4) to train
three classifiers including neural networks, random forests and support vector machines.
Use the trained models to predict whether there is a link from gene u to gene v .

3.3 Experiments and Results
We conducted a series of experiments to evaluate the performance of the proposed
learning framework and the three classifiers used in the framework. Below, the datasets
and experimental methodology used in the study are described, and then the experimental
results are presented.
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3.3.1 Datasets
We adopted the five time-series gene expression datasets available in the DREAM4
100-gene insilico network inference challenge [21, 77, 89, 90]. Each dataset contains 10
times series, where each time series has 21 time points, for 100 genes. Each gene has (10

 21) = 210 gene expression values. Each link consists of two genes, and hence is
represented by a 420-dimensional feature vector; cf. Equation (3.5). Through principal
component analysis, each reduced feature vector has only 10 dimensions.
Each time-series dataset is associated with a gold standard file, where the gold
standard represents the ground truth of the network structure for the time-series data.
Each link in the gold standard represents a true regulatory relationship between two
genes. For a given time-series dataset, Inferelator [27] constructs a directed network, in
which each link has a weight and represents an inferred regulatory relationship between
two genes.
Table 3.1 presents details of the five networks, true and inferred, used in the
experiments. The table shows the numbers of true present and missing links in each gold
standard, and the numbers of inferred present and missing links in each network
constructed by Inferelator. Each network contains 100 nodes or genes, which form 9,900
ordered gene pairs totally.
Table 3.1 Networks Used in the Experiments

Directed
Nodes
True present links
True missing links
Inferred present links
Inferred missing links

Net1
Yes
100
176
9,724
6,232
3,668

Net2
Yes
100
249
9,651
6,066
3,834
45

Net3
Yes
100
195
9,705
6,186
3,714

Net4
Yes
100
211
9,689
5,930
3,970

Net5
Yes
100
193
9,707
6,180
3,720

For each network, four sets of testing data are created. Each testing dataset
contains 50 randomly selected links from the gold standard. Among the 50 links, 25 are
true present links and 25 are true missing links in the gold standard. The label (+1 or -1)
of each selected link is known, where +1 represents a true present link and -1 represents a
true missing link. These testing data were excluded from the training datasets used to
train the classifiers studied in the paper. There were 20 testing datasets totally.

3.3.2 Experimental Methodology
Three classification algorithms are considered, namely neural networks (NN), random
forests (RF) and support vector machines (SVM). Software used in this work included:
the neuralnet package in R [79], the random forest package in R [78], and the SVM
program with the polynomial kernel of degree 2 in the LIBSVM package [80]. The
principal component analysis (PCA) program was based on the prcomp function in R
[91]. The graph sparsification method (GeneProbe) was implemented in C++. In addition,
R was used to write some utility tools for performing the experiments.
The performance of each classification algorithm was evaluated as follows. Each
classification algorithm was trained as described in Section 3.2.3. For each link in a
testing dataset, the trained model is used to predict its label. In evaluating the link
prediction algorithm, a true positive is defined to be a true present link that is predicted as
a present link. A false positive is a true missing link that is predicted as a present link. A
true negative is a true missing link that is predicted as a missing link. A false negative is a
true present link that is predicted as a missing link. In evaluating Inferelator, a true
positive is defined to be a true present link that is an inferred present link. A false positive

46

is a true missing link that is an inferred present link. A true negative is a true missing link
that is an inferred missing link. A false negative is a true present link that is an inferred
missing link. Let TP (FP, TN, FN, respectively) denote the number of true positives (false
positives, true negatives, false negatives, respectively) for a testing dataset. The balanced
error rate (BER) was adopted [16], defined as

1
FN
FP
BER   (

)
2 TP  FN FP  TN

(3.13)

Each classification algorithm was applied to each testing dataset and recorded the BER
for that testing dataset. The lower BER a classification algorithm has, the better
performance that algorithm achieves. The improvement rate, denoted IR, is defined on a
testing dataset to be ( P*  P) 100% where P* is the BER of Inferelator and P is the BER
of a classification algorithm (NN, RF or SVM) for that dataset. Statistically significant
performance differences were calculated using Wilcoxon signed rank tests [83] . As in
[87], p-values below 0.05 are considered to be statistically significant.

3.3.3 Experimental Results
Table 3.2 shows the improvement rate (IR) each classification algorithm achieves on each
of the 20 testing datasets. A positive (negative, respectively) IR for a classification
algorithm indicates that the algorithm performs better (worse, respectively) than
Inferelator. The larger the positive IR a classification algorithm has, the more
improvement over Inferelator that algorithm achieves. For each testing dataset, the
classification algorithm with the best performance, i.e., the largest positive IR, is shown
in boldface. It can be seen from Table 3.2 that SVM (support vector machines)
outperforms Inferelator, NN (neural networks) and RF (random forests). SVM improves
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Inferelator on 16 testing datasets, and the improvement is statistically significant
according to Wilcoxon signed rank tests (p < 0.05). NN improves Inferelator on 12
testing datasets; however, the improvement is not statistically significant according to
Wilcoxon signed rank tests (p > 0.05).
Table 3.2 Improvement Rates of Three Classification Algorithms on Twenty Datasets
Dataset
Net1.test1
Net1.test2
Net1.test3
Net1.test4
Net2.test1
Net2.test2
Net2.test3
Net2.test4
Net3.test1
Net3.test2
Net3.test3
Net3.test4
Net4.test1
Net4.test2
Net4.test3
Net4.test4
Net5.test1
Net5.test2
Net5.test3
Net5.test4

NN
+11.10%
+17.00%
+7.10%
+5.20%
+5.80%
+14.80%
+4.40%
-0.60%
+0.20%
+0.00%
-8.00%
-2.00%
+10.40%
-5.70%
+10.80%
-3.00%
+1.20%
-1.70%
-7.00%
-3.00%

RF
+0.90%
+1.80%
+4.90%
+2.10%
+1.80%
-6.20%
-12.10%
+1.20%
-9.40%
+8.00%
-6.00%
-10.00%
-4.80%
-6.00%
+2.50%
+8.20%
-5.00%
-13.10%
-13.30%
-7.20%

SVM
+17.90%
+12.30%
+13.60%
+9.20%
-1.60%
+0.90%
+1.20%
+5.20%
-1.10%
+4.00%
+2.00%
+8.00%
+3.00%
+4.50%
+5.20%
+2.60%
+7.10%
+2.90%
-3.50%
-1.10%

Experiments were also carried out to evaluate the performance of different SVM
kernel functions, including the linear kernel (SVM_L), polynomial kernel of degree 2
(SVM_P2), polynomial kernel of degree 15 (SVM_P15), Gaussian kernel (SVM_G), and
sigmoid kernel (SVM_S). Figure 3.2 shows the BER values, averaged over the 20 testing
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datasets, for the different kernel functions. It can be seen that SVM with the polynomial
kernel of degree 2 (SVM_P2) used in this study performs the best.
Finally, experiments are conducted to evaluate the effectiveness of the
components of the proposed learning framework. There are two core components: graph
sparsification (GeneProbe) and feature selection (PCA). Figure 3.3 compares the
approach with graph sparsification (GS) only, the approach with feature selection
(FS) only, and the proposed approach, which combines both graph sparsification
(GS) and feature selection (FS). Each bar represents the average BER over the 20 testing
datasets. The classifier used to generate the results was the SVM program with the
polynomial kernel of degree 2. It can be seen from Figure 3.3 that the proposed approach
combining GS and FS performs the best.

Figure 3.2 Performance evaluation of different SVM kernel functions.
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Figure 3.3 Effectiveness of the components of the proposed learning framework.

3.4 Summary
Given gene regulatory networks constructed by unsupervised network inference methods,
the goal is to predict and clean the links in the networks. To achieve this goal, a learning
framework is proposed, which employs (i) a graph sparsification technique (GeneProbe)
for generating inference subgraphs from a given network, and (ii) principal component
analysis (PCA) for selecting significant features from high-dimensional feature vectors.
The selected feature values are then used to train three classifiers including neural
networks (NN), random forests (RF) and support vector machines (SVM) for performing
link prediction and link cleaning in the given network.
In this case study, the proposed framework is able to learn better quality training
data from noisy networks constructed by a widely used network inference tool
(Inferelator). Among the three classification algorithms studied in the paper, SVM with
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the polynomial kernel of degree 2 outperforms NN and RF in terms of improving the
accuracy of Inferelator. This kernel is the best among all SVM kernel functions tested
here. Experimental results also show that combining both graph sparsification and PCA is
better than using PCA or graph sparsification alone.
To the best of found knowledge, this is the first study to predict and clean the
links in gene regulatory networks constructed by unsupervised network inference
methods.
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CHAPTER 4
INFERRING GENE REGULATORY NETWORKS BY COMBINING
SUPERVISED AND UNSUPERVISED METHODS

4.1 Introduction
Supervised methods for inferring gene regulatory networks (GRNs) perform well with good
training data. However, when training data is absent, these methods are not applicable.
Unsupervised methods do not need training data but their accuracy is low. In this chapter,
supervised and unsupervised methods are combined to infer GRNs using time-series gene
expression data. Specifically, results obtained from unsupervised methods are used to train
supervised methods. Since the results contain noise, a data cleaning algorithm is developed to
remove noise, hence improving the quality of the training data. These refined training data
are then used to guide classifiers including support vector machines and deep learning tools
to infer GRNs through link prediction. Experimental results on several data sets demonstrate
the good performance of the classifiers and the effectiveness of the proposed data cleaning
algorithm.

4.2 Related Work
Widely used unsupervised methods for time-series gene expression data include BANJO
(Bayesian Network Inference with Java Objects) [18], TimeDelay-ARACNE (Algorithm
for the Reconstruction of Accurate Cellular Networks) [92], tlCLR (Time-Lagged
Context Likelihood of Relatedness) [93, 94], DFG (Dynamic Factor Graphs) [22], Jump3
[95], ScanBMA [26], and Inferelator [27].
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BANJO models GRNs as a first-order Markov process; it searches through all
possible GRNs, seeking the network with the best score. TimeDelay-ARACNE infers
GRNs from time-series data using mutual information from information theory. The
tlCLR method also uses mutual information and depends on ordinary differential
equations to model time-series data. DFG models experimental noise as a fitted Gaussian
and then infers GRNs based on an assumed underlying, idealized gene expression pattern.
Jump3 uses a non-parametric procedure based on decision trees to reconstruct GRNs.
ScanBMA is a Bayesian inference method that incorporates external information to
improve the accuracy of GRN inference. Inferelator uses ordinary differential equations
that learn a dynamical model for each gene using time-series data. Recent extensions of
Inferelator incorporate prior knowledge into the tool, and are resilient to noisy inputs.
On the other hand, supervised methods use training data along with a
classification algorithm such as support vector machines (SVMs) [5, 34, 43, 96]. The
training data includes known regulatory relationships between genes, also called links,
which are used to guide the classification algorithm to reconstruct GRNs through link
prediction. The performance of the supervised methods depends on the quality and the
amount of available training data.

4.3 Background and Overview
Central to the proposed approach of combining supervised and unsupervised methods for
GRN inference is a linear algebra-based data cleaning algorithm. The input of the data
cleaning algorithm contains a portion of a weighted directed graph G = (V, E) that
represents the topological structure of a GRN. This GRN is inferred by an unsupervised
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method based on a time-series gene expression dataset. E is the set of directed edges or
links, and V is the set of vertices or nodes in G, where each link represents a regulatory
relationship and each node represents a gene. Each edge e = (u , v )  E is associated with
a weight, denoted by W(e), where 0  W (e)  1. As a case study, Inferelator [27] is used
as the unsupervised method in this paper. Inferelator is one of the most widely used
unsupervised methods in the field.
The main drawback of employing an unsupervised method such as Inferelator for
GRN inference is that the method often creates missing and spurious links [33]. Let G be
a network constructed by Inferelator. A missing link or edge em refers to a regulatory
relationship that exists in the ground truth but is not created by Inferelator, and hence

em  G. A spurious link es refers to a regulatory relationship that does not exist in the
ground truth, but is created by Inferelator, and hence es  G. These missing and spurious
links will be used to train supervised methods. The goal is to develop a data cleaning
algorithm for removing the errors or noises in the links to get better quality training data.
Since an inferred network is sizable, m links are selected with the largest weights and m
links with the smallest weights to form an original training set. Then, feature vectors are
constructed for the selected 2m links in the training set.
The proposed data cleaning algorithm consists of three steps. First, a distance
matrix is calculated for the feature vectors using Laplacian kernel function. Second, a
linear algebra technique is adopted to project the training set onto the eigenvectors of the
distance matrix to obtain noise-removed features. Third, important features are selected
from the noise-removed features. The feature vectors containing the selected important
features form a cleaned training set.
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Classifiers are built using the cleaned training set and apply these classifiers to
predicting links in a regulatory network. The classification algorithms considered here
include support vector machines and variants of deep neural networks. Support vector
machines are commonly used in bioinformatics [97] while deep neural networks have
recently received increasing attention for deep learning. This case study shows how the
proposed data cleaning algorithm improves the quality of training examples used to guide
the classifiers for inferring GRNs through link prediction.

4.4 Methodology
4.4.1 Feature Vector Construction
A sample of links is selected from the weighted network constructed by Inferelator. The
sample contains m links (positive training examples) with the largest weights and m links
(negative training examples) with the smallest weights in the constructed network. These
2m links form the original training set. (In the study presented here, m = 100.) For each
ordered pair of genes u, v in a selected link, a feature vector x is created by
concatenating the gene expression profiles of u and v as done in [4, 5]. That is,

x  [u1, u2 ,..., u p , v1, v2 ,..., v p ]

(4.1)

where u1, u 2 ,..., u p are the gene expression values of u , and v1, v2 ,..., v p are the gene
expression values of v. Each gene expression value is a feature.
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4.4.2 Data Cleaning
To facilitate the discussion of the proposed data cleaning algorithm, the mathematical
symbols and notation used here are first summarized. Matrices (vectors, respectively) are
denoted by uppercase (lowercase, respectively) letters. The notation xi denotes the ith
vector in matrix X. Elements of a vector are denoted by italic lowercase with a
superscript, e.g., xi is the ith element of vector x; scalars are denoted by italic lowercase.
A feature matrix X 

2m 2 p

is constructed in which each row corresponds to a

link (feature vector) in the original training set. The proposed data cleaning algorithm
consists of three steps.
Step 1: Compute the distance matrix D in Equation (4.2):

D [d (xi , x j )]ij 

2m2m

(4.2)

where
d (xi , x j )  exp   || x i  x j ||  ,  i, j  1,..., 2m.

(4.3)

Here x i (x j , respectively) is the ith (jth, respectively) feature vector of the feature matrix
X, || xi  x j || is the Euclidean distance between xi and x j , and  is a user-determined
parameter. (In the study presented here,   1.) The element of the distance matrix in the
left hand side of Equation (4.3) corresponds to the element of the kernel K calculated
using the Laplacian kernel function [58, 98] in Equation (4.4) below:

K [k (xi , x j )]ij 

2m2m

(4.4)

where

k (xi , x j )  exp   || xi  x j ||.
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(4.5)

Step 2: Denote by 1   2  ...   2m the eigenvalues of the distance matrix D, and

v1 , v2 ,..., v2m the corresponding eigenvectors. According to Courant-Fischer Theorem
[99], one has

v1  arg min zTDz

(4.6)

z:||z||2 1

and

vl  arg

min

z:||z||2 1,z span{v1,v2 ,...,vl1}

zT D z.

(4.7)

Here || z ||2 is the 2-norm of the eigenvector z, i.e.
1

 2m
2
|| z ||2   | zi |2  .
 i1


(4.8)

The notation span{v1, v2 ,..., vl1} is the span of the set of orthonormal eigenvectors,
z span{v1, v2 ,..., vl1} represents that the orthonormal eigenvector z is perpendicular to the

span of the set of orthonormal eigenvectors, span{v1, v2 ,..., vl1} [100, 101].
Step 3: Let Vt 

2 mt

, 1  t  2m, be the matrix whose columns are the first t

eigenvectors of the distance matrix D with the smallest eigenvalues. (In the study
presented here, t  1.) X is projected onto Vt to obtain C 

2 m 2 p

with noise-removed

features. That is,

C  Vt VtTX.
Finally, M 

2p

(4.9)

are calculated using Equation (4.10):

M  1T C
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(4.10)

where 1 is a 2m-dimensional column vector of all ones. The bottom k elements in M
corresponding to the k minimum values in M are selected and their positions are stored
in P  k . (In the study presented here, k  10.) Construct feature vectors by selecting
only k features, based on the positions in P, from the feature vectors in C, and store the
feature vectors of k features in the transformed (cleaned) training set, C.

4.4.3 Link Prediction
The cleaned training set C (with feature vectors of k features obtained from step 3 above)
is used to train classification algorithms including support vector machines [58, 98], deep
neural networks with weights initialized by deep belief networks, and deep belief
networks with weights initialized by stacked AutoEncoder [102]. Given a testing set with
n ordered gene pairs whose labels are unknown, the goal here is to predict the label of
each gene pair (u, v) in the testing set using a trained classification model. That is, the
classification model will predict whether there is a link from gene u to gene v. The
predicted label is +1 if it is predicted that there is a link from u to v, and −1 otherwise.
To perform the link prediction, a feature vector is constructed for each gene pair
(u, v) in the testing set by concatenating the gene expression values of u and v as shown
in Equation (4.1). A feature matrix S is created for the testing set, selecting k features
based on the positions in P, and store the feature vectors of k features of the testing set in

S. The labels of the testing examples are then predicted by a trained classification model.
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4.5 Experiments and Results
4.5.1 Datasets
A series of experiments are carried out to evaluate the performance of the proposed
approach, using three time-series gene expression datasets available in the DREAM4
100-gene in silico network inference challenge [20, 21]. Each dataset contains 10 times
series, where each time series has 21 time points, for 100 genes. Each gene has (10 × 21)
= 210 gene expression values. Each link consists of two genes, and hence is represented
by a 420-dimensional feature vector.
Each time-series dataset is associated with a gold standard file, where the gold
standard represents the ground truth of the network structure for the time-series data.
Each link in the gold standard represents a true regulatory relationship between two
genes. For a given time-series dataset, Inferelator [27] outputs a list of ordered gene pairs
where each gene pair is associated with a positive, non-zero weight. Gene pairs not
shown in the output list are assumed to have a weight of −1. m gene pairs (positive
training examples) with the largest weights and m gene pairs (negative training examples)
with the smallest weights are selected in the output list of Inferelator. These 2m links
formed the original training set. The proposed data cleaning algorithm is then used to
clean the 2m links to obtain a cleaned training set.
Table 4.1 presents details of the data used in the experiments. The table shows the
numbers of true present and true missing links in each gold standard network, as well as
the numbers of gene pairs in the output list of Inferelator and the numbers of gene pairs
not shown in the output list of Inferelator for each time-series dataset. Each network
contains 100 nodes or genes, which form 9,900 ordered gene pairs totally.
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Table 4.1 Data Used in the Experiments
Net1
Yes
100
176
9,724
6,232
3,668

Directed
Nodes
True present links
True missing links
Gene pairs in output
Gene pairs not in output

Net2
Yes
100
249
9,651
6,066
3,834

Net3
Yes
100
195
9,705
6,186
3,714

For each network, three sets of testing data are generated. Each testing set
contains 50 randomly selected links from the gold standard. Among the 50 links, 25 are
true present links and 25 are true missing links in the gold standard. The label (+1 or −1)
of each selected link is known, where +1 represents a true present link and −1 represents
a true missing link. These testing data were excluded from the training sets, so the testing
sets and training sets were disjoint. There were 9 testing sets totally.

4.5.2 Experimental Setup
Three classification algorithms are considered, namely support vector machines (SVM),
deep neural networks with weights initialized by deep belief networks (DNN_DBN), and
deep neural networks with weights initialized by stacked AutoEncoder (DNN_Auto).
Software used in this work included: the deepnet package in R [103], the SVM program
with the linear kernel in the LIBSVM package [104] and other kernel functions in the
kernlab package [105]. In addition, R is used to write some utility tools for performing
the experiments.
The performance of each classification algorithm was evaluated as follows. As in
[104], each classification program is trained where the option of probability estimation in
each program was turned on. Given a testing link x, the program calculates the
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probability of x being in the positive class C , i.e., P( C |x). Each gene pair in a testing
test is predicted to have the label +1 (i.e., predicted as a present link) if its probability is
greater than or equal to the median of the probability estimates produced by the program.
The gene pair is predicted to have the label −1 (i.e., predicted as a missing link) if its
probability is less than the median probability. In evaluating the classification algorithms,
a true positive is defined to be a true present link that is predicted as a present link. A
false positive is a true missing link that is predicted as a present link. A true negative is a
true missing link that is predicted as a missing link. A false negative is a true present link
that is predicted as a missing link.
In evaluating Inferelator, a gene pair is considered as an inferred present link if its
weight is greater than or equal to the median of the weighs produced by Inferelator. The
gene pair is an inferred missing link if its weight is less than the median weight. A true
positive is defined to be a true present link that is an inferred present link. A false positive
is a true missing link that is an inferred present link. A true negative is a true missing link
that is an inferred missing link. A false negative is a true present link that is an inferred
missing link.
Let TP (FP, TN, FN, respectively) denote the number of true positives (false
positives, true negatives, false negatives, respectively) for a testing set. The performance
measure used in the study is the Area Under the ROC Curve (AUC) [97], defined as

1  TP
TN 
AUC  

.
2  TP+FN TN+FP 

(4.11)

Each classification algorithm is applied to each testing set and the AUC the
algorithm obtains is recorded for the testing set. The larger AUC a classification
algorithm has, the better performance that algorithm achieves. MAUC is used to denote
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the mean of the AUC values averaged over the three testing sets generated from a
network, and use AMAUC to denote the average of the MAUC values over the three
networks used in the experiments.

4.5.3 Experimental Results
Experiments are conducted first to evaluate the performance of SVM with different
kernel functions, including the linear kernel (SVM_L), Gaussian kernel (SVM_G),
sigmoid kernel (SVM_S), and polynomial kernel of degree 2 (SVM_P). Figure 4.1 shows
the AMAUC values of SVM with the different kernels. It can be seen from Figure 4.1
that SVM with the linear kernel (SVM_L) performs the best. The non-linear kernels
including SVM_G, SVM_S and SVM_P yield smaller AMAUC values, and hence
perform worse, than SVM_L.

Figure 4.1 Comparison of the AMAUC values of SVM with four different kernels
including the linear kernel (SVM_L), Gaussian kernel (SVM_G), sigmoid kernel
(SVM_S), and polynomial kernel of degree 2 (SVM_P).

In subsequent experiments, the SVM kernel is fixed at the linear kernel. Table 4.2
lists the MAUC values of SVM_L, deep neural networks with weights initialized by deep
belief networks (DNN_DBN), deep neural networks with weights initialized by stacked
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AutoEncoder (DNN_Auto), and Inferelator (Inf). For each network, the classification
algorithm with the best performance, i.e., the largest MAUC, is highlighted in boldface.
Table 4.2 MAUC Values of Three Classifiers and Inferelator
Dataset
Net1
Net2
Net3
Average

SVM_L
0.726
0.460
0.506
0.564

DNN_DBN
0.626
0.440
0.546
0.537

DNN_Auto
0.546
0.480
0.506
0.511

Inf
0.380
0.353
0.380
0.371

It can be seen from Table 4.2 that SVM_L is the best classifier for Net1 and
yields the largest average MAUC (i.e., AMAUC) of 0.564. DNN_DBN is the best
classifier for Net3 and yields the second largest average MAUC of 0.537. DNN_Auto is
the best classifier for Net2 with the average MAUC of 0.511. All the three classifiers
(i.e., supervised methods) perform better than the unsupervised method, Inferelator,
whose average MAUC is 0.371.
It is worth noting that the kernel-based program, SVM_L, performs better than the
deep learning programs DNN_DBN and DNN_Auto. Deep learning is a powerful tool for
image classification on big data with hundreds of classes. The deep learning programs
model high-level abstractions in data through multiple non-linear transformations. In
contrast, this work focuses on binary classification with relatively small datasets in which
the learned linear relationship between feature vectors and labels was shown to be
effective in testing data classification. As a consequence, the deep learning programs
perform worse than the kernel-based program.
Figure 4.2 shows the AMAUC values of the three classifiers, SVM_L,
DNN_DBN and DNN_Auto, into which the proposed data cleaning algorithm was not
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incorporated. Thus, the classifiers were trained by uncleaned data. Comparing Figure 4.2
with Table 4.2 where data was cleaned, one can see that the AMAUC values in Figure
4.2 are smaller than those in Table 4.2. The performance of the classifiers degrades when
running on uncleaned data, showing the effectiveness of the proposed data cleaning
algorithm. Notably, SVM_L suffers the most when data is not cleaned.

Figure 4.2 Comparison of the AMAUC values of three classifiers SVM_L, DNN_DBN
and DNN_Auto where the AMAUC values were obtained by running the classifiers on
uncleaned data.

One component of the data cleaning algorithm is feature selection where Equation
(4.10) is used to select k most important features to form feature vectors of k features.
Figure 4.3 shows the AMAUC values of the three classifiers, SVM_L, DNN_DBN and
DNN_Auto, for varying k values. It can be seen from Figure 4.3 that SVM_L continues
to be the best classifier when k values change. Its behavior is stable with respect to k.
Selecting k features makes the proposed approach computationally efficient for large
datasets with good predictive performance.
We also tested on different values for the parameters m in Equation (4.2),  in
Equation (4.3) and t in Equation (4.9) used in the proposed data cleaning algorithm. The
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results obtained were similar to those of using the default values for these parameters (m
= 100,   1, t  1), and the qualitative conclusion remains the same.

Figure 4.3 Impact of the number of selected features, k, on the performance of three
classifiers SVM_L, DNN_DBN and DNN_Auto.

4.6 Summary
Machine learning in biomedicine has received increasing attention recently [16, 106,
107]. In this paper a hybrid approach is presented for learning gene regulatory networks
(GRNs) by combining supervised and unsupervised methods. Central to the proposed
approach is a linear algebra-based algorithm for cleaning the results of unsupervised
methods. The cleaned results are then used to train supervised methods to perform GRN
inference through link prediction. In this case study, a widely used unsupervised method
is adopted, Inferelator, as well as three popular classifiers including support vector
machines (SVM), deep neural networks with weights initialized by deep belief networks
(DNN_DBN) and deep neural networks with weights initialized by stacked AutoEncoder
(DNN_Auto). The experimental results show the superiority of the proposed hybrid
approach over the unsupervised method. Among the three classifiers, SVM with the
linear kernel outperforms the two variants of deep neural networks, DNN_DBN and
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DNN_Auto. This linear kernel is the best among all SVM kernel functions tested here.
The experimental results also show the effectiveness of the proposed data cleaning
algorithm.
This data cleaning algorithm is related to the noise-filtering algorithm developed
by Ouyang et al. [108]. While both algorithms aim to improve the quality of network
data, they differ in two major ways. First, Ouyang et al.’s method is designed for
undirected networks and employs the Laplacian matrix, which is symmetric for
undirected networks. The eigenvalues of the symmetric matrix are real numbers, and the
corresponding eigenvectors are orthonormal. In contrast, the networks considered here
are directed networks. When applying Ouyang et al.’s method to directed networks, one
would get a non-symmetric Laplacian matrix, whose eigenvalues may contain complex
numbers. In such a situation, an orthonormal set of eigenvectors cannot be found, nor
even any pair of eigenvectors that are orthogonal (except perhaps by rare chance) [109].
Thus, instead of using the Laplacian matrix, a distance matrix D is introduced as shown
in Equation (4.2), which can be calculated by using the Laplacian kernel function as
shown in Equation (4.5). The eigenvalues of this symmetric positive semidefinite
distance matrix D are real, non-negative numbers, and the corresponding eigenvectors are
orthonormal. Second, Ouyang et al.’s method does not include feature selection. In
contrast, Equation (4.10) is used to select k most important features and use the selected
features for link prediction. It should also be pointed out that the work of Ouyang et al.
did not consider machine learning algorithms. In contrast, data cleaning algorithm is used
here to get better quality training data, which are then used to guide machine learning
tools to perform link prediction.
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To the best of found knowledge, the proposed hybrid approach is the first work to
combine supervised methods with an unsupervised method (Inferelator) for GRN
inference.
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CHAPTER 5
REVERSE ENGINEERING GENE REGULATORY NETWORKS USING
SAMPLING AND BOOSTING TECHNIQUES

5.1 Introduction
Reverse engineering gene regulatory networks (GRNs), also known as network inference,
refers to the process of reconstructing GRNs from gene expression data. Biologists model
a GRN as a directed graph in which nodes represent genes and links show regulatory
relationships between the genes. By predicting the links to infer a GRN, biologists can
gain a better understanding of regulatory circuits and functional elements in cells.
Existing supervised GRN inference methods work by building a feature-based classifier
from gene expression data and using the classifier to predict the links in GRNs.
Observing that GRNs are sparse graphs with few links between nodes, this chapter
presents a new approach to supervised GRN inference. The imbalanced classification
problem is tackled by using sampling techniques, including under-sampling and
over-sampling, to obtain a balanced training set. This balanced training set, containing
the same number of positive and negative training examples, is used to train a machine
learning algorithm to make predictions. Furthermore, several boosting techniques are
developed to enhance the prediction performance. As the experimental results show later,
this new approach outperforms the existing supervised GRN inference methods [8, 43].
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5.2 Methods
5.2.1 Problem Statement

n genes are given where each gene has p expression values. The gene expression
profile of these n genes is denoted by G  Rn p , which contains n rows, each row
corresponding to a gene, and p columns, each column corresponding to an expression
value [8, 16, 17, 43, 110]. In addition, known regulatory relationships or links among
some genes are given. Suppose these known regulatory relationships are stored in a
matrix X  R m3 , which forms the training dataset. X contains m rows, where each row
shows a known regulatory relationship between two genes, and three columns. The first
column shows a transcription factor (TF). The second column shows a target gene. The
third column shows the label, which is 1 if the TF is known to regulate the expression
of the target gene or 1 if the TF is known not to regulate the expression of the target
gene. The matrix X represents a partially observed or known gene regulatory network
for the n genes. If the label of a row in X is 1, then the TF in that row regulates the
expression of the target gene in that row, and hence that row represents a directed link or
edge of the network. That row is a positive training example. If the label of a row in X is

1, then there is no link between the corresponding TF and target gene in that row. That
row is a negative training example. The positive and negative training examples in X are
used to train a machine learning or classification algorithm. There are much more
negative training examples than positive training examples in X .
The test dataset contains ordered pairs of genes ( g1, g2 ) where the regulatory
relationship between g1 and g2 is unknown. Given a test example, i.e., an ordered pair of
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genes ( g1, g2 ) in the test dataset, the goal of link prediction is to use the trained classifier
to predict the label of the test example. The predicted label is either 1 (i.e., a directed
link is predicted to be present from g1 to g2 ) or 1 (i.e., a directed link is predicted to be
absent from g1 to g2 ). Here, the present link means g1 (a transcription factor) regulates
the expression of g2 (a target gene) whereas the absent link means g1 does not regulate
the expression of g2 .

5.2.2 Feature Vector Construction
To perform training and prediction, a feature matrix D  Rq2 p with q feature vectors
based on the gene expression profile G is constructed. Let g1 and g2 be two genes. Let

g11, g12 ,..., g1p be the gene expression values of g1 and g12 , g 22 ,..., g 2p be the gene expression
values of g2 . The feature vector of the ordered pair of genes ( g1, g2 ) , denoted Dd , is
stored in the feature matrix D and constructed by concatenating their gene expression
values as follows:

Dd  ( g11, g12 ,..., g1p , g12 , g22 ,..., g2p )

(5.1)

Thus, the ordered pair of genes ( g1, g2 ) corresponds to a point in 2p-dimensional
space. Each training and test example is represented by a 2p-dimensional feature vector.
For a positive training example, the label of its feature vector is 1. For a negative
training example, the label of its feature vector is 1. For a test example, the label of its
feature vector is unknown and to be predicted. This feature vector construction method
has been widely used by existing supervised GRN inference methods [8, 16, 17, 43, 110].
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5.2.3 Under-sampling
Given is a training dataset X that is the union of two disjoint subsets X  and X  . X  is
the minority class, containing positive training examples (i.e., known present links). X 
is the majority class, containing negative training examples (i.e., known absent links).

X  is much smaller than X  . The under-sampling method works as follows [111-113]. It
samples a random subset X s  X  such that the size of X s is equal to the size of X 
(i.e., | X s | = | X  | ). Thus, X s = X   X s forms a balanced dataset. Then X s is used to
train a machine learning algorithm. The trained model will be used to predict the labels of
test examples.

5.2.4 Over-sampling
The over-sampling method is based on SMOTE [111, 114, 115]. Given is the training
dataset X = X   X  as described above. The proposed over-sampling method creates a
new dataset X  that contains all examples in X  and many synthetic examples
generated as follows. For each example xi  X  , h -nearest neighbors of xi are selected,
where

1.1 | X  | 
h

 | X | 

(5.2)

Here, Euclidean distances are calculated to find the h -nearest neighbors. Denote these

h -nearest neighbors as xr , 1  r  h .
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A new synthetic example xnew along the line between xi and xr , 1  r  h , is
created as follows:

xnew  xi  ( xr  xi )  

(5.3)

where   (0,1) is a random number. xnew is added to X  . Generating and adding such
synthetic examples to X  is continued until X  is larger than X  . Then a random
s
s
 X  is selected such that the size of X 
subset X 
is equal to the size of X  (i.e.,

s
s
| X 
| = | X  | ). Thus, X s = X 
 X  forms a balanced dataset. X s is then used to train

a machine learning algorithm. The trained model will be used to predict the labels of test
examples.

5.2.5 Boosting
The performance of the proposed link prediction algorithms is further improved through
boosting. Boosting algorithms such as AdaBoost [116-119], described below, have been
used in various domains with great success. A weighted decision tree [120] is used as the
base learning algorithm and a strong classifier is created through an iterative procedure as
follows. Let X be the set of training examples x1, x2 ,..., xm  . The label associated with
example xi is yi such that

+1 if xi is a positive example (i.e., present link)
yi  
-1 if xi is a negative example (i.e., missing link)

(5.4)

Initially, in iteration 1, each example is assigned an equal weight, i.e., W1 ( xi ) 

1
,
m

1  i  m . In iteration k , 1  k  K , AdaBoost generates a base learner (i.e., model) H k
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by calling the base learning algorithm on the training set X with weights Wk . Then H k
is used to classify each training example xi as either 1 (i.e., xi is a predicted present
link) or 1 (i.e., xi is a predicted absent link). That is,

+1 if H k classifies xi as a positive example (i.e.,presentlink)
H k ( xi )  
-1 if H k classifies xias a negative example (i.e.,absentlink)

(5.5)

Let Ek  xi | H k ( xi )  yi  . The error  k of H k is:

k 

 W (x )

xi Ek

k

i

(5.6)

The weight k of H k is:

1
2

 1 k 

 k 

k  ln 

(5.7)

AdaBoost then updates the weight of each training example xi , 1  i  m , as follows:

Wk ( xi ) k
 Z  e if H k ( xi )  yi

Wk 1 ( xi )   k
Wk ( xi )  ek if H ( x )  y
k
i
i
 Z k


(5.8)

Wk ( xi )exp( k yi H k ( xi ))
Zk

where Zk is a normalization factor chosen so that Wk 1 is normally distributed. The
weights of incorrectly classified examples will increase in iteration k  1 . Then, in
iteration k  1 , AdaBoost generates a base learner Hk 1 by calling the base learning
algorithm again on the training set X with weights Wk 1 . Such a process is repeated K
times. Using this technique, each weak classifier Hk 1 should have greater accuracy than
its predecessor H k . The final, strong classifier H is derived by combining the votes of
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the weighted weak classifiers H k , 1  k  K , where the weight k of a weak classifier

H k is calculated as shown in Equation (5.7).
Specifically, given an unlabeled test example x̂ , H ( xˆ ) is calculated as follows:
K

H ( xˆ )  sign( k H k ( xˆ))

(5.9)

k 1

The sign function indicates that if the sum of the results of the weighted K weak
classifiers is greater than or equal to zero, then H classifies x̂ as +1 (i.e., x̂ is a predicted
present link); otherwise H classifies x̂ as -1 (i.e., x̂ is a predicted absent link).
Extensions of AdaBoost are proposed by modifying Equation (5.8) to obtain the
following variants:
Boost I:

 ek
 Z if H k ( xi )  yi

Wk 1 ( xi )    k
k
 e if H ( x )  y
k
i
i
 Z k
exp( k yi H k ( xi ))

Zk

(5.10)

Boost II:
k

Wk 1 ( xi ) 

exp( j H j ( xi ) yi )
j 1

Zk
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(5.11)

Boost III:

 C  ek
 Z
k

 ek

Z
Wk 1 ( xi )    k
k
e
 Zk
 
e k
Z
 k

if H k ( xi )  1 and yi  1
if H k ( xi )  1 and yi  1
(5.12)

if H k ( xi )  1 and yi  1
if H k ( xi )  1 and yi  1

where C is the number of examples in the majority class (i.e., negative class) divided by
the number of examples in the minority class (i.e., positive class) in the training set.
Each one of the above variants is taken as a new boosting technique. Boost I is a
simplified version of AdaBoost. For each training example xi , 1  i  m , Boost I does not
consider Wk ( xi ) when calculating Wk 1 ( xi ) . Boost II is an accumulative version of
AdaBoost. It considers all weak classifiers H j , 1  j  k , obtained in the previous k
iterations when calculating the weight Wk 1 ( xi ) . Specifically, Boost II will increase the
weight of a training example xi in iteration k  1 if the majority of the weak classifiers
obtained in the previous k iterations incorrectly classify xi . Boost III can be regarded as
a cost-sensitive boosting technique. For an imbalanced dataset, positive examples (i.e.,
those with labels of 1) are much fewer than negative examples (i.e., those with labels of

1). The objective here is to improve the classification performance on the minority (i.e.,
positive) class. Hence the cost C is introduced, giving more weights to misclassified
examples in the minority class where the examples are classified as negative though they
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have labels of 1. For a training example xi that is correctly classified in iteration k , its
weight is decreased in iteration k  1 so that the next classifier Hk 1 pays less attention to

xi while focusing more on the other examples that are incorrectly classified in iteration
k.

5.2.6 The Proposed Approach
Figure 5.1 presents an overview of the proposed approach. In (A), a training set is given
containing imbalanced labeled links. These labeled links include few positive examples
(i.e., known present links with labels of 1) and a lot of negative examples (i.e., known
absent links with labels of 1). In addition, a test set is given in which each test example
is an unlabeled ordered gene pair. Feature vectors are constructed for both training
examples and test examples as described in Section 8.2.2. In (B), a sampling technique is
applied, either under-sampling as described in Section 8.2.3 or over-sampling as
described in Section 8.2.4, to the training set to obtain a balanced training set. In
(C), a boosting technique is applied as described in Section 8.2.5 to the balanced training
set to learn K models (weak classifiers). These models predict the labels of the test
examples. In (D), the weighted majority vote is taken from the weak classifiers as shown
in Equation (5.9) to make final predictions of the labels of the test examples. A test
example is a predicted present link if its predicted label is 1; a test example is a
predicted absent link if its predicted label is 1.
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Figure 5.1 The proposed approach for link prediction in gene regulatory networks.

5.3 Experiments and Results
5.3.1 Datasets
GeneNetWeaver

[77] is used to generate the datasets related to yeast and E. coli.

Specifically four different networks are built for each organism where the networks
contained 50, 100, 150, 200 genes (or nodes) respectively. Table 5.1 presents details of
the yeast networks, showing the number of nodes (edges, respectively) in each network.
The present edges or links in a network form positive examples. The absent edges or
links in a network form negative examples. Table 5.2 presents details of the E. coli
networks.
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Table 5.1 Yeast Networks Used in the Experiments
Network
Yeast 50
Yeast 100
Yeast 150
Yeast 200

Directed
Yes
Yes
Yes
Yes

#Nodes
50
100
150
200

#Edges
63
281
333
517

#Positive examples
63
281
333
517

#Negative examples
2387
9619
22017
39283

For each network, three files of gene expression data are generated. These files
were labeled as knockouts, knockdowns and multifactorial, respectively.
Table 5.2 E. Coli Networks Used in the Experiments
Network
E. coli 50
E. coli 100
E. coli 150
E. coli 200

Directed
Yes
Yes
Yes
Yes

#Nodes
50
100
150
200

#Edges
68
177
270
415

#Positive examples
68
177
270
415

#Negative examples
2382
9723
22080
39385

A knockout is a technique to deactivate the expression of a gene, which is simulated by
setting the transcription rate of this gene to zero [7]. A knockdown is a technique to
reduce the expression of a gene, which is simulated by reducing the transcription rate of
this gene by half [7]. Multifactorial perturbations are simulated by randomly increasing
or decreasing the activation of the genes in a network simultaneously [7]. Totally there
were twelve gene expression datasets for yeast and E. coli respectively.

5.3.2 Experimental Methodology
The proposed approach is compared with existing supervised GRN inference methods [7,
8]. The existing methods employ support vector machines (SVM) and use the same
feature vector construction method as the proposed approach (cf. Section 8.2.2);
however, they lack sampling and boosting techniques. Table 5.3 lists the abbreviations of
78

the fifteen algorithms that have been evaluated and compared in this study where twelve
algorithms are boosting-related and three algorithms are SVM-related.
Table 5.3 Abbreviations of the Fifteen Algorithms Studied in This Paper
Abbreviation
AdaBoost
AdaBoost+U
AdaBoost+O
Boost I
Boost I+U
Boost I+O
Boost II
Boost II+U
Boost II+O
Boost III
Boost III+U
Boost III+O
SVM
SVM+U
SVM+O

Algorithm
AdaBoost technique
AdaBoost with under-sampling technique
AdaBoost with over-sampling technique
Boost I technique
Boost I with under-sampling technique
Boost I with over-sampling technique
Boost II technique
Boost II with under-sampling technique
Boost II with over-sampling technique
Boost III technique
Boost III with under-sampling technique
Boost III with over-sampling technique
SVM technique
SVM with under-sampling technique
SVM with over-sampling technique

The performance of each algorithm was evaluated through 10-fold cross
validation. The positive examples (negative examples, respectively) were evenly
distributed to the ten folds. When testing a fold, the Area Under the ROC Curve (AUC)
of an algorithm was calculated where the AUC is defined as

1  TP
TN 
AUC   

2  TP  FN TN  FP 

(5.13)

Here TP (FP, TN, FN, respectively) denotes the number of true positives (false positives,
true negatives, false negatives, respectively) for the test set. A true positive (true
negative, respectively) is a predicted present link (a predicted absent link, respectively)
that is indeed a known present link (a known absent link, respectively). A false positive
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(false negative, respectively) is a predicted present link (a predicted absent link,
respectively) that is in fact a known absent link (a known present link, respectively). For
each algorithm, the mean AUC, denoted MAUC, over the ten folds was computed and
recorded. The higher MAUC an algorithm has, the better performance that algorithm
achieves.

5.3.3 Experimental Results
Experiments are first conducted to evaluate the performance of SVM with different
kernel functions, including the linear kernel, polynomial kernel of degree 2, Gaussian
kernel, and sigmoid kernel. It was observed that the Gaussian kernel performed the best.
In subsequent experiments, the SVM kernel is fixed at the Gaussian kernel.
Figure 5.2 shows the AMAUC values of the three SVM-related algorithms,
namely SVM, SVM+U, SVM+O, on the twelve yeast datasets used in the experiments.
For each algorithm, the AMAUC was calculated by taking the average of the MAUC
values the algorithm received over the twelve yeast datasets. It can be seen from Figure
5.2 that SVM+U performed better than SVM+O and SVM. Figure 5.3 shows the
AMAUC values of the twelve boosting-related algorithms on the twelve yeast datasets
used in the experiments. It can be seen from Figure 5.3 that Boost III+U performed the
best on the twelve yeast datasets.
Table 5.4 shows the MAUC values of Boost III+U and SVM+U, and compares
them with the existing approaches using SVM only [7, 8] on the twelve yeast datasets.
For each dataset, the algorithm with the best performance (i.e., the highest MAUC) is
shown in bold. It can be seen from Table 5.4 that Boost III+U has the best overall
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performance on the yeast datasets, and beats the existing approaches using SVM only [7,
8].
Figure 5.4 shows the AMAUC values of the three SVM-related algorithms,
namely SVM, SVM+U, SVM+O, on the twelve E. coli datasets used in the experiments.
It can be seen that SVM+O outperformed SVM+U and SVM. Figure 5.5 shows the
AMAUC values of the twelve boosting-related algorithms on the twelve E. coli datasets
used in the experiments. It can be seen from Figure 5.5 that Boost II+U performed the
best among the twelve boosting-related algorithms. Table 5.5 shows the MAUC values of
Boost II+U and SVM+O, and compares them with the existing approaches using SVM
only [7, 8] on the twelve E. coli datasets. It can be seen from Table 5.5 that Boost II+U
has the best overall performance on the E. coli datasets, and beats the existing approaches
using SVM only [7, 8].

Figure 5.2 AMAUC values of three SVM-related algorithms on twelve yeast datasets.
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Figure 5.3 AMAUC values of twelve boosting-related algorithms on twelve yeast
datasets.

Table 5.4 MAUC Values of Three Algorithms on Twelve Yeast Datasets
Dataset
Yeast 50 knockouts
Yeast 50 knockdowns
Yeast 50 multifactorial
Yeast 100 knockouts
Yeast 100 knockdowns
Yeast 100 multifactorial
Yeast 150 knockouts
Yeast 150 knockdowns
Yeast 150 multifactorial
Yeast 200 knockouts
Yeast 200 knockdowns
Yeast 200 multifactorial
AMAUC

Boost III+U
0.709
0.664
0.679
0.729
0.706
0.701
0.633
0.673
0.68
0.599
0.612
0.608
0.666
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SVM+U
0.802
0.79
0.736
0.638
0.69
0.639
0.529
0.519
0.538
0.622
0.623
0.54
0.638

SVM
0.534
0.529
0.526
0.487
0.489
0.472
0.486
0.494
0.474
0.49
0.49
0.471
0.495

Figure 5.4 AMAUC values of three SVM-related algorithms on twelve E. coli datasets.

Figure 5.5 AMAUC values of twelve boosting-related algorithms on twelve E. coli
datasets.
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Table 5.5 MAUC Values of Three Algorithms on Twelve E. Coli Datasets
Dataset
E. coli 50 knockouts
E. coli 50 knockdowns
E. coli 50 multifactorial
E. coli 100 knockouts
E. coli 100 knockdowns
E. coli 100 multifactorial
E. coli 150 knockouts
E. coli 150 knockdowns
E. coli 150 multifactorial
E. coli 200 knockouts
E. coli 200 knockdowns
E. coli 200 multifactorial
AMAUC

Boost II+U
0.872
0.866
0.879
0.77
0.758
0.75
0.625
0.597
0.636
0.702
0.705
0.678
0.736

SVM+O
0.767
0.776
0.819
0.708
0.712
0.711
0.567
0.596
0.584
0.683
0.682
0.666
0.689

SVM
0.669
0.505
0.706
0.493
0.492
0.49
0.498
0.5
0.508
0.504
0.495
0.495
0.529

To summarize, one of the proposed boosting methods coupled with the
under-sampling technique achieves the best performance among all the fifteen algorithms
studied in this paper on the yeast and E. coli datasets respectively. For the yeast datasets,
this proposed boosting method is Boost III. For the E. coli datasets, this proposed
boosting method is Boost II. Both boosting methods coupled with the under-sampling
technique are superior to the existing approaches using SVM only [7, 8].
The proposed boosting techniques are based on a weighted decision tree [120].
The boosting techniques are combined with other machine learning algorithms including
random forests [121], SVM with the linear kernel, SVM with the sigmoid kernel, SVM
with the Gaussian kernel, and SVM with the polynomial kernel of degree 2. However, the
performance of these other machine learning algorithms is inferior to the performance of
the weighted decision tree used in this paper. As a consequence, the results from the other
machine learning algorithms are not reported here.
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To evaluate the effectiveness of the proposed sampling and boosting techniques,
the following four algorithms have also been tested and compared: (i) the weighted
decision tree without boosting and sampling techniques; (ii) the weighted decision tree
with boosting techniques only; (iii) the weighted decision tree with sampling techniques
only; and (iv) the weighted decision tree with both boosting and sampling techniques.
The results from the yeast and E. coli datasets are similar. For example, for the yeast
datasets, the AMAUC value for the weighted decision tree without boosting and
sampling techniques is 0.45. This is lower than the existing approaches using SVM only
(with AMAUC being 0.495 as shown in Table 5.4). When the weighted decision tree is
coupled with only the Boost III technique, its AMAUC value is 0.53. When the weighted
decision tree is coupled with only the under-sampling technique, its AMAUC value is
0.61. When the weighted decision tree is coupled with both Boost III and under-sampling
techniques, its AMAUC value is 0.666 as shown in Table 5.4, which is much higher than
the AMAUC value of 0.45 achieved by the weighted decision tree without boosting and
sampling techniques.

5.4 Summary
In this chapter a new approach is presented to gene network inference through regulatory
link prediction. The proposed approach uses a weighted decision tree as the base learning
algorithm coupled with sampling and boosting techniques to improve prediction
performance. Experimental results demonstrated the superiority of the proposed approach
over existing methods [7, 8], and the effectiveness of the proposed sampling and boosting
techniques.
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CHAPTER 6
LEARNING APPROACHES TO IMPROVE PREDICTION OF DRUG
SENSITIVITY IN BREAST CANCER PATIENTS

6.1 Introduction
Predicting drug response to cancer disease is an important problem in modern clinical
oncology that attracted increasing recent attention from various domains such as
computational biology, machine learning, and data mining. Cancer patients respond
differently to each cancer therapy owing to disease diversity, genetic factors, and
environmental causes. Thus, oncologists aim to identify the effective therapies for cancer
patients and avoid adverse drug reactions in patients. By predicting the drug response to
cancer, oncologists gain full understanding of the effective treatments on each patient,
which leads to better personalized treatment. This chapter presents three learning
approaches to address the problems. The instance selection approach selects
representative training cell lines for guiding the learning model through utilizing a
learning scenario. The oversampling approach generates synthetic cell lines to improve
the accuracy of prediction algorithms. The hybrid approach selects the top-k genes and
then selects cell lines as in the first approach. Experimental results show later, the three
approaches statistically significantly outperform the baseline drug sensitivity prediction
approach proposed by Geeleher et al. [54].
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6.2 Proposed Approaches
6.2.1 The Instance Selection Approach
Figure 6.1 outlines the instance selection approach, which works as follows. (A) Given
expression profiles denoted by X R m x n , which contains m cell lines, each cell line
corresponding to a sample, and n columns, each column corresponding to a gene. To
learn a model, the continuous real-values drug responses Y (i.e., drug IC50 values) are
needed

to

be

known,

where

YR m .

A

training

set

is

defined

as

S  {( x1, y1),( x2 , y2 ),...,( xm , ym )} where xi X and yi Y. Similarly, for given expression
profiles denoted by X' R p x n , containing p samples and n genes. The test set is defined
as X'  {x1' , x2' ,..., x'p}. (B) Slight modification of IPRed is adapted [122], to select
representative training cell lines, consisting of the following two steps
1. Store m distances, which correspond to the m minimum distances between each
training cell line xi X and all tumors of patients (i.e., instances) in X' defined as

w( xi )  dist(xi , x'j* ) with j*  arg min dist( xi , x'j )

(6.1)

j{1,2,...,|X'|}

where w( xi ) is the distance between xi and x'j* , s.t. x 'j* is the nearest patient to cell line

xi , dist( xi , x'j* ) 

n

( x
d 1

id

, x'j*d )2 is the Euclidean distance.

2. Let W  (w( x1), w( x2 ),..., w( xm )). Each cell line xi X is selected, s.t. w( xi )  c,
where c = percentile(W, %75), i =1,...,m. That is, each cell line whose weight is
below the 75th percentile of W is selected. All cell lines satisfying the condition
are then stored in S' . Eventually, S'  R m x n where m'  m. The learning algorithm
'
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is applied on S ' , to induce model h1. (C) Model h1 is applied to perform
prediction on the test set. In the rest of the paper the approach is referred to as the
instance selection approach employing machine learning algorithms (SVR and
RR) as: IS+SVR+L, IS+SVR+S, and IS+RR (abbreviations are listed in Table
6.1).
Table 6.1 Abbreviation of Drug Sensitivity Prediction Algorithms
Abbreviation Prediction Algorithm
The instance selection approach using support vector regression with
IS+SVR+L
linear kernel
The instance selection approach using support vector regression with
IS+SVR+S
sigmoid kernel
IS+RR
The instance selection approach using ridge regression
The oversampling approach using support vector regression with linear
O+SVR+L
kernel
The oversampling approach using support vector regression with sigmoid
O+SVR+S
kernel
O+RR
The oversampling approach using ridge regression
C+SVR+L
The hybrid approach using support vector regression with linear kernel
C+SVR+S
The hybrid approach using support vector regression with sigmoid kernel
C+RR
The hybrid approach using ridge regression
SVR+L
The baseline approach using support vector regression using linear kernel
The baseline approach using support vector regression using sigmoid kerSVR+S
nel
RR
The baseline approach using ridge regression
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Figure 6.1 Data flow diagram showing the instance selection approach to predicting in
vivo drug sensitivity.

6.2.2 The Oversampling Approach
As shown in Figure 6.2, (A) The oversampling approach receives training set S and test
set X' , which are defined as in Section 4.2.1 (A).
A

Test Set

B

C

Clinical
Trial
Expression
Data
Training Set
Cell Lines
Expression
Data
Drug IC50
Data for
Cell Lines

Generate
Synthetic Cell
Lines using
Oversampling
algorithm

Oversampled
Cell Lines
Expression
Data

Apply Learning
Algorithm to
Learn Model

Model h

Apply Model h to
Predict in vivo
Drug Sensitivity Predictions

Figure 6.2 Data flow diagram showing the oversampling approach to predicting in vivo
drug sensitivity.
(B) Synthetic Minority Oversampling Approach (SMOTE) is employed [123] for
generating synthetic cell lines according to the following steps:
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1. Find k nearest neighbors x1* , x2* ,..., xk* of each xi S . (In the study presented here,
k=1.)
2. Generate synthetic cell lines along the lines between the randomly selected k
nearest neighbors and each xi by the following lines of code:
2.2. for i=1 to m
2.1. for j=1 to k
2.1.1. xnew  xi  ( x*j  xi )
2.1.2. Label( xnew )  Label( xi )
2.1.3. Store xnew in X++
2.2. end for
2.3. end for
Where  .is a random number. A learning algorithm is called on S'  {X++ , S} , to induce
model h. (C) Model h is applied for the prediction on the test set. For brevity, the
following abbreviations are assigned to the oversampling approach employing machine
learning algorithms: O+SVR+L, O+SVR+S, and O+RR (see Table 6.1).

6.2.3 The Hybrid Approach
Figure 6.3 shows the data flow diagram of the hybrid approach. (A) Given training set S
'

and test set X , which are described as in Section 4.2.1. (B) LASSO (least absolute
shrinkage and selection operator) has been used successfully in genomics, which
performs feature selection and regularization to improve prediction accuracy [124-126].
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Given cell lines xi  R n and the drug response values yi  R, i  1,..., m. The objective
function for LASSO is

min
R  (β)  min
n1
n1

βR

βR

n
n
1 m
2
(
y

x

)


j
 i 

ij j
2m i1
j 0
j 0

(6.2)

1

n

where   0 is the tuning parameter ,  j 1  |  j |is the 1 penalty. In LASSO penalty, it is
j0

expected to have many coefficients in β to be close to zero, and small subset to be larger
and nonzero [126]. Coordinate descent is applied to solve the problem in Equation 6.2
minimizing one-at-a-time one parameter and fixing all others [127], which works as
follows:
1. Initialize all  j  0
2. Cycle over j= 0,1,2,…,n,0,1,2,…, till convergence:
2.1 * 

1 m
xill )
 xij ( yi  
m i1
l j

*   if *  0 and   | * |

2.2  j  *   if *  0 and   | * |
0
if   | * |


Step 2.1 measures the correlation of the jth gene (xij ) and the partial residual of the
predicted drug response value without jth gene (  xill ) and the true value (yi). Higher
l j

* value means that jth gene (feature) is regarded as more correlated and an important
*
gene. Similarly, lower  value means that jth gene (feature) is regarded as less
correlated

gene.

Step

2.2

updates

j
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by

soft-thresholding

[126,

127].

Coefficients β j0  R n are stored, i.e., consisting of all coefficients except coefficient 0 ,
produced by coordinate descent in U . Then rerun coordinate descent q-1 times (in this
study for model h1, q=10), where each β is stored in U. That is, UR q x n , where U
contains q different β coefficients produced through rerunning coordinate descent. Then
the columns sum is performed as:

M  1T U
where

1

(6.3)

is the q-dimensional column vector of all ones, and M  R . The top-k in M
n

corresponding to the k maximum values are then selected and their positions are in

IR k . (In the study presented here, k=50.) Top-k genes in the training set are selected
using positions in I . Cell lines are then selected as in Section 4.2.1 and stored in S' . A
learning algorithm is called on S ' , to induce model ht=1.
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Figure 6.3 Data flow diagram showing the hybrid approach to predicting in vivo drug
sensitivity.

(C) Top-k genes in the test set are selected using positions of I , and model h1 is applied
on the test set. Such processes (A, B, C) as in Figure 6.3 are repeated T times except that
q=15 (q=20, respectively) for t=2 (t=3, respectively). (In the study presented here, T=3.)
(D) For each test instance xi'  X' where i  1,..., p , the final prediction is obtained by
taking average prediction of T models [128]

H ( xi' ) 

1 T
ht ( xi' )

T t 1

(6.4)

6.3 Experiments and Results
In this section, the performance of the learning approaches is evaluated and compared
against the baseline approach proposed by Geeleher et al. [54]. Below, the experimental
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datasets in the study are described, experimental methodology, and then present
experimental results.

6.3.1 Experimental Datasets
482
The training set S  R 482 x 6539 consists of Y  R drug IC50 values and cell lines

expression data X  R 482 x 6538 (i.e., 482 cell lines and 6538 genes). The test set
X' R 24 x 6538 , which contains 24 breast cancer tumors of patients and 6538 genes. Both

the training set and test set were downloaded and processed according to the approach
proposed by Geeleher et al. [54] as follows. The drug IC50 values for docetaxel
(chemotherapy

drug)

[129,

130]

were

downloaded

from

(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The cell lines expression
data
[131]

were
(accession

downloaded
number

from
is

ArrayExpress

E-MTAB-783

or

repository
available

at

https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783).
Clinical trial data were downloaded from Gene Expression Omnibus (GEO) repository
(http://www.ncbi.nlm.nih.gov/geo/) with accession numbers GSE350 and GSE349
[132-134]. Data with accession number GSE350 (GSE349, respectively) contain 10 (14,
respectively) samples (i.e., instances). If the remaining of tumor was  25% (  25% ,
respectively), breast cancer patient would be considered as sensitive (resistant,
respectively) to docetaxel treatment. Following data processing steps of Geeleher et al.
[54].
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6.3.2 Experimental Methodology
12 drug sensitivity prediction algorithms are considered, which are listed and abbreviated
in Table 6.1. SVR+L (SVR+S, respectively) employs the same proposed approach by
Geeleher et al. [54]. RR is the baseline approach [54]. The remaining prediction
algorithms correspond to the prediction algorithms employing the proposed approaches.
Software used in this work included: support vector regression with linear and
sigmoid kernels [80], ridge regression [54], LASSO [135], R code for processing datasets
and performance evaluation [54].
R is used to write SMOTE [123], IPRed [122], and perform the experiments. The
Area Under the ROC Curve (AUC) [54] is employed to measure the accuracy of
prediction algorithms. The higher AUC an algorithm has, the better performance that
algorithm achieves. We assess the stability of prediction algorithm, where stable
prediction algorithm is the one for which prediction accuracy on the test set does not
change dramatically by small changes to the training set

[136, 137]. This kind of

assessment is important, where the best prediction algorithm is the one that outperforms
other algorithms many times. Statistical significance is measured between all pairs of the
prediction algorithms [76, 83].

6.3.3 Experimental Results
Table 6.2 shows the AUC of six prediction algorithms on several runs of the clinical trial
data used in the experiment. IS+SVR+L, O+SVR+S and IS+RR represent the top-3
prediction algorithms employing the learning approaches. The other three prediction
algorithms employ the existing approach: SVR+S, RR, and SVR+L. For each run, the
prediction algorithm having the best performance (i.e., the highest AUC) is shown in
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bold. Table 6.3 shows the p-values of Wilcox rank test (two tailed) between all pairs of
algorithms, where the algorithm with statistical significance is shown in bold. It can be
seen from Table 6.2 that IS+SVR+L is better than the prediction algorithms including
RR, the proposed approach by Geeleher et al. [54]. In particular, IS+SVR+L gives the
highest mean AUC (MAUC) of 0.907 and performed the best in 11 out of 11 runs. The
second best is O+SVR+S that gives MAUC of 0.883. The third best is IS+RR that
achieves MAUC of 0.874. SVR+S performs better than RR giving MAUC of 0.855. The
remaining prediction algorithms, RR and SVR+L, yield MAUC of 0.828 and 0.825,
respectively. IS+SVR+L and IS+RR keep approximately 75% of the cell lines provided
during learning the model (see column (“m+IS”) in Table 6.2). The removing of 25% cell
lines did not degrade the performance of IS+SVR+L and IS+RR, compared to the
baseline RR. Column (“m+O”) shows the number of cell lines which consists of all | m |
cell lines in the training set plus | m | generated synthetic cell lines. Combining the
generated synthetic cell lines with the cell lines in the learning stage improved the
performance of O+SVR+S when compared to RR (results shown in Table 6.2). These
results show the stable performance of the learning approaches under different settings of
the training set size.
In Table 6.3, the p-values of Wilcox rank test are reported to measure the
statistical significance between algorithms [76]. The p-values indicate that IS+SVR+L
statistically significantly outperforms the other algorithms.
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Table 6.2 AUC of Prediction Algorithms on the Test Set. The Column (“m”) Shows the
Number of Cell Lines (Instances) in the Training Set That Were Provided to Each
Prediction Algorithm. Column (“m+o”) Shows the Number of Cell Lines Used in
O+SVR+S. Column (“m+IS”) Shows the Number of Cell Lines Used in IS+SVR+L and
IS+RR. The Algorithm with the Highest AUC Is Shown in Bold. MAUC, Mean AUC
m

482
478
473
468
463
458
453
448
443
438
433
MAUC

IS
+
SVR+L
0.871
0.878
0.900
0.907
0.892
0.900
0.914
0.921
0.928
0.942
0.921
0.907

O
+
SVR+S
0.864
0.864
0.871
0.892
0.871
0.892
0.878
0.892
0.914
0.907
0.871
0.883

m+O

964
956
946
936
926
916
906
896
886
876
866
-

IS
+
RR
0.850
0.871
0.871
0.871
0.871
0.871
0.885
0.885
0.878
0.878
0.878
0.874

m+IS

SVR+S

RR

SVR+L

361
358
354
351
347
343
339
336
332
328
324
-

0.842
0.871
0.864
0.857
0.857
0.857
0.842
0.864
0.857
0.857
0.842
0.855

0.814
0.814
0.821
0.821
0.821
0.821
0.835
0.835
0.842
0.842
0.842
0.828

0.835
0.814
0.800
0.821
0.835
0.850
0.828
0.835
0.814
0.821
0.828
0.825

Table 6.3 P-Values of Wilcox Rank Test (Two-Tailed) between All Pairs of Prediction
Algorithms. Shown in Bold Is the Prediction Algorithm with Statistical Significance
Where p<0.05

IS+SVR+L
O+SVR+S
IS+RR
SVR+S
RR

O+SVR+S
0.0033
-

IS+RR
0.0033
0.0727
-

SVR+S
0.0033
0.0051
0.0051
-

RR
0.0033
0.0033
0.0033
0.0051
-

SVR+L
0.0033
0.0033
0.0033
0.0033
0.7789

In Figure 6.4 all prediction algorithms are ranked from the highest to the lowest
MAUC. Each MAUC is calculated over the 11 runs on the clinical data. It can be seen
from Figure 6.4 that the three proposed approaches outperform RR [54] ranked the 9th
w.r.t MAUC.
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Figure 6.4 Mean AUC (MAUC) of prediction algorithms. Prediction algorithm with
highest MAUC (to be ranked first from left) and lowest MAUC (to be ranked the last
from the left.
Figure 6.5 shows the predictions of three prediction algorithms on the test set
(clinical data of 24 breast cancer patients.) using training set with m=482 (i.e., the
complete training set without any change). Figure 6.5(a) (Figure 6.5(b), Figure 6.5(c),
respectively) shows the predictions of IS+SVR+L (SVR+S, RR, respectively). Figures
6.5(a) and 6.5(b) show the difference between the predicted drug sensitivity in breast
cancer patients was statistically significant (P= 0.001 from a t-test) between trial-defined
sensitivity and resistant groups for IS+SVR+L and SVR+S, respectively. RR (see Figure
6.5(c)) achieved statistical significance (P= 0.004 from a t-test). Training set size is 482
when learning a model. In Figure 6.5(d) the ROC reveals AUC of 0.871, 0.842, and 0.814
for IS+SVR+L, SVR+S, and RR, respectively, as in Table 6.2.
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Figure 6.5 Prediction of docetaxel sensitivity in breast cancer patients. Strip chart a
(b,c, respectively) showing the difference in predicted drug sensitivity for individuals
sensitive or resistant to docetaxel treatment using IS+SVR+L (SVR+S, RR,
respectively) prediction algorithm. (d) ROC curves of prediction algorithms showing
the proportion of true positives against the proportion of false positives. ROC,
receiver operating characteristic.

It is worth mentioning that the performance of other machine learning algorithms
are assessed, including random forests [78], support vector regression with polynomial
kernel of degree 2, support vector regression with Gaussian kernel. However, these
algorithms did not show good predictive performance (results not shown here).
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6.4 Summary
This chapter introduces three learning approaches to improve the prediction of drug
sensitivity. The first learning approach employs (i) IPRed algorithm to select cell lines.
The second learning approach employs (i) SMOTE algorithm to generate synthetic cell
lines. The third learning approach employs (i) LASSO for gene selection, (ii) IPRed
algorithm to select cell lines, and (iii) ensemble averaging of predictions obtained from
different models.
The learning approaches use two machine learning algorithms: support vector
regression and ridge regression. The experimental results on clinical trial data of breast
cancer patients demonstrate the stable performance of the learning approaches achieving
statistically significant improvements over the existing approach.
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CHAPTER 7
A LINK PREDICTION APPROACH TO CANCER DRUG SENSITIVITY
PREDICTION

7.1 Introduction
Predicting the response to a drug for cancer disease patients based on genomic
information is an important problem in modern clinical oncology. This problem occurs in
part because many available drug sensitivity prediction algorithms do not consider better
quality cancer cell lines and the adoption of new feature representations; both lead to the
accurate prediction of drug responses. By predicting accurate drug responses to cancer,
oncologists gain a more complete understanding of the effective treatments for each
patient, which is a core goal in precision medicine.
In this chapter, cancer drug sensitivity is modeled as a link prediction, which is
shown to be an effective technique.

The proposed link prediction algorithms are

evaluated and compared with an existing drug sensitivity prediction approach based on
clinical trial data. The experimental results based on the clinical trial data show the
stability of the proposed link prediction algorithms, which yield the highest area under
the ROC curve (AUC) and are statistically significant.

7.2 Related Work
7.2.1 Link Prediction in Gene Regulatory Networks
Given m genes, in which each gene has n expression values, their gene expression
profiles can be denoted by G

m n

, which contains m rows—each row corresponds to a

gene—and n columns—each column corresponds to an expression value [16].
101

To learn a model, the regulatory relationships (i.e., labels) among the genes are needed to
be known, which are stored in the matrix H

p3

. H contains p rows—each row

shows a known regulatory relationship between two genes—and three columns. The first
column shows the source gene (i.e., the transcription factor). The second column shows
the target gene, and the third column shows the label, which is denoted as +1 (i.e., present
link) when the source gene regulates the target gene or -1 (i.e., missing link) when the
source gene does not regulate the target gene. Thus, H represents the observed (i.e.,
known) gene regulatory network. To learn a model, the training set D

p  2 n1

is needed

to be constructed. The p examples in D are constructed as follows: For each pair of genes
with the associated label in matrix H , the n expression values of each pair of genes in
matrix G are extracted, and the concatenation of the n expression values of each pair of
genes and the corresponding label is performed. For example, consider the ith example in
the training set D, which is denoted by Di and defined as

Di  [g 1i ,g i2,...,g in,g 1l ,g l2,...,g ln , yi ] ,

(7.1)

1
2
n
where g i ,g i ,...,g i are the n expression values of g i (also called the expression

1
2
n
profile of gi ), g l ,g l ,...,g l are the n expression values of gl , and yi {1, 1} . The

ith example of the test set, T, is denoted by Ti and constructed as follows:

Ti  [g1i ,g i2,...,gin,g 1j,g 2j,...,g nj ] ,

(7.2)

1
2
n
where g i ,g i ,...,g i are the n expression values of gi , and g1j,g 2j,...,g nj are the n

expression values of g j . These feature vector definitions have been used by the existing
supervised inference of gene regulatory networks [4, 5, 7, 16, 17, 110]. After constructing
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the feature vectors, the learning algorithm is applied to D to induce (i.e., learn) the model
h. The resulting model is used to perform prediction on T . The known regulations among
genes enable using the induction principle to predict new regulations (i.e., labels): If gene

g j has an expression profile that is similar to gene gl , which is known to be regulated by

gi , then g j is likely to be regulated by gi [8]. Genes with similar expression profiles
that are likely to be co-regulated have been used in the unsupervised clustering of
expression profiles [138-140].

7.2.2 Cancer Drug Sensitivity Prediction
The gene expression profiles denoted by X

pn

, which contains p rows—each row

corresponds to a cell line or a sample—and n columns—each column corresponds to a
gene. Y  ( y1,..., y p )T consists of the corresponding real-value drug responses (i.e., drug
IC50 values) to X , where Y 

p

(i.e., the p-dimensional column vector). IC50 is defined

as the concentration of a compound that is required to produce 50% cancer cell growth
p
inhibition after 48 hours of treatment [66]. A training set is defined as D={(gi , yi )}i1 ,

where gi  Xand yi  Y. Let the ith example of the training set D , denoted by Di , be
defined as

Di  [g 1i ,g i2,...,g in , yi ] ,

(7.3)

1
2
n
where g i ,g i ,...,g i represent the n genes of the cancer cell line gi (also called the

expression

profile

of

gi ), and

yi 
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is

the

drug

response

value.

The ith example of the test set T, denoted by Ti , is constructed as follows:

Ti  [g 1j,g 2j,...,g nj ] .

(7.4)

These feature vector definitions have been used by existing supervised cancer drug
sensitivity prediction algorithms [52-54, 56, 66, 141, 142]. A learning algorithm is
applied to D to induce model h, which is subsequently used to perform predictions on

T . Known cancer cell lines with associated drug responses enabled the use of the
induction principle: If tumor g j has an expression profile similar to gi , then g j is likely
to have a drug response value closer to the drug response value associated with gi .

7.3 Methods
The fundamental task of cancer drug sensitivity prediction is to correctly predict the
response of a tumor to the drug. This prediction is typically achieved based on how
closely this tumor (also referred to as the test example) is related to a known cancer cell
line with the associated drug response. Proximity, which is a measure of closeness, lies at
the heart of both link prediction in gene regulatory networks and cancer drug sensitivity
prediction [8, 143].

7.3.1 Feature Vector Construction
To bridge link prediction and cancer drug sensitivity, the feature representations of
Equations (7.3) and (7.4) are transformed to the corresponding Equations (7.1) and (7.2)
p
as follows: Let {(gi , yi )}i1  D be the cancer cell lines, where D
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p n1

,b  p .

3. Find the k’ nearest neighbors g1* , g*2 ,..., g*k ' of each gi in D . (In this study
k’=1.)
4. Generate synthetic cell lines along the lines between the randomly selected k’
nearest neighbors and each gi using the following lines of code:

2.1 for i=1 to p
2.1.1 for j=1 to k’
2.1.1.1 b  b  1
2.1.1.2 gb  gi  (g*j  gi )
2.1.1.3 Store [gi , gb , yi ] in G
2.1.2 end for
2.2 end for

where the index b refers to only those synthetic cell lines (e.g., g p1 when the index
b=p+1) that differ from the cell lines in D , whose indexes run from 1 to p,   0.3 ,
and G 

p  2 n 1

is the new feature representation of the cell lines of the training set.

Step 2.1.1.2 creates the synthetic cell line g b . Let G i be the ith row of G , defined as

Gi  [g1i ,gi2,...,gin,g1p1,g 2p1,...,g np1, yi ] ,
where

g 1i ,g i2,...,g in

represent

n

genes

of

the

cancer

(7.5)

cell

line

gi ,

g 1p1,g 2p1,...,g np1 represent the synthetic n genes of the synthetic cancer cell line

g p1 , and yi 

denotes that both gi and g p1 are linked by sharing the same drug
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q
response value. Let {(gi , yi )}i 1  T be the test set of tumors, where T

q n

. Note

that Steps 1–2 are similar to the Synthetic Minority Oversampling Approach (SMOTE)
[123, 144], However, Step 2.1.1.3 is a different core step in which the dimensionality
(i.e., the number of features) is increased instead of the size, as SMOTE does. We then
apply the previous steps (i.e., Steps 1 and 2—changing Step 2.1 to i=1 to q and Step
2.1.1.3 to Store [gi , gb ] in G ' ) to T to obtain G' 

q2n

. G ' is the new feature

representation of the clinical trial expression data of the test set. Let G i' be the ith row of
G ' , which is defined as

Gi'  [g 1j,g 2j,...,g nj,g 1p2k ' 1,g 2p2k ' 1,...,g np2k ' 1 ] .

(7.6)

where g 1j,g 2j,...,g nj represent n genes of tumor g j , and g 1p2k ' 1,g 2p2k ' 1,...,g np2k ' 1
represent n synthetic genes of the synthetic tumor g p2 k ' 1 . A learning algorithm is called
on the training set, G to induce the model h, which is subsequently used to perform
predictions on the test set G ' . The logic behind the mechanism of the induction principle
is as follows: If the expression profiles of the pair of tumors (g j , g p2 k ' 1 ) are similar to
those of the cell lines (gi , g p1 ) , then (g j , g p2 k ' 1 ) is likely to have a drug response value
closer to the drug response value associated with (gi , g p1 ) . In machine learning terms, let

(gi , g p1, yi ) 

2 n1

be a row feature vector that encodes information about the pair of

cancer cell lines (gi , g p1 ) . Given a new pair of tumors encoded by (g j , g p2k 1 ) , if
'

(g j , g p2 k ' 1 ) has feature values similar to (gi , g p1 ) , whose label is yi , then (g j , g p2 k ' 1 )
is more likely to have a closer response (i.e., label) value to yi .
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7.3.2 Notations and Algorithms
7.3.2.1 Notations.

To provide a better understanding of the proposed prediction

algorithms, the notations used throughout the remainder of this paper are summarized as
follows: Matrices are denoted by boldface uppercase letters, e.g., matrix X . The row
vectors of a matrix is denoted by boldface uppercase letters with a subscript, e.g., X j is
the jth row of matrix X . Vectors are denoted by boldface lowercase letters, e.g., vector v .
Vector entries are denoted by italic lowercase letters with a subscript, e.g., vi is the ith
entry of vector v . The number of entries of a vector is denoted by the cardinality symbol,
e.g. | v | is the number of elements of vector v . Scalars are denoted by italic lowercase
letters, e.g., m. f , f * ,and h are reserved letters, where f refers to a learning algorithm
(e.g., SVR), f * refers to an induced (i.e., learned) model, and h is an induced model
used to perform predictions on the test set. specific learning algorithms and induced
models are referred to using subscripts. For example, fi ( fi* ,respectively) denotes the ith
learning algorithm and induced model, respectively.
7.3.2.2 The Supervised Link Prediction Algorithm (A1). Figure 7.1 outlines the
supervised link prediction algorithm, which is designated as A1, as follows. (A) Given a
training set of cancer cell lines with associated drug responses D
tumors T 

qn

p  n 1

and a test set of

that are described as in cancer drug sensitivity prediction subsection.

(B) Transform D and T using the feature vector construction method described in
feature vector construction subsection, to obtain a new feature representation G 
for the training set and a new feature representation G ' 

q2n

p  2 n 1

for the test set.

(C) The proposed link filtering method aims to select a better quality training set that
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works as follows: Each row (i.e., feature vector) in the new representations G and G '
can be viewed as a cell line or tumor, represented by a 2n-dimensional row vector when
the drug responses of the training set G are excluded. Each cell line [122] gi in the
training set G is weighted by the minimum distance from the cell line gi to all tumors

g'j in the testing set G ' :
wi  dist(gi , g'j* ) with j*  arg min dist(gi , g'j ) ,
j{1,...,q}

where gi 

2n

, g 'j 

2n

(7.7)

, wi is the weight assigned to gi , and dist(gi , g'j* ) is the

Euclidean distance. Let w  (w1 , w2 ,..., wp ) . Then, the following steps are performed to
select better quality training cell lines using the modified version of Query by Committee
(QBC) [145-147]:
1. Let med be the median of the w vector of weights of each gi in G
2. Let X  {(g,
i yi ) | (g,
i yi )  G and wi  med}
3. Let X'  {gi | gi in G and wi  med}
4. Let Z  {(g,
i yi ) | (g,
i yi )  G and wi  med}
5. Let Z'  {gi | gi in G and wi  med}
6. Apply the learning algorithm, f1 or f 2 , to X or Z , respectively, to induce the model

f1* ( f 2* ,respectively) . (In this study, ridge regression is chosen as the learning algorithm)
7. Apply the model

f1* ( f 2* , respectively) to perform predictions on Z' or X′,

respectively) and store predictions in v or b respectively)
8. Let q = | v |  | b |
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9. Let P  ( v, b)T
10. Let r  {yi | yi in Z}and e { yi | yi in X}
11. Let R  (r, e)T
12. j*  arg max
j{1,2}

1
( Pj  R j ) 2
q

X if j*  1
13. S  
Z otherwise

Z if j*  1
14. U  
X otherwise
QBC aims to partition the training set G into S and U , where S or U is treated
as the labeled or unlabeled set, respectively. QBC is accompanied by two major items:
(1) the set of models (i.e., the committee) that are consistent with all labeled cell lines in
S ; and (2) given the unlabeled set, U , the QBC applies the models (i.e., the committee)

to U to select the unlabeled tumor that maximizes the disagreement because it represents
the most important tumor that will be added to S , in addition to querying the drug
response value associated with the tumor. The main obstacle of the first major step of
QBC is to find models that agree on all the labels of set S with reasonable computational
complexity [147]. Thus, the first major step is relaxed according to Steps 1–14, where
relaxation is practiced to address the first major step [145]. Steps 1–5 partition the
training set into X and Z using the median as a threshold, where X or Z contains cell
lines from G that are near or far, respectively, from the test set G ' . Steps 6–14 aim to
assign the set of cell lines where the model incurred fewer errors (or more errors,
respectively) to S or U, respectively. The logic behind these steps (i.e., Steps 13–14) is
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that S or U, respectively, is wanted to contain the set of cell lines that are more or less,
respectively, correctly labeled by one model (i.e., one member of the committee). Steps
1–14 are motivated by other QBC approaches [145-147], in which the success of the
second major step of QBC is dependent on the first major step.
15. Repeat k’’ times

f1, f2 ,..., ft on S to induce the models (i.e.,

15.1. Apply the learning algorithms

committee) f1* , f 2* ,..., ft * . (In this study, t=3, and the learning algorithms include
support vector regression with a linear kernel (SVR+L), SVR with a polynomial
kernel of degree 5, and SVR with a sigmoid kernel (SVR+S))
t

15.2. Let wi' be the weight of the ith model fi * where w'   w'i  1 . (In this study,
i 1

1
t=3 and w1'  w2'  w3'  )
3
t

15.3. For each g j in U , let f ' (g j )   wi' fi * (g j ) where fi* (g j ) is the prediction of
i 1

the ith learned model on the jth cell line g j , and f ' (g j ) is the weighted ensemble
average of the jth cell line g j .
15.4. Find the cell line g j* that maximizes the disagreement:
t

w ( f
j{1,...,|v|}

15.4.1. j*  arg max

i 1

'
i

*
i

(g j )  f ' (g j ))2

15.5. Find the label y j* of g j* in U
15.6. Add the pair (g j* , y j* )U to S and remove the pair (g j* , y j* ) from U
15.7. Update | v || v | 1
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16. Return S

Figure 7.1 Data flow diagram that shows the proposed supervised link prediction
algorithm to predict in vivo drug sensitivity.

Steps 15.1–15.4.1 return the index of the cell line in set U that maximizes the
disagreement, where disagreement is defined in Step 15.4.1 [148]. Then, (g j* , y j* ) is
added to or removed from S or U respectively, as shown in Steps 15.5–15.6. (In this
study, k’’=5.) Step 15.7 updates |v| as the size of U is reduced after each iteration. S (Step
16) is the returned set that will be used as the training set. (D) A learning algorithm is
applied on S to induce the model h. Finally (i.e., (E in Figure 7.1)), model h is applied to
perform predictions on the test set G ' (i.e., the set of new feature representations of the
clinical trial expression data). In the remainder of this paper, the supervised link
prediction algorithms that employ the following machine learning algorithms (SVR and
RR) is referred to as: A1+SVR+L, A1+SVR+S, and A1+RR (abbreviations are listed in
Table 7.1).
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Table 7.1 Abbreviations of the Drug Sensitivity Prediction Algorithms
Abbreviation Prediction Algorithm
A1+SVR+L The supervised link prediction algorithm using support vector regression
with a linear kernel
A1+SVR+S The supervised link prediction algorithm using support vector regression
with a sigmoid kernel
A1+RR
The supervised link prediction algorithm using ridge regression
A2+SVR+L The extended supervised link prediction algorithm using support vector
regression with a linear kernel
A2+SVR+S The extended supervised link prediction algorithm using support vector
regression with a sigmoid kernel
A2+RR
The extended supervised link prediction algorithm using ridge regression
B+SVR+L
The baseline approach using support vector regression with a linear kernel
B+SVR+S
The baseline approach using support vector regression with a sigmoid
kernel
B+RR
The baseline approach using ridge regression

7.3.2.3 The Extended Supervised Link Prediction Algorithm (A2).

Figure 7.2

shows the data flow diagram of the extended supervised link prediction (A2). Steps (A),
(B), and (C) are the same as Steps (A), (B), and (C) of the supervised link prediction
algorithm. (D) Mahoney et al. [149] proposed CUR matrix decomposition as a
dimensionality reduction paradigm that aims to obtain a low rank approximation of
matrix S , which is expressed in terms of the actual rows and columns of the original
matrix S :

S  CUR ,

(7.8)

where C consists of a small number of the actual columns of S , R consists of a small
number of the actual rows, and U is a constructed matrix that guarantees that CUR is
close to S . k genes are selected based on their importance score (refer to Equation 7.9),
which depends on matrix S and the input rank parameter l (in this study, the default
parameter value for l in CUR function is used [150].) If vj is the j-th element of the
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  th right singular vector of S , then the normalized statistical leverage scores are equal
to

j 
2n

for all j=1..2n, and



j

1 l  2
 (v j )
l 1

(7.9)

 1 . Statistical leverage scores have been successfully employed

j1

in data analysis to identify the most influential genes and outlier detection [149]. A high
statistical leverage score for a given gene indicates that the gene is regarded as an
important (i.e., influential) gene. A low statistical leverage score for a given gene
indicates that the gene is regarded as a less important gene. The indexes of the highest k
leverage scores are stored in I ; these correspond to the positions of the k most influential
genes in matrix S . k genes are selected from the training set S using their positions in I
and store subsampled cell line expression data with k genes in S ' . (E) A learning
algorithm is called on S ' to induce model h. (F) The k genes in the test set G ' are
selected using their positions in I and stored in G '' .
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Figure 7.2 Data flow diagram showing the major steps in the proposed extended
supervised link prediction algorithm to predict in vivo drug sensitivity.

Model h is applied on the test set G '' to perform predictions. The extended supervised
link prediction algorithms that employ machine learning algorithms is referred to as
A2+SVR+L, A2+SVR+S, and A2+RR (see Table 7.1).

7.4 Experiments and Results
The proposed approach is empirically evaluated and compared against the baseline
approach proposed by Geeleher et al. [54] on clinical trial datasets. This section first
describes the datasets and experimental methodology and presents the experimental
results.

7.4.1 Datasets
Data Pertaining to Breast Cancer. The training set D 

482  6539

contains 482 cancer

cell lines, 6,538 genes, and drug IC50 values that correspond to a 482-dimensional column
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vector. The test set T 

24  6538

consists of 24 breast cancer tumors and 6538 genes. The

drug IC50 values for docetaxel (a chemotherapy drug) [129, 130] were downloaded from
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The cell line expression data
were

downloaded

(accession

number

from
is

the

ArrayExpress

E-MTAB-783,

repository

also

[131]

available

at

https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783).
The clinical trial data corresponding to the test set were downloaded from the Gene
Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo/) with accession
numbers GSE350 and GSE349 [132-134]. The data with accession numbers GSE350 and
GSE349 contain 10 and 14 samples, respectively. If the remaining tumor was <25% or
≥25%, a breast cancer patient is considered to be sensitive or resistant, respectively, to
docetaxel treatment. All the data were downloaded and processed according to the
approach proposed by Geeleher et al. [54].
Data Pertaining to Multiple Myeloma. The training set D 

280  9115

contains 280

cancer cell lines, 9,114 genes, and drug IC50 values that correspond to a 280-dimensional
188  9114

column vector. The test set T 

is composed of 188 multiple myeloma patients

and 9,114 genes. The drug IC50 values for bortezomib [151, 152] were downloaded from
(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/), and the data for the cancer cell
lines
(accession

were

downloaded
number

is

from

the

E-MTAB-783

ArrayExpress
or

repository

available

at

https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783).
The clinical trial data corresponding to the test set were downloaded from the Gene
Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo/) with accession
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number GSE9782 [153]. The data were downloaded, processed and mapped according to
Geeleher et al. [54].
Data pertaining to non-small cell lung cancer and triple-negative breast cancer. The
training sets correspond to an 258  9508

matrix and an 497  9621 matrix for

non-small cell lung cancer and triple-negative breast cancer, respectively. The test sets
correspond to an 25  9507 matrix (excluding labels) and an 24  9620 matrix
(excluding labels) for non-small cell lung cancer and triple-negative breast cancer,
respectively.

The

data

were

downloaded

from

(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54].

7.4.2 Experimental Methodology
Kernel-based methods, such as SVM and support vector regression (SVR), are popular
machine learning algorithms and exhibit state-of-art performance in many applications
[154, 155], including biological fields [156]. Therefore, in the experiments, SVR with
linear kernel (SVR+L) and sigmoid kernel (SVR+S) are used as machine learning
algorithms, coupled with the proposed link prediction algorithms (A1 or A2). The
proposed link prediction algorithms are also employed with linear ridge regression (RR).
In total, 9 drug sensitivity prediction algorithms are considered, as summarized in Table
7.1.
Each prediction algorithm was trained on the same training set, whose labels are
continuous to yield models (see Methods section). Then, each model is applied to the
same test set to yield predictions, as discussed in Methods section. The test set consists of
the clinical trial expression data of patients, including baseline tumor expression data
from primary tumor biopsies prior to treatment with an anticancer drug. The responses
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(i.e., labels) of the test set are categorical (e.g., either “sensitive” or “resistant”). These
labels were clinically evaluated by the degree of reduction in tumor size to the given drug
[54].
To evaluate whether the proposed approach exhibits stable superior performance
as the sample size changes, the sample size for the training set was gradually reduced by
1% to 4% in each run. That is, 5 runs with sample sizes of 482, 478, 473, 468, and 463
and 280, 278, 275, 272, and 269 were performed for the two datasets, respectively.
The accuracy of the prediction algorithms is measured using the Area Under the
ROC Curve (AUC), as shown in [54]. The higher is the AUC of an algorithm is, the
better the performance that it achieved is. The mean of the AUC values averaged over the
five runs of the test set is denoted as the MAUC. A run of the test set is defined as
predictions of a learned model on the test set, such that the model is learned from the
training set. The size of this training set is varied to assess the stability of prediction
algorithms, in which a stable prediction algorithm is one for which the prediction
accuracy on the test set does not change dramatically due to small changes in the size of
the training set [136, 137]. This type of assessment is important in biological systems, in
which the best prediction algorithm outperforms other algorithms many times in the
conducted experiments. Statistical significance is measured between all pairs of the
prediction algorithms.
The software employed in this study included support vector regressions with
linear and sigmoid kernels in the LIBSVM package [80], ridge regression [54], gene
selection using CUR and topLeverage functions in the rCUR package [150], and R code
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for processing the datasets and performance evaluation [54]. R is used to write the code
for the link prediction algorithms and perform the experiments.

7.4.3 Experimental Results
Tables 7.2 and 7.3 show the AUC of 9 docetaxel and bortezomib, respectively, sensitivity
prediction algorithms on clinical breast cancer or multiple myeloma trial data. For each
variation in training set size the prediction algorithm with the best performance (i.e., the
highest AUC) on the clinical trial data is shown in bold.
Table 7.2 shows that the proposed prediction algorithms perform better than the
baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) including B+RR, which
is a prediction algorithm proposed by Geeleher et al. Row “m” and “d”, shows the
number of cell lines or genes, respectively, in the training set that were provided to each
prediction algorithm. The same training set was provided to each prediction algorithm.
Rows “m+A1” and “m+A2”, or “d+A1” and “d+A2” show the number of selected cell
lines or genes, respectively, that were used in the prediction algorithms that employed the
proposed approach for learning the models. The results of the proposed prediction
algorithms are dominant compared with the baseline prediction algorithms that employ
clinical trial data of breast cancer in terms of the AUC of four runs and the MAUC. In
contrast to the baseline prediction algorithms, the performance of the proposed prediction
algorithms on the test set outperforms in terms of the AUC when the training set size is
reduced.
Table 7.3 shows that the proposed prediction algorithms perform better than the
baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) and B+RR, which is a
prediction algorithm proposed by Geeleher et al. Row “m” or “d”, respectively, shows
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the number of cell lines or genes, respectively, in the training set that were provided to
each prediction algorithm. The same training set is provided to each prediction algorithm.
Rows “m+A1” and “m+A2” or “d+A1” and “d+A2” show the number of selected cell
lines or genes, respectively, used in the prediction algorithms that employ the proposed
approach for learning the models. The results of the proposed prediction algorithms are
dominant compared with the baseline prediction algorithms on the clinical breast cancer
trial data in terms of the AUC of each run and the MAUC. In particular, A2+RR achieves
the highest mean AUC (MAUC) of 0.693 and performed the best in all runs. In contrast
to the baseline prediction algorithms, the performance of A2+RR on the test results in the
best AUC as the training set size is reduced, which indicates that A2+RR has a stable
performance.

Table 7.2 AUC Scores of Docetaxel Sensitivity Prediction Algorithms in Breast Cancer
Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in Bold. MAUC
= Mean AUC
M
D
A1+SVR+L
A1+SVR+S
A1+RR
m+A1
d+A1
A2+SVR+L
A2+SVR+S
A2+RR
m+A2
d+A2
B+SVR+L
B+SVR+S
B+RR

482
6538
0.878
0.871
0.850
246
13076
0.892
0.871
0.857
246
13000
0.835
0.842
0.814

478
6538
0.864
0.857
0.828
244
13076
0.857
0.850
0.842
244
13000
0.814
0.871
0.814

473
6538
0.871
0.814
0.821
242
13076
0.864
0.814
0.835
242
13000
0.800
0.864
0.821
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468
6538
0.857
0.828
0.850
239
13076
0.864
0.814
0.835
239
13000
0.821
0.857
0.821

463
6538
0.871
0.878
0.842
237
13076
0.864
0.878
0.835
237
13000
0.835
0.857
0.821

MAUC
0.868
0.849
0.838
0.868
0.845
0.841
0.821
0.858
0.818

Table 7.3 AUC Scores of Bortezomib Sensitivity Prediction Algorithms in Multiple
Myeloma Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in
Bold. MAUC = Mean AUC
m
d
A1+SVR+L
A1+SVR+S
A1+RR
m+A1
d+A1
A2+SVR+L
A2+SVR+S
A2+RR
m+A2
d+A2
B+SVR+L
B+SVR+S
B+RR

280
9114
0.668
0.638
0.685
145
18228
0.678
0.661
0.686
145
9114
0.613
0.602
0.614

278
9114
0.669
0.623
0.673
144
18228
0.678
0.657
0.689
144
9114
0.609
0.600
0.611

275
9114
0.665
0.637
0.679
143
18228
0.671
0.659
0.696
143
9114
0.622
0.601
0.603

272
9114
0.663
0.642
0.677
141
18228
0.668
0.659
0.695
141
9114
0.628
0.605
0.607

269
9114
0.656
0.662
0.690
140
18228
0.654
0.668
0.699
140
9114
0.632
0.598
0.606

MAUC
0.664
0.640
0.681
0.670
0.661
0.693
0.621
0.601
0.608

Table 7.4 shows the p-values of the two-tailed Wilcoxon signed rank test [76, 83]
to measure the statistical significance between the prediction algorithms using clinical
trial data of breast cancer and multiple myeloma patients. The p-values indicate that
A1+SVR+L and A2+SVR+L prediction algorithms significantly outperformed the
baseline prediction algorithms B+SVR+L, B+SVR+S, and B+RR. The remaining
prediction algorithms that employ the proposed approach are not statistically different
from B+SVR+S.
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Table 7.4 P-Values of Wilcoxon Signed Rank Test (Two-Tailed) between All Pairs of
Prediction Algorithms. Values with Statistical Significance (p<0.05) Are Shown in Bold
A1+SVR+S

A1+RR

A2+SVR+L

A2+SVR+S

A2+RR

B+SVR+L

B+SVR+S

B+RR

A1+SVR+L

0.0160

0.5092

0.3077

0.0836

0.8807

0.0051

0.0149

0.0051

A1+SVR+S

-

0.1675

0.0208

0.1282

0.0929

0.0051

0.1830

0.0080

A1+RR

-

-

0.2846

0.5418

0.0672

0.0051

0.1388

0.0076

A2+SVR+L

-

-

-

0.0587

0.5754

0.0051

0.0207

0.0047

A2+SVR+S

-

-

-

-

0.1388

0.0069

0.0836

0.0124

A2+RR

-

-

-

-

-

0.0076

0.1675

0.0051

B+SVR+L

-

-

-

-

-

-

0.5754

0.1609

B+SVR+S

-

-

-

-

-

-

-

0.2040

Figures 7.3 and 7.4 show the ranking of all prediction algorithms from the highest
to the lowest MAUC using clinical trial data pertaining to breast cancer and multiple
myeloma patients, respectively. Each MAUC is calculated over the 5 runs of the clinical
trial data. As shown in Figures 7.3 and 7.4, the proposed prediction algorithms
outperform the baseline prediction algorithms [54] w.r.t the MAUC.
Figure 7.5 shows the predictions of three prediction algorithms on the test set
(clinical data samples of 24 breast cancer patients) when the prediction algorithms were
trained on a dataset with the size m=482 (i.e., the complete training set without any
reductions).
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Figure 7.3 Mean AUC (MAUC) results of docetaxel sensitivity prediction algorithms in
breast cancer patients ranked from the highest MAUC (left) to the lowest MAUC (right).

Figure 7.4 Mean AUC (MAUC) of bortezomib sensitivity prediction algorithms in
multiple myeloma patients ranked from highest MAUC (left) to lowest MAUC (right).
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Figure 7.5 Prediction of docetaxel sensitivity in breast cancer patients. Strip charts and
boxplots in (a), (b), and (c) show the differences in predicted drug sensitivity for
individuals who are sensitive or resistant to docetaxel treatment using the prediction
algorithms A2+SVR+L, A1+SVR+L and B+SVR+S, respectively, while (d) shows the
ROC curves of prediction algorithms, revealing the proportion of true positives
compared to the proportion of false positives. ROC = receiver operating characteristics.

Figure 7.5(a), Figure 7.5(b) and Figure 7.5(c) show the predictions of A2+SVR+L
A1+SVR+L and B+SVR+S, respectively. For A2+SVR+L in Figure 7.5(a), the
difference between the predicted drug sensitivity in breast cancer patients was highly
statistically significant (P= 472 106 from the result of a t-test) between the trial-defined
sensitive and resistant groups. The result of A1+SVR+L in Figure 7.5(b) was also highly
123

statistically significant (P= 614 106 from a t-test). B+SVR+S in Figure 7.5(c) achieved
statistical significance (P= 1176 106 from a t-test). Higher sensitivity or higher resistance,
respectively, denote the greater or lesser effectiveness of the drug. In Figure 7.5(d), the
ROC reveals AUC values of 0.892, 0.878 and 0.842 for A2+SVR+L, A1+SVR+L, and
B+SVR+S, respectively, as shown in Table 7.2.
In Figure 7.6, the predictions of three prediction algorithms are reported on the
test set (clinical trial data of 188 multiple myeloma samples of patients) when prediction
algorithms learned models from a training set of size m=280 (i.e., the training set without
any reductions). Figure 7.6(a) Figure 7.6(b) and Figure 7.6(c) show the predictions of the
A2+RR, A1+RR, and B+RR, algorithms, respectively. For A2+RR (Figure 7.6(a)), the
difference between the predicted drug sensitivity in multiple myeloma patients was
highly significant (P= 8106 from a t-test) between trial-defined responder groups and
non-responder groups. The result of A1+RR was also highly significant (P= 11106 from
a t-test), while B+RR achieved statistically significant result (P= 2612106 from a t-test).
Figure 7.6(d), Figure 7.6(e), and Figure 7.6(f)) break down the responders and
non-responders of Figure 7.6(a), Figure 7.6(b), and Figure 7.6(c), respectively, to CR,
PR, MR, NC or PD. In Figure 7.6 (g), The ROC reveals AUCs of 0.686, 0.685, and 0.614
for A2+RR, A1+RR, and B+RR, respectively, as shown in Table 7.3.
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Figure 7.6 Prediction of bortezomib sensitivity in multiple myeloma
patients. Strip charts and boxplots in (a), (b), and (c) show predicted drug
sensitivity for in vivo responders and non-responders to bortezomib
using A2+RR, A1+RR and B+RR prediction algorithms, respectively.
Strip charts and boxplots d, e, and f further break down responders and
non-responders of strip charts and boxplots a, b, and c as showing CR,
PR, MR, NC or PD using A2+RR, A1+RR and B+RR, respectively,
prediction algorithms. (g) ROC curves illustrating estimated prediction
accuracy of prediction algorithms. CR, complete response; PR, partial
response; MR, minimal response; NC, no change; PD, progressive
disease.
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The performance of prediction algorithms is also evaluated on the clinical trial
data pertaining to non-small cell lung cancer patients and the triple-negative breast cancer
patients. Similar results are observed that the proposed prediction algorithms noticeably
outperform the baseline prediction algorithms (See Appendix A: Table A.1 and Table
A.2).
It is worth mentioning that the performance of other machine learning algorithms
was also assessed, including random forests [121], support vector regression with a
polynomial kernel of degree 2, and support vector regression with a Gaussian kernel.
Moreover, other dimensionality reduction methods were applied such as principal
component analysis (PCA) [157] based on the prcomp package in R [91], sparse PCA
[158, 159], non-negative and sparse cumulative PCA, and negative and sparse PCA [160,
161]. However, they did not exhibit acceptable predictive performance; consequently,
their results are not included in this paper.

7.5 Summary
In this chapter, a link prediction approach to cancer drug sensitivity prediction is
introduced. The benefit of introducing a link prediction approach is to obtain satisfactory
feature representation for better prediction performance. Two algorithms that employ the
link prediction approach are proposed: (1) A supervised link prediction algorithm, which
selects better quality training cancer cell lines using a modified version of QBC; and
(2) An extended supervised link prediction, which selects both better training cancer cell
lines and a subset of important genes using state of the art CUR matrix decomposition.
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In this study, the link prediction algorithms use two machine learning algorithms:
support vector regression and ridge regression. The experimental results demonstrate the
stability of the proposed link prediction algorithms, which outperform drug sensitivity
prediction algorithms of an existing approach as measured by their higher and statistically
significant AUC scores.
Gene (feature) selection is important to the success of the proposed method. After
many years of biomedical research, some signaling pathways have been known for being
implicated in various cancers. It is tempted to exploit this pathway information for feature
selection. For example, adding the signaling pathways might be considered as a
constraint to get reliable feature sets. Consequently, the performance of the proposed
prediction algorithms was assessed using only the genes in the signaling pathways that
are known to the cancers. Inferior results were obtained (See Appendix B for details). It
is noted that the current pathway information is limited. If those signaling genes are only
considered, those important genes not identified yet by domain knowledge may be
missed. This may hurt the overall performance as shown in this case. Therefore, a better
strategy may be to include all genes but assign more weights to those signaling pathway
genes.
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CHAPTER 8
A NOISE-FILTERING APPROACH FOR CANCER DRUG SENSITIVITY
PREDICTION

8.1 Introduction
Accurately predicting drug responses to cancer is an important problem hindering
oncologists' efforts to find the most effective drugs to treat cancer, which is a core goal in
precision medicine. The scientific community has focused on improving this prediction
based on genomic, epigenomic, and proteomic datasets measured in human cancer cell
lines. Real-world cancer cell lines contain noise, which degrades the performance of
machine learning algorithms. This problem is rarely addressed in the existing approaches.
In this chapter, a learning approach is proposed that removes the noisiest cell lines,
allowing a model to be learned from better quality cell lines to improve the predictive
performance. The proposed approach consists of three steps. First, a distance matrix is
calculated that corresponds to all the inner products of the rows of a given matrix
constructed using the Manhattan distance of the training input. Second, technique from
linear algebra is adopted to project the training input on the eigenvectors of the distance
matrix to yield transformed training input that corresponds to feature vectors with
noise-filtered features. Third, information retrieval technique [162] is adopted to retrieve
(i.e., select) a subset of better quality cell lines with the associated drug responses from
the training set using the degrees between the training input cell lines and the
corresponding transformed training input cell lines, where smaller degrees denote better
quality cell lines. Then, a learning algorithm is applied to the better quality training set to
induce (i.e., learn) a model used for prediction on the test set. The learning algorithms
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considered here are support vector regression and ridge regression [54, 98]. Other
learning algorithms are excluded such as random forests [121] because of their poor
performance, as in

[54]. As the experimental results show, the proposed approach

outperforms the baseline prediction algorithms proposed by Geeleher et al. [54].

8.2 The Proposed Approach
Figure 8.1 outlines the proposed approach, which works as follows. Consider the gene
expression profiles denoted by X 

mn

., which consists of m cell lines (i.e., samples)

and n genes. Y ( y1,..., ym )T consists of the corresponding real-value drug responses to

X . A training set is define as S= { (x i , yi )}im1 , xi Xand yi  Y. A test set is defined as
T  {x i' } ip 1, where x i' 

n

. (B) The distance matrix D is computed as

D  LLT

(8.1)

L [l (xi ,x j )]ij  mm

(8.2)

l (x i , x j ) || x i  x j ||1,i, j  1,..., m.

(8.3)

Where

and

Note that D 

mm

, x i (x j , respectively) is the i th ( j th, respectively) feature vector of

feature matrix S, and || xi  x j ||1  a1| xia  xaj | is the Manhattan distance between
n

x i and x j . The eigenvalues of the distance matrix D are denoted by 1  2  ...  m , and

v1, v2 ,..., vm denote the corresponding eigenvectors. According to the Courant-Fischer
Theorem [108], we then have
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Figure 8.1 Data flow diagram showing the proposed approach to predicting in vivo drug
sensitivity.

v1 arg min zT Dz

(8.4)

z:||z||2 1

and

vl arg

min

z:||z||2 1,z  span{v1 ,v2 ,...,vl 1}

zT Dz.

(8.5)

Let Vt  [v1, v2 ,..., vt ] be the matrix whose columns are the first t eigenvectors of the
distance matrix D with the smallest eigenvalues (in this study, t  1.) The training input
of cell lines X is projected onto Vt to obtain the transformed training input X 

m n

with noise-filtered features. That is,
T
X  VV
t t X.

(8.6)

(C) Compute the degrees between each training input xi  X and the corresponding
transformed training input x i  X for i =1.. m

i* arg min i
i{1,2,...,m}

and
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(8.7)



 180
x i .x i
.

 || x i ||2 || x i ||2  

i cos 1 

(8.8)

In this case, i * is the index of x i*  X , whose degree is  i* . Denote by

S  {( xi* , yi* )}iq* 1  S the reduced training set whose q feature vectors correspond to the
training set with the smallest q degrees (i.e., i* 1  i* 2  ...  i* q where q  m ).
(D) A learning algorithm is called on the training set S of size q to induce model h .
(E) Model h is applied to make predictions on the test set. In the rest of this paper, the
prediction algorithms that employ the proposed approach using the abbreviations will be
referred to as PA+SVR+L, PA+SVR+S, and PA+RR (see Table 8.1).

Table 8.1 Abbreviation of Drug Sensitivity Prediction Algorithms
Abbreviation Prediction Algorithm
PA+SVR+L
The proposed approach using support vector regression with a linear
kernel
PA+SVR+S

The proposed approach using support vector regression with a sigmoid
kernel

PA+RR

The proposed approach using ridge regression

B+SVR+L

The baseline approach using support vector regression with a linear
kernel

B+SVR+S

The baseline approach using support vector regression with a sigmoid
kernel

B+RR

The baseline approach using ridge regression
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8.3 Experiments and Results
8.3.1 Datasets
The training sets correspond to an 482  6539 matrix and an 280  9115 matrix for
breast cancer and multiple myeloma, respectively. The test sets correspond to an

24  6538 matrix (excluding labels) and an 188  9114 matrix (excluding labels) for
breast cancer and multiple myeloma, respectively. Cell lines expression data for breast
cancer and multiple myeloma were download from the ArrayExpress repository
(accession number E-MTAB-783). The drug IC50 values for docetaxel and bortezomib
were downloaded from (http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/). The
clinical trial data for breast cancer (multiple myeloma, respectively) were downloaded
from the Gene Expression Omnibus (GEO) repository with accession numbers GSE350
and GSE349 (GSE9782, respectively) [132, 133]. The responses (i.e., labels) of the
clinical trial data are categorical (e.g., “sensitive” or “resistant”). These labels were
clinically evaluated by the degree of reduction in tumor size to the given drug [54]. The
downloaded data were processed according to Geeleher et al. [54].

8.3.2 Experimental Methodology
10-fold cross validation is not suitable in this study as labels of the testing sets are
categorical while the labels of the corresponding training sets are real values. Hence, to
evaluate whether the proposed approach exhibits stable superior performances as sample
size changes, the sample size for the training set was reduced by 1% for each run, until
the reduction reached 4%. In other words, 5 runs with sample sizes of (482, 478, 473,
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468, 463) and (280, 278, 275, 272, 269) were performed for the two real datasets,
respectively.
Each prediction algorithm was trained on the same given training set, whose
labels were continuous, to yield models. Then, each model was applied to the same test
set to yield predictions, where the accuracy of the prediction algorithms were measured
using the Are Under the ROC Curve (AUC) as in [54].
The software used in this work included support vector regression with linear and
sigmoid kernels in the LIBSVM package [104], ridge regression [54], and R code for
processing the datasets and performance evaluation [54]. R was used to write code for the
prediction algorithms and to perform the experiments.

8.3.3 Experimental Results
Table 8.2 and Table 8.3 show the AUCs of 6 docetaxel and bortezomib sensitivity
prediction algorithms on the clinical trial data for breast cancer and multiple myeloma,
respectively. Columns “ m ” and “ d ” show the number of cell lines and genes,
respectively, in the training sets that were provided to each prediction algorithm; the
same training sets were provided to each prediction algorithm. Column “ q +PA” shows
the number of selected (i.e., retrieved) cell lines that were used in PA+SVR+L,
PA+SVR+S, and PA+RR to learn the models.
Table 8.2 and Table 8.3 show that the proposed prediction algorithms perform
better than the baseline prediction algorithms (i.e., B+SVR+L and B+SVR+S) and
B+RR, the proposed prediction algorithm by Geeleher et al [54]. The results are
dominant compared to the other prediction algorithms on the clinical trial data in terms of
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the AUC of each run and of MAUC. These results indicate the stability of the proposed
prediction algorithms.

Table 8.2 The AUC of Docetaxel Sensitivity Prediction Algorithms for Breast Cancer
Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in Bold. MAUC
Is the Mean AUC
m
482
478
473
468
463
MAUC

d
6,538
6,538
6,538
6,538
6,538
-

PA+SVR+L
0.842
0.807
0.814
0.828
0.857
0.829

PA+SVR+S
0.878
0.871
0.878
0.864
0.864
0.871

PA+RR
0.821
0.814
0.821
0.828
0.821
0.821

q+PA
478
474
469
464
459
-

B+SVR+L
0.835
0.814
0.800
0.821
0.835
0.821

B+SVR+S
0.842
0.871
0.864
0.857
0.857
0.858

B+RR
0.814
0.814
0.821
0.821
0.821
0.818

Table 8.3 The AUC of Bortezomib Sensitivity Prediction Algorithms for Multiple
Myeloma Patients on the Test Set. The Algorithm with the Highest AUC Is Shown in
Bold. The MAUC Is the Mean AUC
m
280
278
275
272
269
MAUC

d
9,114
9,114
9,114
9,114
9,114
-

PA+SVR+L
0.659
0.656
0.679
0.685
0.681
0.672

PA+SVR+S
0.635
0.623
0.626
0.641
0.658
0.636

PA+RR
0.654
0.65
0.647
0.653
0.657
0.652

q+PA
210
209
207
204
202
-

B+SVR+L
0.613
0.609
0.622
0.628
0.632
0.62

B+SVR+S
0.602
0.600
0.601
0.605
0.598
0.601

B+RR
0.614
0.611
0.603
0.607
0.606
0.608

Figures 8.2 and 8.3 show the predictions of three prediction algorithms on the test
sets when the prediction algorithms learned models from the training sets with sizes

m =482 and m =280, respectively. For PA+SVR+S in Figure 8.2(a), the difference
between the predicted drug sensitivity in breast cancer patients was highly statistically
significant ( P  67105 from a t -test) between trial-defined sensitivity and resistant
groups. The B+SVR+S (Figure 8.2(b)) and B+RR (Figure 8.2(c)) achieved significant
results with P  117105 and P  434105 , respectively, from t -tests. PA+SVR+L
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(Figure 8.3(a)) achieved highly significant results ( P  10105 from a t -test). The
results of B+RR (Figure 8.3(b)) and B+SVR+L (Figure 8.3(c)) were also significant with

P  261105 and P  556105 , respectively, from t -tests.

Figure 8.2 Predictions of docetaxel sensitivity in breast cancer patients. Strip
charts (a), (b), and (c) show the differences in predicted drug sensitivity for
individuals sensitive or resistant to docetaxel treatment using PA+SVR+S,
B+SVR+S, and B+RR prediction algorithms, while (d) shows the ROC curves of
the prediction algorithms, which reveal the proportion of true positives compared
to the proportion of false positives. ROC = receiver operating characteristic.
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Figure 8.3 Prediction of bortezomib sensitivity in multiple myeloma patients. The
strip charts and boxplots in (a), (b), and (c) show predicted drug sensitivity for in
vivo responders and non-responders to bortezomib using the PA+SVR+L, B+RR,
and B+SVR+L prediction algorithms, respectively. The ROC curve in (d) illustrates
the estimated prediction accuracy of the prediction algorithms.
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8.4 Summary
In this chapter, a noise-filtering approach is proposed that blends the following
techniques: (1) Numerical linear algebra to yield transformed training input
corresponding to noise-filtered features; (2) Information retrieval to retrieve better quality
cancer cell lines from the training set according to the minimum degrees between the
training input and the transformed training input; (3) Machine learning to learn a model
from better quality, reduced-size training sets and perform predictions on test sets. The
proposed approach uses two machine learning algorithms: support vector regression and
ridge regression. Compared to an existing drug sensitivity approach, the proposed
approach results in higher and statistically significant AUC values when using clinical
trial data.
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CHAPTER 9
TRANSFER LEARNING APPROACHES TO IMPROVE DRUG SENSITIVITY
PREDICTION IN MULTIPLE MYELOMA PATIENTS

9.1 Introduction
Traditional machine learning approaches to drug sensitivity prediction assume that
training data and test data must be in the same feature space and have the same
underlying distribution. However, in real-world applications, this assumption does not
hold. For example, we sometimes have limited training data for the task of drug
sensitivity prediction in multiple myeloma patients (target task), but we have sufficient
auxiliary data for the task of drug sensitivity prediction in patients with another cancer
type (related task), where the auxiliary data for the related task are in a different feature
space or come from a different distribution. In such cases, transfer learning, if applied
correctly, would improve the performance of the prediction algorithms on the test data of
the target task via leveraging the auxiliary data from the related task. In this chapter,
transfer learning approaches are presented that combine the auxiliary data from the
related task with the training data of the target task to improve the prediction performance
on the test data of the target task. The performance of the proposed transfer learning
approaches is evaluated exploiting three auxiliary datasets and compare them against
baseline approaches using the area under the ROC curve (AUC) on test data of the target
task. Experimental results demonstrate the good performance of the proposed approaches
and their superiority over the baseline approaches when auxiliary data are incorporated.
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In the sequel, the terms "sensitive" ("resistant", respectively) and "responder"
("non-responder", respectively) are used interchangeably. The terms "genes" and
"features" are also used interchangeably throughout the paper.

9.2 Background
This section provides an introduction to the methods related to the proposed work:
synthetic minority over-sampling technique (SMOTE) [123] and CUR matrix
decomposition [149]. Each of them is introduced respectively after summarizing
notations used in the paper.

9.2.1 Notations
To give a better understanding of the algorithms, the notations used in the paper are first
summarized. Matrices are written as uppercase letters, e.g., matrix X . Vectors are
denoted by lowercase letters, e.g., x . Vector elements are denoted by italic lowercase
letters as scalars, e.g., yi or x . A transpose of a matrix or a vector is indicated by T . So,
for example, if x is a row vector, xT is the corresponding column vector.

9.2.2 Synthetic Minority Over-sampling Technique (SMOTE)
SMOTE [123] is a popular and a powerful over-sampling method that has shown a great
deal of success in many applications [163-165]. Here, we are given a dataset D  D .

D 

m d

contains examples from the minority class, D 

from the majority class, and m

n d

contains examples

n . For each example xi  D , SMOTE finds the

k -nearest neighbors x1i , x i2 ,..., x ik of xi  D , where x ij 
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d

, 1  j  k , refers to the jth

nearest neighbor of the ith example xi in D .

Then SMOTE generates synthetic

examples z1i , zi2 ,..., zik along the line between each minority example xi  D and its
selected k nearest neighbors in the minority class as follows:
1. for i = 1 to m
1.1. for j = 1 to k
1.1.1. zij  x i  (x ij  x i )
1.1.2. Store [ zij ,+] in D
1.2. end for
2. end for
where zij 

d

refers to the jth synthetic example generated from the ith example

xi  D ,  (0,1) is a random number, and the + sign indicates that synthetic examples
are labeled with the minority class label. A random subset D'  D is then selected,
where D ' consists of n-m synthetic examples. A learning algorithm could be called on
the balanced dataset D'  D  D , to induce a model and perform predictions on a
given test set.

9.2.3 CUR Matrix Decomposition
Suppose that a dataset F 

m p

is given. Mahoney et al. [149] proposed CUR matrix

decomposition as a dimensionality reduction paradigm that aims to obtain a low rank
approximation of matrix F , which is expressed in terms of the actual rows and columns
of the original matrix F :

140

F  CUR,

(9.1)

where C consists of a small number of the actual columns of F , R consists of a small
number of the actual rows of F , and U is a constructed matrix that guarantees that CUR
is close to F . Let vj be the jth element of the  th right singular vector of F. Let l be the
rank of F. Then the normalized statistical leverage scores equal:

j 
p

for all j =1.. p , and



j

1 l  2
 (v j )
l  1

(9.2)

 1. C , U , and R matrices are constructed after calling

j1

COLUMNSELECT algorithm of Mahoney et al., which takes an input matrix F , a rank
parameter l , and an error parameter  , and then performs the following steps:
1. Compute v1,v2 ,...,vl (the top l right singular vectors of F) and the normalized
statistical leverage scores of Eq. 9.2.
2. Keep the j th column of F with probability p j  min{1, c j } for all j =1.. p , where

c  O(l log l /  2 ) .
3.

Return the matrix C consisting of the selected columns of F .

In step 1, the singular value decomposition SVD of F is computed, which decomposes F
to UVT , where U 
of

F, 

l l

ml

is orthogonal matrix containing the top l left singular vectors

is diagonal matrix containing singular values of F , VT 

l p

is

orthogonal matrix containing the top l right singular vectors of F, and l is the rank of F .
The columns of U are pairwise orthogonal and normal (i.e., orthonormal), but its rows
are not orthonormal as Euclidean norm is between 0 and 1. The rows of VT are pairwise
orthogonal and normal (i.e., orthonormal), but its columns are not orthonormal as
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Euclidean norm is between 0 and 1 [166]. The other matrices (i.e., R , and U ) are
constructed as follows:
1. Run COLUMNSELECT on FT with c  O(l log l /  2 ) to choose rows of F (columns
of FT ) and construct matrix R.
2. Matrix U is defined as U=CFR  , where C  and R  denote the Moore–Penrose
generalized inverse of the matrix C and R, respectively.

Statistical leverage scores have been successfully employed in data analysis to identify
the most influential genes and outlier detection [149]. A high statistical leverage score for
a given gene indicates that the gene is regarded as an important (i.e., influential) gene. A
low statistical leverage score for a given gene indicates that the gene is regarded as an
unimportant gene. To select the q most important genes from matrix F , where q  p , we
find the highest q statistical leverage scores used in computing matrix C of F, which
correspond to the q most influential (i.e., important) genes.

9.3 Proposed Approaches
9.3.1 The Transfer Learning Approach
Figure 9.1 illustrates the proposed transfer learning approach, which works as follows.
Suppose that we are given a target training set F = { (x1,y1 ),...,(x m , ym )} and a target test
set T = { t1,..., t r } . In the target training set, x i 

p genes (i.e., features), yi 

p

is the ith target training example with

is the corresponding label of xi , and t i 

p

is the i th

target testing example of p genes. The target training set and target test set are disjoint,
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where m and r are the numbers of training and testing examples in the target task,
respectively. In addition, we also have an auxiliary dataset S= { (s1, u1),...,(sl , ul )} , where

si 

n

is the ith example (i.e., cell line of a cancer type) with n genes, ui 

is the

corresponding label of si , and n , the number of genes in the auxiliary data, is different
from p , the number of genes used in the target task. Our goal is to improve the
prediction performance on the target test set T of the target task (prediction of
bortezomib sensitivity in multiple myeloma patients) via learning an accurate model
using the auxiliary dataset S and the target training set F . We summarize the problem
definition in Table 9.1.
To incorporate the auxiliary data with the target training set, the following steps
are performed.
(i) If the number of genes p in the target training set F is greater than the number of
genes n in the auxiliary data S , then gene (i.e., feature) selection is performed on F as
explained in step (ii). Otherwise, gene selection is performed on S . Assume without loss
of generality that p  n .
(ii) q genes are selected from F based on their importance scores as defined in Equation
(9.2), which depends on computing matrix C of F and the input rank parameter l (in this
study, q  n and the default parameter values are used for l , c , and  in CUR function
[150].) Then, the indexes of the highest q leverage scores are stored in I (where q  p );
these correspond to the positions of the q most influential genes in matrix F . q genes
are selected from the target training set F using their positions in I and stored in

F'  {(x1' , y1' ),...,(x 'm , ym' )} .
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Table 9.1 Problem Formulation
Learning objective
Target task
Related task

Make predictions on the target test set of the target task
Prediction of bortezomib sensitivity in multiple myeloma patients
Prediction of specific drug sensitivity in patients with a cancer type
Target Training set: F = { (x i ,yi ) } im1

Target task data

r
Target Test set: T= { t i } i
1

Related task data

Auxiliary Data: S = { (si ,ui )} il1
Cancer Types: Breast Cancer, Triple-Negative Breast Cancer, and
Non-Small Cell Lung Cancer

Figure 9.1 Flowchart of the proposed transfer learning approach to predicting in vivo
drug sensitivity.
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(iii) The following steps are based on a modified version of SMOTE [123] where each
example in the auxiliary dataset gets a representation closer to the target training set F' :
1. Select b examples from the auxiliary dataset S. (In the study presented here,

b  100. ) For each example si , 1  i  b , selected from S, pick one of si 's nearest
target training examples from F' , denoted x *i , such that the picked example is
different from all the target training examples previously picked for s j , 1  j  i .
More precisely, suppose si 's k nearest target training examples are among the target
training examples previously picked for s j , 1  j  i . Then x *i is si 's (k + 1)th
nearest target training example from F' . Let yi' be the corresponding label of x *i .
2. Change the representation of the examples selected from S using the following lines
of code:
2.1 for i = 1 to b
2.1.1

s*i  si  (x*i  si )

2.1.2

Store [s*i ,( yi'   )] in S

2.2 end for
where   0.99 ,   0.01, and S contains the new representations of the auxiliary data.
Let D = S  F' contain the combined cell lines expression data, where D 

m' n

, and

m'  m  b.
(iv) A learning algorithm is called on D to induce a model h .
(v) The n genes in the target test set T are selected using their positions in I and stored
in T ' . The model h is applied to the target test set T' to perform predictions.
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9.3.2 The Boosted Transfer Learning Approach
Figure 9.2 illustrates the proposed boosted transfer learning approach. Steps (i), (ii), and
(iii) are the same as steps (i), (ii), and (iii) of the transfer learning approach. Steps
(iv) and (v) work as follows.
(iv) A modification of AdaBoost [116-118, 167] is employed, which works as follows.
Initially, each training example (xi , yi )  D is assigned a weight wi  1 for i = 1,, m' .
The probability for selecting the ith training example (xi , yi ) in the training set D is

pi 

wi
m'

w
i 1

m'

where

p
i 1

i

(9.3)

i

 1 . Select m ' training examples (without replacement) from D , to form the

training set D' . A learning algorithm is called on D' to learn a model h and perform
predictions on D , where predictions are then stored in y'  ( y1' ,..., ym' ' ). Select the n
genes in the target test set T using positions in I , and store the selected data with n
genes in T' . Apply the model h on the target test set T' , to yield predictions, which are
stored as the first row vector in a matrix G . Repeat the following j times. (In this study,

j = 6.)
1. Update the weights: wi  ( yi  yi' )2 . for i =1,…, m ' .
2. Calculate probabilities p  ( p1, p2 ,..., pm' ) of the training examples in D , where

pi , 1  i  m' , is as defined in Equation (3).
3. Calculate the median of probabilities p1, p2 ,..., pm' and store the median in v .
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4. Select training examples from D where the weight of each selected example must
be greater than or equal to v . Store the selected training examples in D' . Let p*
contain the probabilities corresponding to the selected training examples.
5. Select m ' training examples (with replacement) from D' according to the
probabilities in p* and store the selected training examples in D'' . The higher
probability a training example is associated with, the more likely this training
example will be included in D'' .
6. A learning algorithm is called on D'' to learn model h and perform predictions on

D.
7. Store the predictions performed on D in q .
8. Let y ' = y ' + q , which corresponds to the cumulative predictions on the training
set D .
9. Apply the learned model h on the target test set T' and store the predictions as the
(j +1)th row vector in G .
(v) Output the final predictions as

Q  eT G

(9.4)

where G is an ( j  1)  r matrix of predictions on the target test set T' , the ith row vector
of G

corresponds to the predictions made in the (i -1)th iteration in step

(iv), e= (

1
1 T
,...,
)
j 1
j 1

is a ( j  1) 1 column vector, and Q is a 1 r row vector

where the ith element in Q is the mean of the values in the ith column of G.
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Figure 9.2 Flowchart of the proposed boosted transfer learning approach to predicting in
vivo drug sensitivity.

9.4 Experiments
9.4.1 Datasets
Data Pertaining to Multiple Myeloma. The target training set F 

280  9115

contains 280

target training examples (i.e., cancer cell lines), 9,114 genes, and drug IC50 values that
correspond to a 280-dimensional column vector. The target test set T 

188  9114

is

composed of 188 samples of multiple myeloma patients and 9,114 genes. The drug IC50
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values

for

bortezomib

[151,

152]

were

downloaded

from

(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54], and the data for the
cancer

cell

(accession

lines

were

number

downloaded
is

from

the

E-MTAB-783

ArrayExpress
or

repository

available

at

https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783)
[131, 168, 169]. The clinical trial data corresponding to the test set were downloaded
from

the

Gene

Expression

Omnibus

(GEO)

repository

(http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE9782. The data were
downloaded, processed and mapped according to Geeleher et al. [54].
Data Pertaining to Breast Cancer. The auxiliary data correspond to an 482  6539
matrix (i.e., 482 examples and 6538 genes plus labels, i.e., drug IC50 values) for breast
cancer patients. The drug IC50 values for docetaxel [130, 170]. (a chemotherapy drug)
were downloaded from (http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/) [54].
The cell line expression data were downloaded from the ArrayExpress repository
(accession

number

is

E-MTAB-783,

also

available

at

https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/?query=EMTAB783)
[131, 168, 169]. All the data were downloaded and processed according to the approach
proposed by Geeleher et al. [54].
Data Pertaining to Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
The auxiliary data correspond to an 258  9508 matrix (i.e., 258 examples and 9507
genes plus labels) and an 497  9621 matrix (i.e., 497 examples and 9620 genes plus
labels) for non-small cell lung cancer and triple-negative breast cancer patients,
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respectively.

The

data

were

downloaded

from

(http://genemed.uchicago.edu/~pgeeleher/cgpPrediction/).

9.4.2 Evaluation and Baseline Approaches
The two proposed transfer learning approaches are compared with two different baseline
approaches, which are described below.
First Baseline (B1). This baseline employs the proposed approach by Geeleher et al.
[54].
Second Baseline (B2). In this baseline, CUR matrix decomposition is applied to F. Then,
the indexes of the largest n statistical leverage scores of F are stored in I , as in the
proposed approaches. The n genes from the target training examples in F are selected
using positions in I . A learning algorithm is called on the auxiliary data with n genes
combined with the target training set with n genes, to learn a model h . Then, the n
genes in the target test set are selected using positions in I . The model h is applied to the
target test examples with n genes, to yield drug sensitivity predictions. Thus, this
baseline, which does not have a transfer learning mechanism (cf. steps (iii) in Section
9.3.1), differs from the proposed transfer learning approaches.
The proposed transfer learning approaches and the baseline approaches employ
two machine learning algorithms, namely support vector regression (SVR) and ridge
regression (RR). Table 9.2 summarizes the twelve prediction algorithms studied in this
chapter.
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Table 9.2 Summary of the Twelve Drug Sensitivity Prediction Algorithms in This
Chapter
Abbreviation

Prediction Algorithm

T+SVR+L

The transfer learning approach using support vector regression with a linear kernel

T+SVR+S

The transfer learning approach using support vector regression with a sigmoid kernel

T+RR

The transfer learning approach using ridge regression

BT+SVR+L

The boosted transfer learning approach using support vector regression with a linear kernel

BT+SVR+S

The boosted transfer learning approach using support vector regression with a sigmoid kernel

BT+RR

The boosted transfer learning approach using ridge regression

B1+SVR+L

The first baseline approach using support vector regression with a linear kernel

B1+SVR+S

The first baseline approach using support vector regression with a sigmoid kernel

B1+RR

The first baseline approach using ridge regression

B2+SVR+L

The second baseline approach using support vector regression with a linear kernel

B2+SVR+S

The second baseline approach using support vector regression with a sigmoid kernel

B2+RR

The second baseline approach using ridge regression

Each prediction algorithm was trained on a training set, whose labels were
continuous, to yield a model. Then, each model was applied to the target test set to yield
predictions. The target test set consists of patients' clinical trial expression data, which are
baseline tumor expression data from primary tumor biopsies before treatment with
anticancer drugs. The labels of the target test set are not translated from continuous to
categorical. Instead, the labels of the target test set are categorical (i.e., either “sensitive”
or “resistant”), where these labels were clinically evaluated by the degree of reduction in
tumor size to the given drug. A cancer patient is categorized as “sensitive” to cancer drug
(e.g., docetaxel or bortezomib) treatment if the cancer patient exhibits less than 25%
residual tumor. A cancer patient is categorized as “resistant” to cancer drug treatment if
the cancer patient exhibits greater than or equal to 25% residual tumor [54].
Using in vitro drug sensitivity of the training data to predict in vivo drug
sensitivity of the target test set is a challenging task and main goal in precision medicine,
which corresponds to predicting the clinical outcome that is crucial for the life of the
151

human being [171]. If the clinical drug response (i.e., clinical response to anticancer
drug) is incorrectly predicted, the tumor size of a cancer patient would increase
significantly over the time, which cause sequelae that lead to death. If the clinical drug
response is correctly predicted, the tumor size would decrease significantly over the time
and that would save the patient. By predicting clinical outcomes in the target test set
correctly, clinicians would benefit from understanding the relationship between in vivo
and in vitro drug sensitivity, which leads to better personalized treatment.
Ten-fold cross validation is not suitable in this study as labels of the target test set
are categorical while the labels of the corresponding target training set are real numbers.
Hence, to evaluate whether the proposed approach exhibits stable superior performances
as sample size changes, the sample size for the target training set was randomly reduced
by 1% for each run, until the reduction reached 4%. In other words, 5 runs were
performed with sample sizes of 280, 278, 275, 272, 269, respectively.
The accuracy of the prediction algorithms was measured using the area under the
ROC curve (AUC), as described in [54]. The higher the AUC score an algorithm
achieves, the better its performance is. MAUC is used to denote the mean of the AUC
values averaged over the five runs of the target test set. A run of the target test set is
defined as the predictions of a learned model on the target test set in which the model was
learned from a training set whose size is varied to assess the stability of the prediction
algorithms. A stable prediction algorithm is the one whose prediction accuracy on the
target test set does not change dramatically owing to small changes of the training set size
[136, 137]. This type of assessment is important in biological systems, where the best
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prediction algorithm is the one that outperforms the other algorithms many times on
conducted experiments. The statistical significance of the approaches was measured.
The software used in this work included support vector regression with linear and
sigmoid kernels (with their default parameter values) in the LIBSVM package [104],
ridge regression [54], gene selection using CUR and topLeverage functions in the rCUR
package [150], and R code for processing the datasets and performance evaluation [54].
R is used to write code for the prediction algorithms and to perform the experiments.

9.4.3 Experimental Results
In this section, the performance of the proposed approaches is evaluated and compared to
the baseline approaches. Each time the target training set of multiple myeloma is used
with one of the auxiliary datasets pertaining to breast cancer, triple-negative breast
cancer, and non-small cell lung cancer respectively to train the approaches (except the
B1 approach that uses only target training set), to yield prediction algorithms and perform
prediction on the target test set.
9.4.3.1 Exploiting Breast Cancer Auxiliary Data. Table 9.3 shows details of the
target training set and auxiliary dataset pertaining to breast cancer used by each
prediction algorithm. The target training set is obtained from the target task (i.e.,
prediction of bortezomib sensitivity in multiple myeloma patients) and the auxiliary data
are acquired from the related task (i.e., prediction of docetaxel sensitivity in breast cancer
patients). Rows “ m / l ” shows the number of examples or cell lines in the target training
set/auxiliary dataset used in each run. Row “ p / n ” shows the number of genes or
features in the target training set/auxiliary dataset used in each run. Row " p  n " shows
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the number of overlapped (i.e., intersected) genes between the target training set and the
auxiliary data in each run. Rows “ Pm/l ” and “ Pp / n ” show the number of selected
examples in the target training set/auxiliary dataset and the number of selected genes in
the target training set/auxiliary dataset, respectively, that were used in the prediction
algorithms employing the approaches during the training stage to learn models. Rows
“ B1m ” and “ B1p ” show the number of selected examples and genes, respectively, in the
target training set that were used during the training stage by the prediction algorithms
employing the first baseline approach (B1). Row “ B2m/l ” and “ B2 p / n ”Show the number
of selected examples and genes, respectively, in the target training set/auxiliary dataset
that were used by the prediction algorithms employing the second baseline approach
(B2). In each run the target training set size is changed to train all machine learning
algorithms employing the approaches as described in Sections 9.3 and 9.4.2, to yield
models (i.e., prediction algorithms).

Table 9.3 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple
Myeloma and Breast Cancer, Respectively, Used by Each Prediction Algorithm
Run
m/l
p/n
p n

1
280/482
9114/6538
5478

2
278/482
9114/6538
5478

3
275/482
9114/6538
5478

4
272/482
9114/6538
5478

5
269/482
9114/6538
5478

Pm/l
Pp / n

280/100

278/100

275/100

272/100

269/100

6538/6538

6538/6538

6538/6538

6538/6538

6538/6538

B1m
B1p

280

278

275

272

269

9114

9114

9114

9114

9114

B2m/l
B2 p/ n

280/482

278/482

275/482

272/482

269/482

6538/6538

6538/6538

6538/6538

6538/6538

6538/6538
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Table 9.4 shows the AUCs of twelve prediction algorithms on the target test set of
multiple myeloma patients. As shown in Table 9.4, BT+SVR+S performs better than the
baseline prediction algorithms (i.e., B2+SVR+L, B2+SVR+S, B2+RR, B1+SVR+L, and
B1+SVR+S and B+RR). In particular, BT+SVR+S achieves the highest AUC in 4 out of
5 runs. The BT+SVR+S results were consistently good compared to the other prediction
algorithms in terms of AUC on the target test set as the target training set size is reduced.
These results indicate that the performance of BT+SVR+S is stable.

Table 9.4 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset
Pertaining to Multiple Myeloma and Breast Cancer Patients, Respectively, Are Used. The
Algorithm with the Highest AUC Is Shown in Bold. Std is the Standard Deviation of the
AUC Values Obtained from the Five Runs
Run
T+SVR+L
T+SVR+S
T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

1
0.644
0.643
0.653
0.658
0.682
0.670
0.613
0.602
0.614
0.440
0.449
0.499

2
0.636
0.642
0.655
0.657
0.682
0.693
0.609
0.600
0.611
0.491
0.485
0.505

3
0.640
0.654
0.652
0.678
0.687
0.668
0.622
0.601
0.603
0.466
0.487
0.511

4
0.647
0.659
0.657
0.665
0.695
0.681
0.628
0.605
0.607
0.501
0.506
0.511

5
0.653
0.666
0.652
0.675
0.703
0.659
0.632
0.598
0.606
0.549
0.500
0.516

Table 9.5 shows the P -values of a two-sample t -test on the target test set for
each run, as in [54]. Each prediction algorithm with a highly statistically significant result
is shown in red ( P  .001 ). Each algorithm with a statistically significant result is shown
in blue ( .001  P  .05 ). As shown in Table 9.5, the proposed prediction algorithms yield
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highly statistically significant results, and these highly statistically significant results
reflect the superior performance of the proposed prediction algorithms (see Table 9.4).

Table 9.5 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to
Multiple Myeloma and Breast Cancer Patients, Respectively, Are Used. Each Prediction
Algorithm with P  0.001 Is Considered As Highly Statistically Significant and Colored
in Red. Each Prediction Algorithm with P  0.05 Is Considered Statistically Significant
and Colored in Blue
Run
T+SVR+L

1
6088106

2
906106

3
674106

4
442106

5
372106

T+SVR+S

765106
188106
218106
4105
3382108
6103
8103
261105
881103
784103
4992104

815106
218106
245106
2172108
9221109
7103
1102
4103
665103
722103
466103

498106
244106
2396106
1506108
4307108
4103
11103
6103
489103
708103
398103

273106
194106
132106
1378108
1169108
2103
9103
4103
724103
607103
386103

219106
313106
6888108
527108
6069108
2103
14103
5103
613103
633103
342103

T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

Figures 9.3(a), 9.3(b), and 9.3(c) show the predictions of BT+SVR+S, B1+RR,
and B2+RR, respectively, on the target test set at the first run. The result of BT+SVR+S
shown in Figure 9.3(a) was highly statistically significant ( P  4105 from a two-sample

t -test) between the trial-defined responder (i.e., sensitive) and non-responder (i.e.,
resistant) groups. The result of B1+RR shown in Figure 9.3(b) was statistically
significant with P  261105 from a two-sample t -test. The result of B2+RR shown in
Figure 9.3(c) was not statistically significant with P  49920105 from a two-sample
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t -test. In Figure 9.3(d), the ROC curves reveal AUC values of 0.682, 0.614, and 0.499
for BT+SVR+S, B1+RR, and B2+RR, respectively.

Figure 9.3 Predictions of bortezomib sensitivity on the target test set of multiple
myeloma patients where the target training set and auxiliary dataset pertaining to
multiple myeloma and breast cancer patients, respectively, are used. Strip charts and
boxplots (a), (b), and (c) show the differences in predicted drug sensitivity to bortezomib
treatment between the responder (i.e., sensitive) group and non-responder (i.e., resistant)
group using BT+SVR+S, B1+RR, and B2+RR, respectively. (d) shows the ROC curves
of the prediction algorithms, which reveal the proportion of true positives compared to
the proportion of false positives. ROC = receiver operating characteristic.
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Figure 9.4 shows the ranking of the twelve prediction algorithms based on their
MAUC values. The MAUC of an algorithm is calculated by taking the mean of the AUC
values the algorithm receives from the 5 runs of experiments. As shown in Figure 9.4, the
proposed prediction algorithms outperform the baseline prediction algorithms w.r.t. the
MAUC.

Figure 9.4 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm
has the lowest MAUC.

9.4.3.2 Exploiting Triple-Negative Breast Cancer Auxiliary Data.

Table 9.6 shows

details of the target training set and the auxiliary dataset pertaining to triple-negative
breast cancer patients used by each prediction algorithm. The target training set is
obtained from the target task (i.e., prediction of bortezomib sensitivity in multiple

158

myeloma patients) and the auxiliary dataset is obtained from the related task (i.e.,
prediction of cisplatin sensitivity in triple-negative breast cancer patients). The only
difference between Table 9.3 and Table 9.6 is that Table 9.6 has different auxiliary data
pertaining to triple-negative breast cancer patients, while the target test set is still the
same.

Table 9.6 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple
Myeloma and Triple-Negative Breast Cancer Patients, Respectively, Used by Each
Prediction Algorithm
Run
m/l
p/n
p n

1
280/497
9114/9620
7911

2
278/497
9114/9620
7911

3
275/497
9114/9620
7911

4
272/497
9114/9620
7911

5
269/497
9114/9620
7911

Pm/l
Pp / n

280/100

278/100

275/100

272/100

269/100

9114/9114

9114/9114

9114/9114

9114/9114

9114/9114

B1m
B1p

280

278

275

272

269

9114

9114

9114

9114

9114

B2m/l
B2 p/ n

280/497

278/497

275/497

272/497

269/497

9114/9114

9114/9114

9114/9114

9114/9114

9114/9114

Table 9.7 shows the AUCs of the twelve prediction algorithms on the target test
set of multiple myeloma patients. As shown in Table 9.7, the proposed prediction
algorithms employing the boosted transfer learning approach (BT) perform better than
the baseline prediction algorithms. Specifically, BT+SVR+S and BT+RR yielded the
highest AUC in 4 out of 5 runs. These results indicate that the proposed prediction
algorithms employing BT approach achieve high performance in terms of AUC on the
target test set. The results also show the stability of the prediction algorithms employing
BT approach.
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Table 9.7 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset
Pertaining to Multiple Myeloma and Triple-Negative Breast Cancer Patients,
Respectively, Are Used. The Algorithm with the Highest AUC Is Shown in Bold. Std Is
the Standard Deviation of the AUC Values Obtained from the Five Runs.
Run
T+SVR+L
T+SVR+S
T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

1
0.601
0.62
0.615
0.628
0.683
0.638
0.613
0.602
0.614
0.528
0.472
0.464

2
0.599
0.621
0.615
0.635
0.641
0.654
0.609
0.600
0.611
0.528
0.466
0.460

3
0.604
0.629
0.614
0.665
0.659
0.675
0.622
0.601
0.603
0.538
0.473
0.466

4
0.617
0.634
0.62
0.627
0.695
0.677
0.628
0.605
0.607
0.536
0.477
0.472

5
0.618
0.632
0.623
0.669
0.667
0.654
0.632
0.598
0.606
0.523
0.471
0.476

In Table 9.8, the P -values of a two-sample t -test on the target test set are
reported for each run. The proposed prediction algorithms BT+SVR+S and BT+RR yield
highly statistically significant results in each run (see results colored in red in Table 9.8),
and these highly statistically significant results reflect the high performance of
BT+SVR+S and BT+RR prediction algorithms (see Table 9.7).
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Table 9.8 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to
Multiple Myeloma and Triple-Negative Breast Cancer Patients, Respectively, Are Used.
Each Prediction Algorithm with P  0.001 Is Considered Highly Statistically Significant
and Colored in Red. Each Prediction Algorithm with P  0.05 Is Considered Statistically
Significant and Colored in Blue
Run
T+SVR+L

1
8701106

2
9608106

3
7425106

4
4303106

5
4126106

T+SVR+S

3877106
3908106
2698106
2716108
382106
6103
8103
261105
4249104
8505104
6622104

3499106
4911106
1171106
719106
111106
7103
1102
4103
426103
8672104
694103

2547106
5189106
188106
185106
2692108
4103
11103
6103
3987104
8341104
6596104

1708106
363105
2163106
1185108
2774108
2103
9103
4103
3964104
8028104
6066104

1897106
3932106
132106
104106
115106
2103
14103
5103
4338104
8263104
57102

T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

Figures 9.5(a), 9.5(b), and 9.5(c) show the predictions of BT+SVR+S, B1+RR,
and B2+RR, respectively, on the target test set at the first run. BT+SVR+S (Figure
9.5(a)) achieved a highly statistically significant result ( P  2716108 from a
two-sample t -test). The result of B1+RR (Figure 9.5(b)) was statistically significant with
( P  261105 from a two-sample t -test). The result of B2+RR (Figure 9.5(c)) was not
statistically significant ( P  6622104 from a two-sample t -test). In Figure 9.5(d), the
ROC curves reveal AUC values of 0.683, 0.614, and 0.464 for BT+SVR+S, B1+RR, and
B2+RR, respectively.
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Figure 9.5 Predictions of bortezomib sensitivity on the target test set of multiple
myeloma patients where the target training set and auxiliary dataset pertaining to
multiple myeloma and triple-negative breast cancer patients, respectively, are used.
Strip charts and boxplots (a), (b), and (c) show the differences in predicted drug
sensitivity to bortezomib treatment between the responder (i.e., sensitive) group
and non-responder (i.e., resistant) group using BT+SVR+S, B1+RR, and B2+RR,
respectively. (d) shows the ROC curves of the prediction algorithms, which reveal
the proportion of true positives compared to the proportion of false positives. ROC
= receiver operating characteristic.
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Figure 9.6 shows that the proposed prediction algorithms BT+SVR+S, BT+RR,
BT+SVR+L, and T+SVR+S outperform the baseline prediction algorithms w.r.t. the
MAUC.

Figure 9.6 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm
has the lowest MAUC.

9.4.3.3 Exploiting Non-Small Cell lung cancer Auxiliary Data.

Table 9.9 shows

details of the target training set and auxiliary dataset pertaining to non-small cell lung
cancer patients used by each prediction algorithm. The target training set is obtained from
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the target task (i.e., prediction of bortezomib sensitivity in multiple myeloma patients)
and the auxiliary dataset is acquired from the related task (i.e., prediction of erlotinib
sensitivity in non-small cell lung cancer patients). Here, different auxiliary dataset
pertaining to non-small cell lung cancer patients is used, while the target test set still
remains the same.

Table 9.9 Details of the Target Training Set and Auxiliary Dataset Pertaining to Multiple
Myeloma and Non-Small Cell Lung Cancer Patients, Respectively, Used by Each
Prediction Algorithm
Run
m/l
p/n
p n

1
280/258
9114/9507
7855

2
278/258
9114/9507
7855

3
275/258
9114/9507
7855

4
272/258
9114/9507
7855

Pm/l
Pp / n

280/100

278/100

275/100

272/100

9114/9114

9114/9114

9114/9114

9114/9114

B1m
B1p

280

278

275

272

9114

9114

9114

9114

B2m/l
B2 p/ n

280/258

278/258

275/258

272/258

9114/9114

9114/9114

9114/9114

9114/9114

Table 9.10 shows the AUCs of twelve prediction algorithms on the target test set
of multiple myeloma patients. The proposed prediction algorithm BT+SVR+S achieved
the highest AUC scores in 4 out of 5 runs. The high performance results indicate the
stability and superiority of BT approach when using SVR+S.
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Table 9.10 AUC Scores of the Twelve Prediction Algorithms on the Target Test Set of
Multiple Myeloma Patients Where the Target Training Set and Auxiliary Dataset
Pertaining to Multiple Myeloma and Non-Small Cell Lung Cancer Patients, Respectively,
Are Used. The Algorithm with the Highest AUC Is Shown in Bold. Std Is the Standard
Deviation of the AUC Values Obtained from the Five Runs
Run
T+SVR+L
T+SVR+S
T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

1
0.6
0.621
0.614
0.67
0.673
0.658
0.613
0.602
0.614
0.403
0.643
0.641

2
0.598
0.619
0.615
0.653
0.653
0.639
0.609
0.6
0.611
0.409
0.644
0.641

3
0.604
0.63
0.61
0.623
0.651
0.619
0.622
0.601
0.603
0.436
0.644
0.642

4
0.617
0.635
0.615
0.663
0.657
0.594
0.628
0.605
0.607
0.422
0.646
0.641

5
0.617
0.634
0.624
0.663
0.678
0.627
0.632
0.598
0.606
0.421
0.648
0.642

Table 9.11 reports the P -values of a two-sample t -test on the target test set for
each run. The proposed prediction algorithm BT+SVR+S yields highly statistically
significant result in each run (see results colored in red in Table 9.11), and these highly
statistically significant results reflect the high performance of BT+SVR+S prediction
algorithm (see Table 9.10).
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Table 9.11 P -Values of a Two-Sample t-Test for the Twelve Prediction Algorithms on
the Target Test Set Where the Target Training Set and Auxiliary Dataset Pertaining to
Multiple Myeloma and Non-Small Cell Lung Cancer Patients, Respectively, Are Used.
Each Prediction Algorithm with P  0.001 Is Considered Highly Statistically Significant
and Colored in Red. Each Prediction Algorithm with P  0.05 Is Considered Statistically
Significant and Colored in Blue
Run
T+SVR+L

1
8887106

2
9892106

3
7654106

4
4282106

5
4214106

T+SVR+S

3883106
3887106
135106
1195107
3887106
6103
8103
261105
939103
5556106
3881106

3735106
49104
368106
261106
49104
7103
1102
4103
9358104
5455106
3855106

2486106
6343106
3893106
394106
6343106
4103
11103
6103
9073104
5414106
3888106

1606106
4458106
212106
383106
4458106
2103
9103
4103
9173104
5493106
3905106

1833106
3918106
18105
4695108
3918106
2103
14103
5103
926103
5196106
3822106

T+RR
BT+SVR+L
BT+SVR+S
BT+RR
B1+SVR+L
B1+SVR+S
B1+RR
B2+SVR+L
B2+SVR+S
B2+RR

Figures 9.7(a), 9.7(b), and 9.7(c) show the predictions of BT+SVR+S, B1+RR,
and B2+RR, respectively, on the target test set at the first run. BT+SVR+S (Figure
9.7(a)) yielded a highly statistically significant result ( P  1195107 from a two-sample

t -test). The result of B1+RR (Figure 9.7(b)) was statistically significant with
( P  261105 from a two-sample t -test). B2+RR (Figure 9.7(c)) yielded a statistically
significant result ( P  3381106 from a two-sample t -test). In Figure 9.7(d), the ROC
curves reveal AUC values of 0.673, 0.614, and 0.641 for BT+SVR+S, B1+RR, and
B2+RR, respectively.
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Figure 9.7 Predictions of bortezomib sensitivity on the target test set of multiple
myeloma patients where the target training set and auxiliary dataset pertaining to
multiple myeloma and non-small cell lung cancer patients, respectively, are used.
Strip charts and boxplots (a), (b), and (c) show the differences in predicted drug
sensitivity to bortezomib treatment between the responder (i.e., sensitive) group and
non-responder (i.e., resistant) group using BT+SVR+S, B1+RR, and B2+RR,
respectively. (d) shows the ROC curves of the prediction algorithms, which reveal
the proportion of true positives compared to the proportion of false positives. ROC =
receiver operating characteristic.
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Figure 9.8 shows that the proposed prediction algorithms BT+SVR+S and
BT+SVR+L outperform the baseline prediction algorithms w.r.t. the MAUC.

Figure 9.8 The Mean AUC (MAUC) values of the twelve bortezomib sensitivity
prediction algorithms for multiple myeloma patients. The algorithms are ranked from left
to right where the leftmost algorithm has the highest MAUC and the rightmost algorithm
has the lowest MAUC.

9.5 Discussion
The experiments show that the proposed approaches significantly outperform existing
approaches. Further, the proposed approaches are well-suited for a wide range of tasks,
such as integration of different types of biological data to increase the accuracy of gene
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regulatory networks (GRN) inference [16, 110, 172, 173], and integration of different
cancer data to improve the prediction performance in a given drug sensitivity task.
As in [54], the mapping of predicted continuous values to categorical labels was
performed using the ROCR package [174]. The details of the mapping algorithm can be
found in [175]. In a nutshell, the algorithm sorts the predicted continuous values in
increasing order. The algorithm works iteratively by examining one value at a time, from
the smallest to the largest value. When examining a particular value v , the algorithm
labels v and all the values larger than or equal to v as "resistant" (i.e., positive) and all
the values smaller than v as "sensitive" (i.e., negative). The algorithm compares these
"resistant" and "sensitive" labels with the corresponding true labels in the target test set to
build a confusion matrix. The true positive rate (TPR) and false positive rate (FPR) with
respect to the value v are then calculated and plotted. After all the predicted continuous
values are examined, multiple points are plotted, where the x -coordinate of a point is a
FPR and the y -coordinate of the point is a TPR. These points constitute the ROC curve
of the prediction algorithm.
The biological rationale behind the superior results of the approaches is that
combining cancer drugs is often used to achieve enhanced therapeutic efficacy in the
treatment [176]. For example, docetaxel (chemotherapy drug) is used to treat breast
cancer in combination with other specific chemotherapy drugs [170] [177]. Bortezomib
and docetaxel combination has been used as a therapy for breast cancer [178, 179].
Hence, the task of predicting bortezomib sensitivity in multiple myeloma patients is
closely related to the task of predicting docetaxel sensitivity in breast cancer patients,
where closeness plays an important role in machine learning. For example, suppose we

169

are given an unseen example (i.e., test example). If the unseen example has an expression
profile closer to given training example with corresponding response (i.e., drug value),
then the unseen example is most likely to have a closer response to the response
associated with the given training example. The same holds for combining bortezomib
and cisplatin, which clinically led to synergistic killing of head and neck squamous cell
carcinoma (HNSCC) cells [180]. In addition, erlotinib plus bortezomib showed
synergistic antitumor activity against the H460 Non-small cell lung cancer (NSCLC) cell
line [181].
In the proposed approaches, it is assumed that the number of features in the target
training set is greater than the number of features in the auxiliary data. Then, the top q
features in the target test set are selected using the highest q statistical leverage scores
computed on the target training set. However, If the number of features in the auxiliary
data is greater than number of features in the target training set (as the case in
triple-negative breast cancer and non-small cell lung cancer auxiliary data), then the top

q features are selected from the auxiliary data using the highest q statistical leverage
scores computed from the auxiliary data, where q equals the number of features as in the
target training set, and no further feature selection is performed on the target training and
target test sets.
In this work, differences in distributions between the target training set and
auxiliary data have contributed to the degraded performance on the target test set for
prediction algorithms employing the second baseline approach (B2), which does not have
a transfer mechanism like ours.
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It is worth mentioning that the performance of other machine learning algorithms
is also assessed, including random forests [121], support vector regression with a
polynomial kernel of degree 2, and support vector regression with a Gaussian kernel.
However, they exhibited poor performance; consequently, their results are not included in
this paper.

9.6 Summary
In this paper, two approaches are presented to improve drug sensitivity prediction: a
transfer learning approach and a boosted transfer learning approach. The transfer learning
approach works by (1) performing a feature selection step to balance the number of
features; (2) changing the representation of auxiliary data of a related task to a new
representation that is closer to the target training set; and (3) combining the target training
set with each one of the auxiliary data separately, and using the result as input to a
standard machine learning algorithm. The boosted transfer learning approach boosts the
performance of the transfer learning approach using a modified version of AdaBoost.
The proposed approaches employ two machine learning algorithms: support
vector regression and ridge regression. The experimental results demonstrate the stability
of the proposed transfer learning approaches. The proposed approaches outperform the
baseline approaches including an existing approach as measured by their higher and
statistically significant AUC scores.
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CHAPTER 10
CONCLUSIONS AND FUTURE WORK

In this dissertation, new machine learning and data mining algorithms have been
developed and applied to solve two important biomedical problems: (i) gene network
inference; and (ii) drug response prediction.
Future work for gene network inference includes: (i) applying the proposed
learning framework in the third chapter to other unsupervised network inference tools and
evaluating its performance when used with those tools; (ii) exploring and assessing the
feasibility of the framework using new feature learning and data classification methods
including deep learning algorithms; (iii) applying the proposed hybrid approach in the
fourth chapter to some well-studied organisms such as E. coli and yeast; (iv) assessing
the feasibility of other unsupervised methods when using the hybrid approach;
(v) exploring new data cleaning and link prediction algorithms such as matrix completion
[182, 183] and evaluating their performance on both the DREAM datasets and datasets
from the well-studied organisms; and (vi) extending sampling and boosting techniques in
the fifth chapter to miRNA-mediated regulatory networks [118, 119].
The work for drug sensitivity prediction opens possibilities for future work, e.g.,
(i) exploiting signaling pathways to select the most important features and incorporating
them into the proposed link prediction approach in the seventh chapter; (ii) extending the
transfer learning approaches in the ninth chapter to handle auxiliary data from multiple
related tasks simultaneously; (iii) collaborating with domain experts, where signaling
pathways are leveraged to improve the prediction performance on a given drug sensitivity

172

prediction task; and (iv) adopting new feature representation methods to improve the
proposed transfer learning approaches for other drug sensitivity prediction tasks.

173

APPENDIX A
EVALUATING PREDICTION ALGORITHMS ON CLINICAL
TRIAL DATA OF NON-SMALL CELL LUNG CANCER
AND TRIPLE-NEGATIVE BREAST CANCER

Table A.1 shows the performance of 9 erlotinib sensitivity prediction algorithms on
non-small cell lung cancer data of patients. The prediction algorithms were evaluated
using Spearman correlation test, where statistical significant results of prediction
algorithms on the test set are shown in bold. The results indicate that prediction
algorithms of the baseline were not statistically significant compared to ours.
Specifically, A1+RR statistically significantly outperforming the baseline prediction
algorithms, where p are calculated according to Spearman correlation test.
As the number of cell lines which respond to erlotinib is small and model is fitting
a huge amount of noisy cell lines that affected the model, B+RR (proposed prediction
algorithm via Geeleher et al.) results were not significant. Geeleher et al. [54] tackled this
problem that caused poor performance as follows. They changed linear ridge regression
and fitted model using logistic ridge regression model on the 15 most sensitive and 55
most resistant samples and then applied model to the test set (i.e., clinical trial data),
where their model then achieved significant results (rho = 0.64

p  5.3104 and

from a

Spearman’s correlation test). In contrast, the proposed prediction algorithms achieved
statistical significant results using linear ridge regression and this shows that the proposed
new feature representation is discriminative guiding the learning algorithm (RR) when
incorporated with the proposed prediction algorithms.
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Table A.1 Prediction of Erlotinib Sensitivity in NSCLC (Non-Small Cell Lung Cancer)
Patients. Values with Statistical Significance (p<0.05) Are Shown in Bold. Results Are
Shown As (p/rho) According to Spearman Correlation Test
m
d
A1+SVR+L
A1+SVR+S
A1+RR
m+A1
d+A1
A2+SVR+L
A2+SVR+S
A2+RR
m+A2
d+A2
B+SVR+L
B+SVR+S
B+RR

258
9507
0.034/-0.368
0.053/-0.330
0.007/-0.480
134
19014
0.394/-0.056
0.275/-0.125
0.028/-0.385
134
9507
0.349/-0.081
0.571/0.037
0.285/-0.119

256
9507
0.099/-0.265
0.061/-0.315
0.018/-0.421
133
19014
0.613/0.060
0.382/-0.063
0.127/-0.236
133
9507
0.399/-0.053
0.668/0.091
0.350/-0.080

253
9507
0.111/-0.252
0.078/-0.292
0.013/-0.441
132
19014
0.569/0.036
0.348/-0.082
0.070/-0.302
132
9507
0.486/-0.007
0.610/0.059
0.309/-0.104

250
9507
0.047/-0.341
0.035/-0.367
0.011/-0.453
130
19014
0.548/0.025
0.290/-0.115
0.069/-0.304
130
9507
0.426/-0.038
0.584/0.045
0.266/-0.130

247
9507
0.047/-0.341
0.065/-0.310
0.010/-0.458
129
19014
0.486/-0.007
0.320/-0.098
0.122/-0.241
129
9507
0.478/-0.011
0.599/0.053
0.273/-0.126

Table A.2 shows the performance of 3 cisplatin sensitivity prediction algorithms
in triple-negative breast cancer patients’ data. The p-values used to evaluate prediction
algorithms are from a linear regression model. Hence, approaches that employ ridge
regression are evaluated. Geeleher et al. [54] assessed the response of 24 triple-negative
breast cancer patients to neoadjuvant cisplatin therapy. Each patient is assigned to one of
four drug response categories based on RECIST [184]. B+RR did not capture variability
in clinical response (see Table A.2 below). The proposed prediction algorithm achieved
comparable results, which were not statistically significant.
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Table A.2 Prediction of Cisplatin Sensitivity in Triple-Negative Breast Cancer Patients.
Results Are Recorded According to p-Values from a Linear Regression Model
m
d
A1+RR
m+A1
d+A1
A2+RR
m+A2
d+A2
B+RR

497
9620
0.1013
254
19240
0.192
254
9620
0.262

493
9620
0.05781
252
19240
0.1413
252
9620
0.2055

488
9620
0.08953
249
19240
0.192
249
9620
0.185
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483
9620
0.1775
247
19240
0.09515
247
9620
0.2119

478
9620
0.1708
244
19240
0.1213
244
9620
0.2306

APPENDIX B
EVALUATING SIGNALING PATHWAYS AS A CONSTRAINT TO GET
RELIABLE FEATURE SETS

The performance of prediction algorithms employing ridge regression was assessed
including, the baseline prediction algorithm of Geeleher et al. (B+RR) on the test sets of
breast cancer and multiple myeloma.
For Breast Cancer: Hedgehog (Hh), Notch, and Wnt signaling pathways were used,
which have been reported as a novel therapeutic target in breast cancer [185-187]. These
pathways consist of 217 unique genes and 113 of them could be found in our dataset
which were used in the proposed model. For Multiple Myeloma (MM), Jak-STAT,
PI3K-Akt, and NF-kappa B were used as the classic signaling pathways underlying MM
[187, 188]. There are 512 unique genes in these pathways and 341 of them could be
found in the dataset which were used in the proposed model. It is found found that the
performance of B+RR (i.e., the baseline) and A1+RR has significantly degraded where
all achieved AUC below 0.60 on both test sets for breast cancer and multiple myeloma.
This shows that removing discriminative features significantly degrade the performance
of all prediction algorithms including the baseline (B+RR) as these discriminative
features are crucial to improve the prediction performance.
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